
<html lang="en"     class="pb-page"  data-request-id="66feefcf-2596-4011-80d5-c99c2fc19e75"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm5005144;issue:issue:10.1021/jmcmar.2015.58.issue-1;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases" /></meta><meta name="dc.Creator" content="Zilan  Song" /></meta><meta name="dc.Creator" content="Yanhong  Yang" /></meta><meta name="dc.Creator" content="Zhiqing  Liu" /></meta><meta name="dc.Creator" content="Xia  Peng" /></meta><meta name="dc.Creator" content="Junfeng  Guo" /></meta><meta name="dc.Creator" content="Xinying  Yang" /></meta><meta name="dc.Creator" content="Kui  Wu" /></meta><meta name="dc.Creator" content="Jing  Ai" /></meta><meta name="dc.Creator" content="Jian  Ding" /></meta><meta name="dc.Creator" content="Meiyu  Geng" /></meta><meta name="dc.Creator" content="Ao  Zhang" /></meta><meta name="dc.Description" content="We have developed a series of new 2,4-diarylaminopyrimidine analogues (DAAPalogues) bearing a flexible amino acid side chain, different from the majority of the literature reported ALK inhibitors t..." /></meta><meta name="Description" content="We have developed a series of new 2,4-diarylaminopyrimidine analogues (DAAPalogues) bearing a flexible amino acid side chain, different from the majority of the literature reported ALK inhibitors t..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 8, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm5005144" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm5005144" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm5005144" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm5005144" /></link>
        
    
    

<title>Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm5005144" /></meta><meta property="og:title" content="Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0011.jpeg" /></meta><meta property="og:description" content="We have developed a series of new 2,4-diarylaminopyrimidine analogues (DAAPalogues) bearing a flexible amino acid side chain, different from the majority of the literature reported ALK inhibitors that often possess a structurally constrained arylpiperazine fragment or its equivalents in the solvent-interaction region. Extensive structural elaboration led to compound 15 possessing IC50 values of 2.7 and 15.3 nM, respectively, in the ALK wild-type and gate-keeper mutant L1196M enzymatic assays. This compound not only showed high proliferative inhibition against ALK-addicted cells across different oncogenic forms but also effectively suppressed several ALK secondary mutant cells, including the gate-keeper L1196M and F1174L. Significant antitumor efficacy was achieved in the ALK-driven SUP-M2 xenograft model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm5005144"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm5005144">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm5005144&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm5005144&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm5005144&amp;href=/doi/10.1021/jm5005144" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 197-211</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm500480k" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm5006034" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zilan++Song">Zilan Song</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yanhong++Yang">Yanhong Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhiqing++Liu">Zhiqing Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xia++Peng">Xia Peng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Junfeng++Guo">Junfeng Guo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xinying++Yang">Xinying Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kui++Wu">Kui Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Ai">Jing Ai</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Ding">Jian Ding</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Meiyu++Geng">Meiyu Geng</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ao++Zhang">Ao Zhang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">CAS Key Laboratory of Receptor Research, Synthetic Organic & Medicinal Chemistry Laboratory, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span></div><div class="corresp-info"><strong>*</strong>For Jing Ai: e-mail <a href="/cdn-cgi/l/email-protection#5d373c341d2e343030733c3e733e33"><span class="__cf_email__" data-cfemail="d6bcb7bf96a5bfbbbbf8b7b5f8b5b8">[email protected]</span></a>; fax 86-21-50806072; tel 86-21-50806072.</div><div class="corresp-info"><strong>*</strong>For Meiyu Geng: e-mail <a href="/cdn-cgi/l/email-protection#c0adb9a7a5aea780b3a9adadeea1a3eea3ae"><span class="__cf_email__" data-cfemail="cba6b2acaea5ac8bb8a2a6a6e5aaa8e5a8a5">[email protected]</span></a>; fax 86-21-50806072; tel 86-21-50806072.</div><div class="corresp-info"><strong>*</strong>For Ao Zhang: e-mail <a href="/cdn-cgi/l/email-protection#55343a2f3d343b3215263c38387b34367b363b"><span class="__cf_email__" data-cfemail="3756584d5f56595077445e5a5a195654195459">[email protected]</span></a>; tel 86-21-50806035; fax 86-21-50806035.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm5005144&amp;href=/doi/10.1021%2Fjm5005144" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 197–211</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 30, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 April 2014</li><li><span class="item_label"><b>Published</b> online</span>8 May 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 January 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm5005144" title="DOI URL">https://doi.org/10.1021/jm5005144</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D197%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DZilan%2BSong%252C%2BYanhong%2BYang%252C%2BZhiqing%2BLiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D1%26contentID%3Djm5005144%26title%3DDiscovery%2Bof%2BNovel%2B2%252C4-Diarylaminopyrimidine%2BAnalogues%2B%2528DAAPalogues%2529%2BShowing%2BPotent%2BInhibitory%2BActivities%2Bagainst%2BBoth%2BWild-type%2Band%2BMutant%2BALK%2BKinases%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D211%26publicationDate%3DJanuary%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm5005144"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3784</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">33</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm5005144" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Zilan&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Yanhong&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Zhiqing&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Xia&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Junfeng&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;Xinying&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Kui&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Ai&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Meiyu&quot;,&quot;last_name&quot;:&quot;Geng&quot;},{&quot;first_name&quot;:&quot;Ao&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;197-211&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm5005144&quot;},&quot;abstract&quot;:&quot;We have developed a series of new 2,4-diarylaminopyrimidine analogues (DAAPalogues) bearing a flexible amino acid side chain, different from the majority of the literature reported ALK inhibitors that often possess a structurally constrained arylpiperazine fragment or its equivalents in the solvent-interaction region. Extensive structural elaboration led to compound 15 possessing IC50 values of 2.7 and 15.3 nM, respectively, in the ALK wild-type and gate-keeper mutant L1196M enzymatic assays. This compound not only showed high proliferative inhibition against ALK-addicted cells across different oncogenic forms but also effectively suppressed several ALK secondary mutant cells, including the gate-keeper L1196M and F1174L. Significant antitumor efficacy was achieved in the ALK-driven SUP-M2 xenograft model.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5005144&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5005144" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5005144&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5005144" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5005144&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5005144" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm5005144&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5005144&amp;href=/doi/10.1021/jm5005144" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm5005144" /></input><a href="/doi/pdf/10.1021/jm5005144" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm5005144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm5005144%26sid%3Dliteratum%253Aachs%26pmid%3D24785465%26genre%3Darticle%26aulast%3DSong%26date%3D2015%26atitle%3DDiscovery%2Bof%2BNovel%2B2%252C4-Diarylaminopyrimidine%2BAnalogues%2B%2528DAAPalogues%2529%2BShowing%2BPotent%2BInhibitory%2BActivities%2Bagainst%2BBoth%2BWild-type%2Band%2BMutant%2BALK%2BKinases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D1%26spage%3D197%26epage%3D211%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=291896" title="Mechanisms of reactions">Mechanisms of reactions</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jmcmar.2015.58.issue-1/20150108/jmcmar.2015.58.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We have developed a series of new 2,4-diarylaminopyrimidine analogues (DAAPalogues) bearing a flexible amino acid side chain, different from the majority of the literature reported ALK inhibitors that often possess a structurally constrained arylpiperazine fragment or its equivalents in the solvent-interaction region. Extensive structural elaboration led to compound <b>15</b> possessing IC<sub>50</sub> values of 2.7 and 15.3 nM, respectively, in the ALK wild-type and gate-keeper mutant L1196M enzymatic assays. This compound not only showed high proliferative inhibition against ALK-addicted cells across different oncogenic forms but also effectively suppressed several ALK secondary mutant cells, including the gate-keeper L1196M and F1174L. Significant antitumor efficacy was achieved in the ALK-driven SUP-M2 xenograft model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/58/1"><issue-title>New Frontiers in Kinases</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44740" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44740" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Anaplastic lymphoma kinase (ALK) is an orphan receptor tyrosine kinase (RTK), structurally belonging to the insulin receptor family.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Implication in brain development and regulation of specific neurons of the central nervous system are the general proposed functions of ALK.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2-4)</a> In 1994, the oncogenic nucleophosmin (NPM)–ALK fusion gene was discovered as an ALK translocation product occurring in 80% of anaplastic large-cell non-Hodgkin’s lymphoma (ALCL) cases.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Subsequently, constitutive activations of ALK due to chromosomal translocations, amplifications, or point mutations have been found in other cancers.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The echinoderm microtubule-associated protein-like 4 (EML4)–ALK fusion gene has characteristics of “oncogene-addicted tumors” and is implicated in the largest non-small-cell lung cancer (NSCLC) patient populations.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6-8)</a> The proof-of-concept of the “tumor-addicted oncogene” EML4–ALK as a novel therapeutic target<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16">(9-16)</a> has been validated by Pfizer’s first-generation ALK inhibitor crizotinib (PF2341066, Xalkori),<a onclick="showRef(event, 'ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20">(17-20)</a> which was approved by FDA in 2011 as the standard treatment for ALK-positive NSCLCs. Unfortunately, despite the appreciable objective response rates and impressive progression-free survival times on crizotinib-treatment,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> resistance to this drug was reported within a year of starting therapy, which led to the majority of patients experiencing relapse and tumor regrowth. Although activation of alternative signaling pathways that bypass ALK may be one of the resistance mechanisms, analyses of the resistant patient samples indicated that dozens of ALK gene secondary mutations<a onclick="showRef(event, 'ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24 ref25">(22-25)</a> have developed following crizotinib-treatment, including the gate-keeper mutation L1196M, F1174L, and others.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> Since the gatekeeper mutation L1196M is believed to cause steric hindrance of crizotinib binding and is similar to the gatekeeper mutations in the EGFR-T790M<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and ABL-T3151<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> kinase domains, a new generation<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> of ALK inhibitors able to overcome the resistant mutant L1196M is greatly needed. Currently, a number of second-generation ALK inhibitors have progressed to clinical trials including 2,4-diarylaminopyrimidine <b>2</b>,<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> triazene <b>3</b>,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and tetracyclic <b>4</b><a onclick="showRef(event, 'ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36">(34-36)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). All these new ALK inhibitors showed high potency against both wild-type and mutant ALK and exerted significant <i>in vivo</i> antitumor efficacy in crizotinib-resistant ALK-positive NSCLC patients.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Marketed ALK inhibitor <b>1</b> and new clinical inhibitors <b>2</b>–<b>4</b> (blue color denotes solvent region).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">By using a scaffold repurposing strategy,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> we recently developed<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> a series of 2,4-diarylaminopyrimidine analogues (DAAPalogues) from Cephalon’s tyrosine kinase c-Met inhibitor <b>5</b><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). These compounds structurally featured a 1-methyl/aryl-<i>N</i><sup>3</sup>-benzazepine framework and showed high potency against both c-Met and ALK kinases. As a continuation of this work,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> we conducted an alternative structural modification approach by opening the azepanone ring of <b>5</b> at the C3–C4 position, thus leading to a series of new DAAPalogues bearing a flexible amino acid side chain. These new compounds differed from most of the reported ALK inhibitors that often contained a structurally constrained arylpiperazine fragment or its equivalent in the solvent-interaction region (as that in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>, blue color). Structural elaboration indicated that subtle change within the amino acid component led to significant difference in the ALK potency and selectivity. Compound <b>15</b> was found to be the most potent and selective ALK inhibitor with efficacy against both wild-type ALK and L1196M mutant. Herein, we present the synthesis and pharmacological results.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Proposed new DAAPalogues containing an amino acid side chain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64761" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64761" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, 4-amine-2,5-dichloropyrimidines <b>8a</b>–<b>f</b><a onclick="showRef(event, 'ref32 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref32 ref38 ref39">(32, 38, 39)</a> were used as the key intermediates, which were prepared from 2,4,5-trichloropyrimidine and commercially available amines <b>7a</b>–<b>f</b> by following literature procedures. Substitution of <b>8a</b> with <i>tert</i>-butyl (2-((3-aminophenyl)amino)-2-oxoethyl) carbamate (<b>9a</b>) in the presence of CSA provided compound <b>10</b> in 78% yield.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Meanwhile, compound <b>11</b> was prepared by treating chloride <b>8b</b> with <b>9a</b> in the presence of Pd(OAc)<sub>2</sub>, X-Phos, and Cs<sub>2</sub>CO<sub>3</sub> in 52% yield.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Urea derivative <b>12</b> was obtained by treating amine <b>10</b> with 1-pyrrolidinecarbonyl chloride in 48% yield. Condensation of <b>10</b> with Boc-<span class="smallcaps smallerCapital">l</span>-proline followed by deprotection led to amino amide <b>13</b> in 67% yield.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Deprotection of compound <b>11</b> followed by reacting with 2-isocyanato-2-methylpropane provided compound <b>14</b> in 47% yield.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>10</b>–<b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) for <b>8a</b>, <b>8b</b>, <b>8d</b>, <b>8e</b>, and <b>8f</b>, DIPEA, IPA; for <b>8c</b>, NaH, DMF; (ii) for <b>10</b>, CSA, IPA, MW, 80 °C; for <b>11</b>, Pd(OAc)<sub>2</sub>, X-Phos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, MW, 100 °C; (iii) 1-pyrrolidinecarbonyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (iv) (a) Boc-<span class="smallcaps smallerCapital">l</span>-Proline, TBTU, DIPEA, DMF; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>; (v) (a) TFA, CH<sub>2</sub>Cl<sub>2</sub>; (b) <i>tert</i>-butylisocyanate, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><div class="NLM_p">Meanwhile, dichloropyrimidine <b>8g</b> was obtained in 76% yield by treating commercially available 1-(methylsulfonyl)-1,2,3,4-tetrahydro-quinoxaline with 2,4,5-trichloropyrimidine. Subsequent condensation of <b>9a</b> with pyrimidines <b>8c</b>–<b>g</b> in the presence of CSA yielded amino amides <b>15</b>–<b>19</b> in 53–82% yields. Meanwhile, treating <b>8c</b> with various amino acid derivatives <b>20</b> under a similar condensation conditions provided DAAPalogues <b>21</b>–<b>27</b> in 42–69% yields (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>15</b>–<b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) DIPEA, IPA; (ii) CSA, IPA, MW,80 °C.</p></p></figure><div class="NLM_p">In addition, <i>N</i>-(3-aminophenyl)-5-chloro-<i>N</i>′-[2-(isopropylsulfonyl)phenyl]pyrimidine-2,4-diamine (<b>29</b>) was prepared from commercially available 3-nitroaniline by following a literature procedure.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Subsequent condensation<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> of <b>29</b> with various amino acids provided compounds <b>31</b>–<b>33</b>, <b>46</b>, and <b>47</b> in 41–68% yields.</div><div class="NLM_p">Amidation of <b>29</b> with 2-chloroacetyl chloride yielded compound <b>30</b>. Compounds <b>34</b>–<b>43</b> bearing a cyclic amine functionality were prepared in 47–78% yields by treating intermediate <b>30</b> with corresponding cyclic amine substrates in the presence of K<sub>2</sub>CO<sub>3</sub> and Et<sub>3</sub>N.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Similarly, compounds <b>44</b> and <b>45</b> were obtained in 48–56% yields by condensation of <b>30</b> with corresponding <i>N</i>-Boc amines followed by deprotection (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>28</b>–<b>48</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) CPA, IPA, MW, 80 °C; (ii) 10% Pd/C, H<sub>2</sub>, MeOH; (iii) chloroacetyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (iv) TBTU, DIPEA, DMF; (v) K<sub>2</sub>CO<sub>3</sub>, Et<sub>3</sub>N, MeCN.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15482" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15482" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Enzymatic Assay</h3><div class="NLM_p">The 2,4-diarylaminopyrimidine (DAAP) scaffold has long been recognized as a classical kinase inhibitor motif;<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> our recent study also confirmed that such compounds displayed high potency against several kinase targets, especially c-Met and ALK.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Therefore, all the new synthetic compounds were initially assayed for their inhibitory effects against both c-Met and ALK, and compounds with high potency and selectivity for ALK over c-Met will be selected for further profiling. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, opening the azepanone ring of Cephalon’s c-Met inhibitor <b>5</b> by deletion of the C4–C5 ethylene unit generated urea <b>12</b>, which retained good inhibitory effect against c-Met, but the potency at ALK was moderate (280 nM). Isomerization of <b>12</b> to dipeptide <b>13</b> led to slightly enhanced potencies at both c-Met and ALK kinases, with IC<sub>50</sub> values of 16 and 80 nM, respectively. <i>N</i>-<i>t</i>-Butyl urea <b>14</b> showed significantly reduced potency at ALK, whereas higher potency against c-Met was retained. Similar high c-Met potency and selectivity were observed as well for compound <b>11</b> bearing a <i>t</i>-butoxycarbonyl moiety as the terminal capping group. Quite interestingly, simple 2-amino-<i>N</i>-ethylacetamide <b>10</b> bearing a naked primary amino group showed high potency at both c-Met and ALK, with IC<sub>50</sub> values of 6.5 and 32.8 nM, respectively.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory Effects of New Compounds against c-Met and ALK Kinases<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0008.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub>’s were calculated by Logit method from the results of at least two independent tests with eight concentrations each and expressed as means ± SD.</p></div></div><div></div></div><div class="NLM_p">With the moderate ALK inhibitor <b>10</b> as our new lead, we optimized the pyrimidin-2-yl aminobenzamide moiety. It was found that replacing the <i>N</i>-methylcarbonyl substituent in the aminobenzamide component of <b>10</b> with the isopropylsulfonyl group as that in clinical ALK inhibitors <b>2</b> and <b>3</b> significantly increased ALK potency and repositioned the selectivity from c-Met to ALK. Compound <b>15</b> showed an IC<sub>50</sub> value of 2.7 nM for ALK and was 56-fold more potent against ALK than against c-Met kinase. Incorporation of the 3-aminobicyclo[2.2.1]hept-5-ene-2-carboxylic amide fragment, a more lipophilic group used by Cephalon<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> for generation of new ALK inhibitors led to compound <b>16</b>, which retained good potency and selectivity at c-Met, but the potency at ALK was moderate. Compared with benzamide <b>10</b>, methanesufonylamine <b>17</b> was 3-fold less potent against the ALK kinase, but much higher potency was observed when an <i>N</i>-methyl substituent was introduced. <i>N</i>-Methylmethanesufonylamine <b>18</b> showed an IC<sub>50</sub> value of 7.7 nM and was 7-fold more potent against ALK than against c-Met. Tetrahydroquinoxaline <b>19</b>, formed by connecting the two <i>N</i>-atoms of the benzene-1,2-diamino component with an ethylene unit lost potency at both ALK and c-Met. The results indicated that the free NH connecting to central pyrimidine core, rather than the NH in the methanesufonylamino moiety, was critical to the interactions with both kinases.</div><div class="NLM_p">Since compound <b>15</b> displayed high potency and selectivity for ALK kinase, our further optimization was focused on exploring the steric and electronic capacities of the amino acetamide side chain based on the structure <b>15</b>. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, we first tested various amino acids bearing a primary amino group. Insertion of a methyl group yielded 2-aminopropanamide <b>21</b>, which retained high potency against ALK (1.8 nM), but the selectivity over c-Met was only 4-fold. More bulky groups such as those in <b>22</b>–<b>25</b> led to slightly increased selectivity, whereas the potency against ALK was sacrificed. Compound <b>26</b> with a one-carbon longer alkyl chain retained high potency against ALK with an IC<sub>50</sub> value of 3.1 nM, which was 14-fold higher than that against c-Met. However, further enlongating the alkyl chain to 4-amino butaneamide <b>27</b> caused reduction in ALK potency.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibitory Effects of New Compounds against c-Met and ALK Kinases<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0009.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub>’s were calculated by Logit method from the results of at least two independent tests with eight concentrations each and expressed as means ± SD.</p></div></div><div></div></div><div class="NLM_p">Meanwhile, to elucidate the necessity of the primary amino group for the high ALK potency of compound <b>15</b>, a large number of 2-amino acetamido fragments bearing diversified substitutions on either the amino group or the alkyl chain or both were investigated. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, substitution on the primary amino group by forming an azetidine ring led to compound <b>31</b>, which showed an IC<sub>50</sub> value of 44 nM against ALK. Notably, the 3-azetidine regiomer <b>32</b> was 2-fold more potent against ALK than <b>31</b> and nearly inactive against c-Met, thus providing a 50-fold ALK/c-Met selectivity. Extremely high potency was observed for the <i>N</i>-4-(dimethylamino)butanoyl substituted azetidine analogue <b>33</b>, which showed an IC<sub>50</sub> value of 0.8 nM at ALK and was over 1000-fold selective versus c-Met. Conversion of the primary amino group in <b>15</b> to morpholines <b>34</b> and <b>35</b> also provided relatively good potency and selectivity for ALK, but they were much less potent than either <b>15</b> or <b>33</b>. Interestingly, replacement of the primary amino group in <b>15</b> by a substituted piperazinyl moiety generated highly potent and selective ALK inhibitors <b>36</b>–<b>40</b>. All these compounds displayed IC<sub>50</sub> values of less than 10 nM at ALK, but the selectivity over c-Met differed. The alkyl substituted piperazine analogues <b>37</b> and <b>38</b> were more selective for ALK over c-Met than the nonsubstituted piperazine <b>36</b>. High potency was observed on <i>N</i>-acyl substituted piperazine analogue <b>39</b>, which showed an IC<sub>50</sub> value of 0.7 nM and an ALK/c-Met selectivity of 145. This compound is superior to compound <b>15</b> in both potency and selectivity for ALK. The <i>N</i>-containing bicyclic analogues <b>41</b>–<b>43</b> generally had moderate selectivity for ALK over c-Met, but compounds <b>41</b> and <b>43</b> still retained high ALK potency, indicating that a remote H-bonding donor is beneficial for interaction with ALK kinase. High potency and selectivity against ALK were also obtained from compounds <b>44</b> and <b>45</b> bearing an octahydropyrrolo[3,4-<i>b</i>]pyrrole terminal group. Replacement of the primary amino group in <b>15</b> with a furan (<b>46</b>) or an indole (<b>47</b>) moiety led to reduction in both potency and selectivity at the ALK kinase.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibitory Effects of New Compounds against c-Met and ALK Kinases<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0010.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub>’s were calculated by Logit method from the results of at least two independent tests with eight concentrations each and expressed as means ± SD.</p></div></div><div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Cellular Inhibition Study</h3><div class="NLM_p">On the basis of the enzymatic assays, potent and selective ALK inhibitors were selected for cellular assay. The antiproliferative effects<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> of the compounds in ALK-addicted lymphoma cell line SUP-M2 harboring NPM–ALK are listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. Meanwhile, tumor cell line A549 whose growth was not dependent on ALK was used to test the potential off-target effects of the selected ALK inhibitors. In parallel with the enzymatic results, all the selected compounds displayed high antiproliferative effects in the SUP-M2 cell lines. Compound <b>15</b> bearing a primary amino group showed an IC<sub>50</sub> value of 15.3 nM and 70-fold selectivity over A549 cells. Compound <b>21</b> bearing a methyl group in the side chain, though equally potent to <b>15</b> in the enzymatic assay, was much more potent (>150-fold) in the cellular assay with an IC<sub>50</sub> value of less than 0.1 nM. Quite disappointingly, this compound also showed high potency in the A549 cells indicating that a general cytotoxicity might exist. Although the exact reason was not clear, the higher cellular potency and cytotoxicity of <b>21</b> might be partially related to the increased lipophilicity by the methyl group. Compound <b>26</b> with a longer side chain and compound <b>33</b> bearing an <i>N</i>-acyl substituted azetidine moiety displayed moderate potency in the SUP-M2 cells, despite their high enzymatic potencies. Although equally potent to compound <b>15</b> in the ALK enzymatic assay, the piperazinyl DAAPalogue <b>37</b> displayed 150-fold higher cellular potency with an IC<sub>50</sub> value of 0.1 nM. However, this compound was also highly potent in the A549 cell lines. In comparison to their high enzymatic potency, <i>N</i>-acyl substituted piperazine analogue <b>39</b> and the octahydropyrrolo[3,4-<i>b</i>]pyrrole <b>44</b> were less potent in the cell and showed higher general cytotoxicity in the A549 cell lines. The bicyclic compound <b>43</b> showed 15-fold higher cellular potency than its enzymatic potency, whereas significant cytotoxicity was observed as well in A549 cells. All these new DAAPalogues were more potent than the marketed drug crizotinib (<b>1</b>) and clinical compound <b>2</b> in both ALK kinase and SUP-M2 cells.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Inhibitory Effects of Potent Compounds on Cell Proliferation</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">IC<sub>50</sub></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left">compd</th><th class="colsep0 rowsep0" align="center" char=".">ALK enzyme IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±">ALK SUP-M2 (nM)</th><th class="colsep0 rowsep0" align="center" char="±">A549 (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>15</b></td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char="±">15.3 ± 3.7</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>21</b></td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char="±"><0.1</td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>26</b></td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char="±">79.0 ± 18.6</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>33</b></td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char="±">365 ± 3.9</td><td class="colsep0 rowsep0" align="char" char="±">3.9 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>37</b></td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char="±">0.1 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>39</b></td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char="±">7.7 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>43</b></td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">0.1 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>44</b></td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">0.8 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>2</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char="±">167 ± 35.9</td><td class="colsep0 rowsep0" align="char" char="±">>1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>crizotinib</b></td><td class="colsep0 rowsep0" align="char" char=".">13.7</td><td class="colsep0 rowsep0" align="char" char="±">174 ± 20.8</td><td class="colsep0 rowsep0" align="char" char="±">>1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Compound <b>2</b> (LDK378) was reported<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> to be more sensitive against BaF3/NPM–ALK cells with an IC<sub>50</sub> value of 26.0 nM.</p></div></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Preliminary Pharmacokinetic Study</h3><div class="NLM_p">From the results above, compound <b>15</b> stood out having high potency against both ALK enzyme and cells and showed less potential for cytotoxicity. This compound was further evaluated in our preliminary pharmacokinetic study<a onclick="showRef(event, 'ref37 ref46'); return false;" href="javascript:void(0);" class="ref ref37 ref46">(37, 46)</a> at a dose of 2.5 mg/kg (i.g., intragastric)  in rats. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, compound <b>15</b> showed a moderate plasma exposure (AUC<sub>0-∞</sub> = 454 ng·h/mL) and a short half-life. It has a moderate lipophilicity but with poor aqueous solubility (less than 0.1 mg/mL). However, the solubility was much improved by forming the corresponding hydrochloride salt (∼4 mg/mL).</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Preliminary PK results.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Overcoming ALK Resistant Gatekeeper Mutant Study</h3><div class="NLM_p">To determine the potential of compound <b>15</b> in overcoming crizotinib’s resistance, it was evaluated against the ALK gatekeeper mutant L1196M.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> An IC<sub>50</sub> value of 15.3 nM was observed indicating that compound <b>15</b> was potent against both wild-type and mutant ALK (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Meanwhile, compound <b>15</b> was further evaluated for the inhibitory activities on a panel of our in-house<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> tyrosine kinases. Compound <b>15</b> was found also to show high potency against LTK kinase, a family member of ALK; otherwise much weaker inhibitory effects were observed on the remaining 17 tested kinases (IC<sub>50</sub> > 1 μM or 0.1 μM) (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Therefore, compound <b>15</b> was a potent ALK family inhibitor with against the resistant gatekeeper mutant.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Kinase Selectivity Profile of Compound <b>15</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="2" align="center">% or IC<sub>50</sub></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><b>15</b></th><th class="colsep0 rowsep0" align="center"><b>1</b> (crizotinib)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK</td><td class="colsep0 rowsep0" align="left">2.7 ± 0.8 nM</td><td class="colsep0 rowsep0" align="left">13.7 ± 1.6 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK-L1196M</td><td class="colsep0 rowsep0" align="left">15.3 ± 0.1 nM</td><td class="colsep0 rowsep0" align="left">122 ± 20.4 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LTK</td><td class="colsep0 rowsep0" align="left">93% @ 0.1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RON</td><td class="colsep0 rowsep0" align="left">32.2% @ 0.1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AXL</td><td class="colsep0 rowsep0" align="left">>1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tyto3</td><td class="colsep0 rowsep0" align="left">>1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Mer</td><td class="colsep0 rowsep0" align="left">>1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR-α</td><td class="colsep0 rowsep0" align="left">>1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR-β</td><td class="colsep0 rowsep0" align="left">>1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">>1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR<sup>T790M-L858R</sup></td><td class="colsep0 rowsep0" align="left">35% @ 0.1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR1</td><td class="colsep0 rowsep0" align="left">50% @ 0.1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Src</td><td class="colsep0 rowsep0" align="left">>1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET</td><td class="colsep0 rowsep0" align="left">43% @ 0.1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KDR</td><td class="colsep0 rowsep0" align="left">>1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt-1</td><td class="colsep0 rowsep0" align="left">>1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Kit</td><td class="colsep0 rowsep0" align="left">>1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abl</td><td class="colsep0 rowsep0" align="left">>1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ErbB4</td><td class="colsep0 rowsep0" align="left">12% @ 0.1 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">IGF1R, insulin-like growth factor 1 receptor; PDGFR, platelet derived growth factor receptor; EGFR, epidermal growth factor receptor; KDR, kinase insert domain receptor; FGFR1, fibroblast growth factor receptor 1; Flt-1: Fms-like tyrosine kinase.</p></div></div></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Antiproliferative Effects against Both ALK-Addicted and Crizotinib-Resistant Cells</h3><div class="NLM_p">Since activated ALK is known to trigger cancer cell proliferation, we then set out to investigate the inhibitory effects of compound <b>15</b> on cell proliferation in a panel of human cancer cell lines harboring different levels of ALK expression and activation. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>, compound <b>15</b> significantly inhibited cell proliferation of ALK constitutively activated SUP-M2, SU-DHL-1, NB-1, H3122, and BaF3/EML4–ALK (V3) cells that cover the frequently occurring oncogenic forms of ALK (ALK amplification, ALK chromosomal rearrangement), with IC<sub>50</sub> values of 15.3, 15.0, 28.6, 96.8, and 41.9 nM, respectively. These results suggested that compound <b>15</b> inhibited ALK-dependent cell proliferation across different oncogenic forms.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Effects of Compound <b>15</b> on Cell Proliferation in ALK-Addicted Cell Lines<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SUP-M2 (NPM-ALK)</td><td class="colsep0 rowsep0" align="char" char=".">15.3 ± 3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SU-DHL-1 (NPM-ALK)</td><td class="colsep0 rowsep0" align="char" char=".">15.0 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NB-1 (ALK Amplification)</td><td class="colsep0 rowsep0" align="char" char=".">28.6 ± 2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H3122 (EML4-ALK variant1)</td><td class="colsep0 rowsep0" align="char" char=".">96.8 ± 15.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3/EML4-ALK (V3)</td><td class="colsep0 rowsep0" align="char" char=".">41.9 ± 9.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">The IC<sub>50</sub> values are shown as the mean ± SD (nM) from three separate experiments.</p></div></div></div><div class="NLM_p">Meanwhile, antiproliferative effects of compound <b>15</b> in a number of crizotinib-resistant cell lines were tested as well (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). Notably, compound <b>15</b> showed an equally high potency against both native EML4–ALK and EML4–ALK L1196M-mediated NIH/3T3 cell proliferation with IC<sub>50</sub> values of 142 and 149 nM, respectively. Moreover, compound <b>15</b> significantly inhibited the proliferation of Kelly cells (IC<sub>50</sub> = 28.1 nM), which harbor crizotinib-induced resistant mutant F1174L. In addition, compound <b>15</b> significantly inhibited the proliferation of cell line LAN-5 (IC<sub>50</sub> = 31.3 nM) harboring another hot spot-activating mutation (R1275Q) in neuroblastoma and a mutant much less sensitive to crizotinib (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> These data further confirmed that compound <b>15</b> was capable of blocking the ALK resistant mutants.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Antiproliferative Effects of Compound <b>15</b> in Crizotinib-Resistant Cells<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center" char="±"><b>15</b></th><th class="colsep0 rowsep0" align="center" char="±">crizotinib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NIH/3T3/EML4–ALK (V1)</td><td class="colsep0 rowsep0" align="char" char="±">142 ± 26.6</td><td class="colsep0 rowsep0" align="char" char="±">95.4 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NIH/3T3/EML4–ALK (V1)-L1196M</td><td class="colsep0 rowsep0" align="char" char="±">149 ± 7.8</td><td class="colsep0 rowsep0" align="char" char="±">606 ± 51.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Kelly (ALK F1174L)</td><td class="colsep0 rowsep0" align="char" char="±">28.1 ± 6.9</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LAN-5 (ALK R1275Q)</td><td class="colsep0 rowsep0" align="char" char="±">31.3 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">The IC<sub>50</sub> values are shown as the mean ± SD (nM) from three separate experiments.</p></div></div></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>In Vivo</i> Antitumor Efficacy Study</h3><div class="NLM_p">Since compound <b>15</b> possessed high ALK enzymatic and cellular potencies and was also effective in blocking the ALK resistant mutants, we proceeded to evaluate its antitumor efficacy <i>in vivo</i>. The SUP-M2 xenograft model,<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47, 48)</a> which was specifically driven by constitutively active ALK, was used (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Compound <b>15</b> was administered orally as its hydrochloride salt with 0.5% CMC-Na (sodium carboxymethyl cellulose) at doses of 50 or 30 mg/kg once daily for 14 consecutive days. Compared with the vehicle treatment, compound <b>15</b> significantly inhibited tumor growth at both doses with tumor growth inhibitory rates of >89% (<i>p</i> < 0.01) and with no significant body weight loss.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antitumor activity of compound <b>15</b> in SUP-M2 xenograft model. Mice bearing SUP-M2 were orally administered compound <b>15</b> in the HCl salt form with 0.5% CMC-Na (sodium carboxymethyl cellulose) or crizotinib in water once daily for 14 days after the tumor volume reached 80 to 100 mm<sup>3</sup> at the indicated doses. The results were expressed as the mean ± standard error (drug-treated group, <i>n</i> = 5; vehicle group, <i>n</i> = 10) **<i>p</i> < 0.01 vs vehicle group on final day, using Student’s <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18518" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18518" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have developed a series of new DAAPalogues bearing a flexible amino acid side chain. These new compounds differed from most of the literature reported ALK inhibitors, which often contain a structurally constrained arylpiperazine fragment or its equivalents in the solvent-interaction region. Structural elaboration indicated that subtle change within the amino acid fragment led to significant difference in both the ALK potency and selectivity. Compound <b>15</b> was identified as a potent and selective ALK inhibitor possessing IC<sub>50</sub> values of 2.7 and 15.3 nM against the ALK wild-type and L1196 mutant enzymes, respectively. It showed high antiproliferative effects toward a number of ALK-dependent cells across different oncogenic forms and was potent as well against several ALK resistant mutant cells, including the gate-keeper L1196M and L1174M. Significant antitumor efficacy was achieved for compound <b>15</b> in the ALK-driven SUP-M2 xenograft model.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75806" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75806" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Chemistry</h3><div class="NLM_p"><sup>1</sup>H NMR spectral data were recorded in CDCl<sub>3</sub>, CDCl<sub>3</sub>/CD<sub>3</sub>OD, or DMSO-<i>d</i><sub>6</sub> on Varian Mercury 300 or 400 NMR spectrometer, and <sup>13</sup>C NMR was recorded in CDCl<sub>3</sub> on Varian Mercury 400 or 500 NMR spectrometer. Low-resolution mass spectra (MS) and high-resolution mass spectra (HRMS) were recorded at anionizing voltage of 70 eV on a Finnigan/MAT95 spectrometer. Column chromatography was carried out on silica gel (200–300 mesh). All reactions were monitored using thin layer chromatography (TLC) on silica gel plates. Compounds <b>8a</b>–<b>f</b><a onclick="showRef(event, 'ref32 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref32 ref38 ref39">(32, 38, 39)</a> were prepared according to the literature procedures.</div><div id="sec5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> General Procedure for Synthesis of Compounds <b>10</b>, <b>15</b>–<b>19</b>, <b>21</b>–<b>27</b>, and <b>28</b></h4><div class="NLM_p">A microwave tube (10 mL) was charged with 4-amine-2,5-dichloropyrimidines (<b>8a</b>–<b>g</b>) (0.2 mmol), an appropriate aniline (<b>9a</b> or <b>20</b>) bearing an amino acid side chain (0.28 mmol), (1<i>S</i>)-(+)-10-camphorsulfonic acid (CSA, 0.4 mmol), and isopropanol (3 mL). The mixture was heated to 80 °C under microwave irradiation (80 W) for 1 h. The solution was concentrated under vacuum, washed with saturated NaHCO<sub>3</sub> and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and purified by chromatography (CHCl<sub>3</sub>/MeOH = 10:1) to afford corresponding target compound.</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> 2-((2-((3-(2-Aminoacetamido)phenyl)amino)-5-chloropyrimidin-4-yl)amino)-<i>N</i>-methylbenzamide (<b>10</b>)</h5><div class="NLM_p last">White solid (78%). <sup>1</sup>H NMR (300 MHz, DMSO) δ 11.68 (s, 1H), 9.47 (d, <i>J</i> = 3.4 Hz, 1H), 8.85–8.68 (m, 2H), 8.25–8.17 (m, 1H), 7.85 (s, 1H), 7.79–7.68 (m, 1H), 7.49–7.33 (m, 2H), 7.31–7.06 (m, 3H), 3.28 (s, 2H), 3.25 (d, <i>J</i> = 3.1 Hz, 2H), 2.79 (t, <i>J</i> = 3.8 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 171.6, 168.9, 157.7, 154.9, 154.4, 140.5, 139.3, 138.8, 131.5, 128.5, 127.9, 121.8, 121.2, 120.4, 115.0, 113.0, 110.8, 105.2, 45.3, 26.3. MS (ESI) <i>m</i>/<i>z</i> 426 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>22</sub>H<sub>21</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 426.1445; found 426.1446.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> 2-Amino-<i>N</i>-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acetamide (<b>15</b>)</h5><div class="NLM_p last">Off-white solid (82%). <sup>1</sup>H NMR (300 MHz, DMSO) δ 10.13 (s, 1H), 9.57 (s, 1H), 8.65 (d, <i>J</i> = 7.7 Hz, 1H), 8.26 (s, 1H), 7.91–7.76 (m, 4H), 7.68 (t, <i>J</i> = 7.5 Hz, 1H), 7.39–7.06 (m, 5H), 6.19 (s, 1H), 3.65 (s, 1H), 3.23 (s, 2H), 1.15 (d, <i>J</i> = 6.7 Hz, 6H).<sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD) δ 164.2, 158.1, 151.8, 141.9, 138.8, 136.2, 135.6, 134.7, 131.3, 129.4, 128.1, 126.4, 126.1, 119.5, 117.4, 114.9, 106.2, 55.5, 40.8, 13.9. MS (ESI) <i>m</i>/<i>z</i> 475 [M + H] <sup>+</sup>. The free base was converted to its HCl salt. Anal. Calcd for C<sub>21</sub>H<sub>23</sub>N<sub>6</sub>O<sub>3</sub>S.2HCl.0. 5H<sub>2</sub>O: C, 45.29, H, 4.71, N, 15.09; found C: 45.17, H: 4.96, N: 15.08.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> (<i>1S,2S,3R,4R</i>)-3-((2-((3-(2-Aminoacetamido)phenyl)amino)-5-chloropyrimidin-4-yl)amino)-<i>N</i>-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide (<b>16</b>)</h5><div class="NLM_p last">Off-white solid (78%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.32 (s, 1H), 8.31 (d, <i>J</i> = 4.6 Hz, 1H), 7.96 (d, <i>J</i> = 7.4 Hz, 2H), 7.68 (d, <i>J</i> = 7.7 Hz, 1H), 7.51–7.43 (m, 1H), 7.18 (d, <i>J</i> = 5.9 Hz, 2H), 6.31 (dd, <i>J</i> = 5.6, 2.8 Hz, 1H), 6.22 (dd, <i>J</i> = 5.4, 3.0 Hz, 1H), 4.17 (t, <i>J</i> = 7.9 Hz, 1H), 2.83 (s, 1H), 2.76 (s, 1H), 2.62 (d, <i>J</i> = 4.5 Hz, 3H), 2.53 (s, 1H), 2.12 (d, <i>J</i> = 8.6 Hz, 1H), 1.39 (d, <i>J</i> = 8.6 Hz, 1H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 174.4, 172.1, 158.5, 156.8, 153.3, 141.5, 139.1, 137.1, 128.9, 114.5, 112.8, 110.5, 104.1, 52.4, 48.1, 47.3, 45.8, 44.8, 44.2, 26.1. MS (ESI) <i>m</i>/<i>z</i> 442 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>21</sub>H<sub>25</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H], 442.1758; found 442.1754.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 2-Amino-<i>N</i>-(3-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acetamide (<b>17</b>)</h5><div class="NLM_p last">Off-white solid (62%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>/MeOD) δ 7.98 (s, 1H), 7.90 (d, <i>J</i> = 7.9 Hz, 1H), 7.55 (s, 1H), 7.33 (d, <i>J</i> = 7.7 Hz, 1H), 7.29–7.25 (m, 1H), 7.18 (d, <i>J</i> = 8.2 Hz, 3H), 7.11 (d, <i>J</i> = 8.0 Hz, 1H), 3.35 (s, 2H), 2.90 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.3, 157.5, 156.2, 154.2, 139.8, 137.7, 134.3, 129.1, 128.9, 127.6, 126.7, 125.8, 125.6, 115.6, 113.9, 110.8, 105.5, 44.6, 38.9. MS (ESI) <i>m</i>/<i>z</i> 462 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>19</sub>H<sub>20</sub>ClN<sub>7</sub>O<sub>3</sub>S [M + H], 462.1115; found 462.1123.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 2-Amino-<i>N</i>-(3-((5-chloro-4-((2-(<i>N</i>-methylmethylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acetamide (<b>18</b>)</h5><div class="NLM_p last">Off-white solid (72%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.44 (s, 1H), 9.55 (s, 1H), 8.41 (s, 2H), 8.22 (s, 1H), 7.83 (s, 1H), 7.64 (d, <i>J</i> = 7.9 Hz, 1H), 7.44–7.38 (m, 2H), 7.23 (dd, <i>J</i> = 19.7, 8.5 Hz, 3H), 3.68 (s, 2H), 3.21 (s, 3H), 3.12 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.4, 158.2, 155.3, 154.7, 141.1, 138.8, 137.0, 132.9, 129.1, 127.4, 124.8, 123.4, 115.8, 113.5, 111.2, 105.1, 42.2, 39.3, 35.5. MS (ESI) <i>m</i>/<i>z</i> 476 [M + H] <sup>+</sup>. HRMS: calcd for C<sub>20</sub>H<sub>22</sub>ClN<sub>7</sub>O<sub>3</sub>S [M + H], 476.1272; found 476.1268.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 2-Amino-<i>N</i>-(3-((5-chloro-4-(4-(methylsulfonyl)-3,4-dihydroquinoxalin-1(2<i>H</i>)-yl)pyrimidin-2-yl)amino)phenyl)acetamide (<b>19</b>)</h5><div class="NLM_p last">Off-white solid (53%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>/MeOD) δ 8.13 (s, 1H), 8.09 (s, 1H), 7.67 (dd, <i>J</i> = 7.7, 1.9 Hz, 1H), 7.22 (dd, <i>J</i> = 12.5, 5.0 Hz, 2H), 7.11–7.02 (m, 3H), 6.78 (dd, <i>J</i> = 7.6, 1.8 Hz, 1H), 4.16 (t, <i>J</i> = 6.1 Hz, 2H), 3.99 (t, <i>J</i> = 6.2 Hz, 2H), 3.40 (s, 2H), 2.85 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ171.1, 158.2, 158.0, 157.9, 139.7, 138.1, 135.4, 129.2, 128.9, 125.6, 125.2, 124.1, 120.5, 115.0, 113.7, 110.3, 109.7, 48.0, 47.2, 44.6, 37.3. MS (ESI) <i>m</i>/<i>z</i> 488 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>21</sub>H<sub>22</sub>ClN<sub>7</sub>O<sub>3</sub>S [M + H], 488.1272; found 488.1280.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> (<i>S</i>)-2-Amino-<i>N</i>-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)propanamide (<b>21</b>)</h5><div class="NLM_p last">Off-white solid (69%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.62 (s, 1H), 9.49 (s, 1H), 8.61 (d, <i>J</i> = 8.2 Hz, 1H), 8.18 (s, 1H), 7.94–7.84 (m, 2H), 7.64–7.56 (m, 1H), 7.47–7.39 (m, 2H), 7.24 (ddd, <i>J</i> = 8.1, 7.5, 3.0 Hz, 3H), 3.63 (q, <i>J</i> = 7.0 Hz, 1H), 3.31–3.21 (m, 1H), 1.95 (s, 2H), 1.43 (d, <i>J</i> = 7.0 Hz, 3H), 1.32 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 173.7, 157.5, 155.2, 155.1, 139.8, 138.3, 134.5, 131.1, 129.2, 124.3, 123.4, 123.0, 115.5, 113.7, 110.8, 106.4, 55.5, 51.1, 21.5, 15.3. MS (ESI) <i>m</i>/<i>z</i> 489 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>22</sub>H<sub>26</sub>ClN<sub>6</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 489.1476; found 489.1487.</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> (<i>S</i>)-2-Amino-<i>N</i>-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-3-methylbutanamide (<b>22</b>)</h5><div class="NLM_p last">Off-white solid (65%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.59 (s, 1H), 8.72 (d, <i>J</i> = 8.1 Hz, 1H), 8.30 (s, 1H), 7.84 (dd, <i>J</i> = 7.8, 1.5 Hz, 2H), 7.72 (t, <i>J</i> = 7.9 Hz, 1H), 7.37 (dd, <i>J</i> = 14.3, 7.2 Hz, 2H), 7.27 (d, <i>J</i> = 8.2 Hz, 1H), 7.18 (t, <i>J</i> = 8.0 Hz, 1H), 3.50–3.43 (m, 1H), 3.11 (d, <i>J</i> = 5.3 Hz, 1H), 1.94 (dd, <i>J</i> = 12.5, 6.6 Hz, 1H), 1.17 (d, <i>J</i> = 6.8 Hz, 6H), 0.92 (d, <i>J</i> = 6.8 Hz, 3H), 0.84 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 174.1, 158.1, 155.6, 140.7, 139.4, 138.5, 135.4, 131.3, 129.0, 124.3, 123.9, 115.5, 113.8, 111.4, 105.4, 61.0, 55.3, 32.1, 20.1, 17.6, 15.3. MS (ESI) <i>m</i>/<i>z</i> 517 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>24</sub>H<sub>30</sub>ClN<sub>6</sub>O<sub>3</sub>S [M + H], 517.1789; found 517.1790.</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 1-Amino-<i>N</i>-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)cyclopropanecarboxamide (<b>23</b>)</h5><div class="NLM_p last">Off-white solid (62%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.95 (s, 1H), 9.59 (s, 1H), 9.53 (s, 1H), 8.68 (d, <i>J</i> = 8.1 Hz, 1H), 8.31 (s, 1H), 7.90 (s, 1H), 7.84 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 7.72 (t, <i>J</i> = 7.8 Hz, 1H), 7.40–7.29 (m, 2H), 7.26 (d, <i>J</i> = 8.2 Hz, 1H), 7.18 (t, <i>J</i> = 8.0 Hz, 1H), 3.50–3.41 (m, 1H), 1.39 (s, 2H), 1.17 (d, <i>J</i> = 6.8 Hz, 6H), 1.16–1.13 (m, 2H), 0.89 (dd, <i>J</i> = 6.9, 3.6 Hz, 2H). <sup>13</sup>C NMR (126 MHz, DMSO) δ173.6, 157.6, 155.2, 154.7, 140.2, 138.7, 137.9, 134.9, 130.9, 128.5, 124.0, 123.5, 115.0, 113.1, 110.7, 104.8, 54.8, 36.0, 26.3, 18.1, 14.8. MS (ESI) <i>m</i>/<i>z</i> 501 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>23</sub>H<sub>26</sub>ClN<sub>6</sub>O<sub>3</sub>S [M + H], 501.1476; found 501.1479.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 2-Amino-<i>N</i>-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-2-methylpropanamide (<b>24</b>)</h5><div class="NLM_p last">White solid (65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.88 (s, 1H), 9.63 (s, 1H), 8.62 (d, <i>J</i> = 8.3 Hz, 1H), 8.20 (s, 1H), 7.93–7.87 (m, 2H), 7.61 (t, <i>J</i> = 7.2 Hz, 1H), 7.41 (d, <i>J</i> = 7.6 Hz, 1H), 7.34 (s, 1H), 7.24 (t, <i>J</i> = 5.1 Hz, 2H), 3.26 (dt, <i>J</i> = 13.8, 6.8 Hz, 1H), 1.45 (s, 6H), 1.33 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ175.7, 157.6, 155.3, 155.2, 139.8, 138.7, 138.3, 134.5, 131.1, 129.2, 124.4, 123.4, 123.0, 115.4, 113.7, 110.7, 106.5, 55.6, 55.3, 29.2, 15.3. MS (ESI) <i>m</i>/<i>z</i> 503 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>23</sub>H<sub>27</sub>ClN<sub>6</sub>O<sub>3</sub>S [M + H], 503.1632; found 503.1642.</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> (<i>S</i>)-2-Amino-<i>N</i>-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-3-(1<i>H</i>-imidazol-4-yl)propanamide (<b>25</b>)</h5><div class="NLM_p last">Off-white solid (42%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.62 (s, 2H), 8.58 (d, <i>J</i> = 8.2 Hz, 1H), 8.15 (s, 1H), 7.92–7.77 (m, 2H), 7.56 (s, 2H), 7.38 (d, <i>J</i> = 7.3 Hz, 1H), 7.20 (s, 3H), 6.87 (s, 1H), 3.74 (s, 1H), 3.49 (s, 1 H) 3.25 (m, 2H), 3.07 (m, 2H), 1.31 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 172.9, 157.5, 155.2, 155.0, 139.9, 138.3, 138.2, 135.2,134.5, 131.2, 129.2, 124.2, 123.3, 123.1, 115.8, 113.9, 110.0, 106.5, 55.6, 55.5, 29.7, 15.3. MS (ESI) <i>m</i>/<i>z</i> 555[M + H] <sup>+</sup>. HRMS: calcd for C<sub>25</sub>H<sub>28</sub>ClN<sub>8</sub>O<sub>3</sub>S [M + H],: 555.1688; found 555.1688.</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 3-Amino-<i>N</i>-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)propanamide (<b>26</b>)</h5><div class="NLM_p last">Off-white solid (45%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.02 (s, 1H), 9.62 (s, 1H), 8.62 (d, <i>J</i> = 7.8 Hz, 1H), 8.16 (s, 1H), 7.89 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.79 (s, 1H), 7.63–7.55 (m, 2H), 7.41 (d, <i>J</i> = 8.0 Hz, 1H), 7.23 (ddd, <i>J</i> = 8.0, 3.2, 1.8 Hz, 2H), 7.16 (d, <i>J</i> = 8.3 Hz, 1H), 3.25 (dt, <i>J</i> = 13.7, 6.9 Hz, 1H), 3.14–3.04 (m, 2H), 2.51–2.44 (m, 2H), 1.89 (s, 2H), 1.32 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.6, 157.7, 154.8, 154.6, 139.3, 138.5, 137.9, 134.0, 130.7, 128.7, 123.9, 123.0, 122.6, 115.0, 113.7, 110.9, 105.9, 55.1, 38.3, 37.4, 14.8. MS (ESI) <i>m</i>/<i>z</i> 489 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>22</sub>H<sub>25</sub>ClN<sub>6</sub>O<sub>3</sub>S [M + H], 489.1476; found 489.1476.</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 4-Amino-<i>N</i>-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)butanamide (<b>27</b>)</h5><div class="NLM_p last">White solid (48%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.06 (s, 1H), 8.60 (d, <i>J</i> = 8.3 Hz, 1H), 8.11 (s, 1H), 7.87 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 7.73 (s, 1H), 7.67 (s, 1H), 7.56 (t, <i>J</i> = 7.2 Hz, 1H), 7.43 (d, <i>J</i> = 7.3 Hz, 1H), 7.24–7.12 (m, 3H), 3.66 (s, 2H), 3.27–3.19 (m, 1H), 2.89 (t, <i>J</i> = 6.5 Hz, 2H), 2.49 (t, <i>J</i> = 6.9 Hz, 2H), 1.95–1.88 (m, 2H), 1.30 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.0, 157.1, 154.7, 154.5, 139.3, 138.4, 137.8, 134.0, 130.7, 128.6, 123.8, 122.9, 122.6, 115.3, 113.7, 110.9, 105.9, 55.2, 40.0, 34.3, 25.9, 14.8. MS (ESI) <i>m</i>/<i>z</i> 503 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>23</sub>H<sub>27</sub>ClN<sub>6</sub>O<sub>3</sub>S [M + H], 503.1632; found 503.1629.</div></div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Synthesis of <i>N</i>-(2-((3-((5-Chloro-4-((2-(methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)amino)-2-oxoethyl)pyrrolidine-1-carboxamide (<b>12</b>)</h4><div class="NLM_p last">A solution of pyrrolidine-1-carbonyl chloride (27 mg, 0.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> was added to the solution of compound <b>10</b> (42 mg, 0.1 mmol) and Et<sub>3</sub>N (40 mg, 0.4 mmol) in CH<sub>2</sub>Cl<sub>2</sub> at 0 °C. The mixture was stirred for 5 h, poured into water, and then extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and purified by chromatography to afford the corresponding product <b>12</b> as a white solid in 48% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>+CD<sub>3</sub>OD) δ 8.74 (d, <i>J</i> = 8.4 Hz, 1H), 8.08 (s, 1H), 7.68 (s, 1H), 7.54 (s, 1H), 7.44 (d, <i>J</i> = 7.5 Hz, 1H), 7.25 (m, 2H), 7.13 (m, 2H), 6.95 (t, <i>J</i> = 7.3 Hz, 1H), 5.57 (s, 1H), 3.81 (s, 2H), 3.25 (s, 4H), 2.86 (d, <i>J</i> = 3.9 Hz, 3H), 1.81 (s, 4H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 169.1, 168.9, 157.7, 156.5, 154.9, 154.4, 140.4, 139.3, 139.0, 131.6, 128.4, 127.9, 121.8, 121.2, 120.4, 115.0, 113.2, 111.1, 105.2, 45.3, 44.1, 26.3, 25.0. MS (ESI) <i>m</i>/<i>z</i> 545 [M + Na]<sup>+</sup>. HRMS: calcd for C<sub>25</sub>H<sub>27</sub>ClN<sub>8</sub>O<sub>3</sub> [M + Na], 545.1792; found 545.1799.</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Synthesis of Pyrimidin-2-yl(amino)-<i>N</i>-(2-((3-(5-chloro-4-(2-(methylcarbamoyl)phenyl)amino)phenyl)amino)-2-oxoethyl)pyrrolidine-2-carboxamide (<b>13</b>)</h4><div class="NLM_p last">TBTU (128 mg, 0.4 mmol) and DIPEA (103 mg, 0.8 mmol) were added successively to a solution Boc-<span class="smallcaps smallerCapital">l</span>-proline (43 mg, 0.3 mmol) and compound <b>10</b> (85 mg, 0.2 mmol) in DMF (3 mL). The reaction was stirred overnight at rt and then diluted with water (8 mL). After filtration, the filter cake was dried to provide <i>tert</i>-butyl 2-((2-((3-((5-chloro-4-((2-(methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)amino)-2-oxoethyl)carbamoyl)pyrrolidine-1-carboxylate as a crude product. The crude compound was then dissolved in a mixed solvent system (CH<sub>2</sub>Cl<sub>2</sub>/TFA = 1:1, 5 mL), and the mixture was stirred at rt for 2 h. After removal of the solvent, the residue was taken up in water (5 mL), alkalified with NaHCO<sub>3</sub> to pH > 7, and then extracted with CHCl<sub>3</sub>.The combined organic layer was washed with brine (10 mL), dried, filtered, and then evaporated. The residue was subjected to column chromatography on silica gel (CHCl<sub>3</sub>/MeOH, 20/1) to give compound <b>13</b> as a white solid in 67% yield. <sup>1</sup>H NMR (400 MHz, DMSO) δ 11.71 (s, 1H), 9.98 (s, 1H), 9.50 (s, 1H), 8.80 (dd, <i>J</i> = 18.6, 6.3 Hz, 2H), 8.30 (t, <i>J</i> = 5.5 Hz, 1H), 8.22 (s, 1H), 7.83 (s, 1H), 7.76 (d, <i>J</i> = 7.6 Hz, 1H), 7.44 (dd, <i>J</i> = 19.7, 7.3 Hz, 2H), 7.21 (d, <i>J</i> = 7.6 Hz, 2H), 7.13 (t, <i>J</i> = 7.5 Hz, 1H), 3.92 (d, <i>J</i> = 5.8 Hz, 2H), 3.63 (dd, <i>J</i> = 8.8, 5.4 Hz, 1H), 2.89 (dd, <i>J</i> = 11.6, 5.0 Hz, 1H), 2.81 (d, <i>J</i> = 4.3 Hz, 3H), 2.04–1.92 (m, 2H), 1.73 (dd, <i>J</i> = 12.5, 5.7 Hz, 1H), 1.63 (dd, <i>J</i> = 6.7, 3.7 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.4, 168.9, 167.4, 157.7, 154.9, 154.4, 140.5, 139.3, 138.8, 131.5, 128.5, 127.8, 121.8, 121.2, 120.4, 115.1, 113.1, 111.0, 105.2, 60.0, 46.6, 42.3, 30.2, 26.2, 25.6. MS (ESI) <i>m</i>/<i>z</i> 523 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>25</sub>H<sub>28</sub>ClN<sub>8</sub>O<sub>3</sub> [M + H], 523.1973; found 523.1969.</div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Synthesis of <i>tert-</i>Butyl (2-((3-((5-Chloro-4-((2-fluoro-6-(methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)amino)-2-oxoethyl)carbamate (<b>11</b>)</h4><div class="NLM_p last">A microwave tube was charged with <b>8b</b> (66 mg, 0.22 mmol), <b>9a</b> (53 mg, 0.2 mmol), Pd (OAc)<sub>2</sub> (7 mg, 0.03 mmol), X-Phos (35 mg, 0.06 mmol), Cs<sub>2</sub>CO<sub>3</sub> (160 mg, 0.5 mmol), and 1,4-dioxane (3 mL) under N<sub>2</sub> atmosphere. The mixture was heated to 100 °C under 80 W for 1.5 h and then concentrated in vacuum. The residue was taken up in water and CHCl<sub>3</sub>. The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo, and the residue was purified by chromatography to afford compound <b>11</b> as an off-white solid in 52% yield. <sup>1</sup>H NMR (300 MHz, DMSO) δ 9.73 (s, 1H), 9.29 (s, 2H), 8.52 (d, <i>J</i> = 4.6 Hz, 1H), 8.15 (s, 1H), 7.53–7.42 (m, 3H), 7.38 (dd, <i>J</i> = 7.3, 4.5 Hz, 1H), 7.29 (d, <i>J</i> = 8.3 Hz, 1H), 7.11 (d, <i>J</i> = 8.1 Hz, 1H), 7.06–6.93 (m, 2H), 3.68 (d, <i>J</i> = 5.9 Hz, 2H), 3.33 (s, 1H), 2.71 (d, <i>J</i> = 4.5 Hz, 3H), 1.37 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 168.4, 167.6, 158.3, 158.2, 156.5, 156.4, 156.3, 154.9, 140.9, 139.2, 132.2, 128.7, 126.9, 126.8, 125.8, 125.7, 124.1, 118.7, 118.6, 114.5, 113.3, 110.6, 105.0, 78.4, 44.1, 28.6, 26.6. MS (ESI) <i>m</i>/<i>z</i> 566 [M + Na]<sup>+</sup>. HRMS: calcd for C<sub>25</sub>H<sub>27</sub>ClN<sub>7</sub>O<sub>4</sub>F [M + Na], 566.1695; found 566.1696.</div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Synthesis of <i>tert</i>-Butyl 2-((2-((3-(2-(3-(<i>tert</i>-Butyl)ureido)acetamido)phenyl)amino)-5-chloropyrimidin-4-yl)amino)-3-fluoro-<i>N</i>-methylbenzamide (<b>14</b>)</h4><div class="NLM_p last">Amine <b>15</b> (54 mg, 0.1 mmol) was dissolved in a mixed solvent system (CH<sub>2</sub>Cl<sub>2</sub>/TFA = 1:1, 5 mL) and stirred at rt for 2 h. After removal of the solvent, the residue was taken up in water (5 mL), alkalified with NaHCO<sub>3</sub> to pH > 7, and then extracted with CHCl<sub>3</sub>. The combined organic layer was washed with brine, dried, filtered, and then evaporated. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5 mL), and 2-isocyanato-2-methylpropane (30 mg, 0.3 mmol) was added. The mixture was stirred for 24 h at rt and extracted with water and CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layer was washed with brine, dried, filtered, and then evaporated. The residue was purified by chromatography to afford compound <b>14</b> as an off-white solid in 47% yield. <sup>1</sup>H NMR (300 MHz, DMSO) δ 9.77 (s, 1H), 9.29 (d, <i>J</i> = 4.9 Hz, 2H), 8.52 (d, <i>J</i> = 4.6 Hz, 1H), 8.15 (s, 1H), 7.56–7.41 (m, 3H), 7.37 (dd, <i>J</i> = 7.4, 4.5 Hz, 1H), 7.28 (d, <i>J</i> = 8.2 Hz, 1H), 7.11 (d, <i>J</i> = 8.2 Hz, 1H), 6.97 (t, <i>J</i> = 8.1 Hz, 1H), 6.04 (s, 1H), 5.93 (t, <i>J</i> = 5.4 Hz, 1H), 3.76 (d, <i>J</i> = 5.4 Hz, 2H), 2.71 (d, <i>J</i> = 4.5 Hz, 3H), 1.20 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 169.3, 167.6, 158.3, 157.7, 156.4, 154.9, 140.9, 139.1, 132.2, 128.7, 126.9, 125.8, 125.7, 124.1, 118.7, 114.6, 113.4, 110.8, 105.0, 49.5, 43.5, 29.7, 26.6. MS (ESI) <i>m</i>/<i>z</i> 543 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>25</sub>H<sub>29</sub>ClN<sub>8</sub>O<sub>3</sub>F [M + H] 543.1957; found 543.2045.</div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Synthesis of 2-Chloro-<i>N</i>-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acetamide (<b>30</b>)</h4><div class="NLM_p last">To a crude compound <b>29</b> (417 mg, 1 mmol) and Et<sub>3</sub>N (404 mg, 4 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added dropwise a solution of 2-chloroacetyl chloride (224 mg, 2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL). The mixture was stirred at rt for 1 h. After being quenched with aqueous sodium bicarbonate, the mixture was extracted with ethyl acetate. The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was used directly without further purification.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> General Procedure for Synthesis of Compounds <b>31</b>, <b>32</b>, <b>46</b>, and <b>47</b></h4><div class="NLM_p">TBTU (64 mg, 0.2 mmol) and DIPEA (52 mg, 0.4 mmol) were added successively to a solution of an appropriate acid (0.15 mmol) and compound <b>30</b> (42 mg, 0.1 mmol) in DMF (2 mL). The reaction was stirred overnight at rt, diluted with water (8 mL), and extracted with CHCl<sub>3</sub>. The combined organic layers were washed with brine (10 mL) and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration, the solvents were evaporated. The residue was subjected to column chromatography on silica gel (CHCl<sub>3</sub>/MeOH, 20/1) to give the expected compound.</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> <i>N</i>-(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)azetidine-2-carboxamide (<b>31</b>)</h5><div class="NLM_p last">White solid (68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.64 (s, 1H), 9.58 (s, 1H), 8.62 (d, <i>J</i> = 8.5 Hz, 1H), 8.19 (s, 1H), 7.92 (dd, <i>J</i> = 8.0, 1.6 Hz, 2H), 7.64 (t, <i>J</i> = 7.1 Hz, 1H), 7.44 (dd, <i>J</i> = 7.6, 3.5 Hz, 1H), 7.28–7.18 (m, 2H), 4.46 (t, <i>J</i> = 8.5 Hz, 1H), 3.86 (q, <i>J</i> = 8.5 Hz, 1H), 3.37 (td, <i>J</i> = 8.3, 3.9 Hz, 1H), 3.27 (dt, <i>J</i> = 13.6, 6.8 Hz, 1H), 2.73 (d, <i>J</i> = 8.0 Hz, 1H), 2.51–2.40 (m, 1H), 1.34 (d, <i>J</i> = 6.4 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.0, 157.5, 155.3, 155.1, 139.8, 138.3, 138.2, 134.5, 131.2, 129.3, 124.5, 123.4, 123.1, 115.6, 113.8, 110.6, 106.6, 59.5, 55.6, 43.4, 26.5, 15.3, 15.3. MS (ESI) <i>m</i>/<i>z</i> 501 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>23</sub>H<sub>25</sub>ClN<sub>6</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 501.1476; found 501.1476.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> <i>N</i>-(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)azetidine-3-carboxamide (<b>32</b>)</h5><div class="NLM_p last">White solid (63%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub><b>+</b>MeOD) δ 8.58 (s, 1H), 8.06 (d, <i>J</i> = 3.9 Hz, 1H), 7.83 (s, 1H), 7.66 (s, 1H), 7.55 (s, 1H), 7.42 (s, 1H), 7.20 (s, 3H), 3.75 (s, 1H), 3.62 (d, <i>J</i> = 6.3 Hz, 1H), 3.21 (s, 1H), 3.10–2.92 (m, 2H), 2.84 (s, 1H), 1.26 (d, <i>J</i> = 4.0 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 170.2, 157.5, 155.2, 154.8, 139.6, 138.4, 138.1, 134.6, 131.1, 129.1, 124.0, 123.4, 123.2, 116.3, 114.4, 111.6, 106.1, 55.6, 50.4, 43.1, 41.2, 15.1. MS (ESI) <i>m</i>/<i>z</i> 501[M + H]<sup>+</sup>. HRMS: calcd for C<sub>23</sub>H<sub>26</sub>ClN<sub>6</sub>O<sub>3</sub>S [M + H], 501.1471; found 501.1470.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> <i>N</i>-(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-2-(furan-2-yl)acetamide (<b>46</b>)</h5><div class="NLM_p last">White solid (78%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.13 (s, 1H), 9.57 (d, <i>J</i> = 16.3 Hz, 2H), 8.69 (d, <i>J</i> = 7.9 Hz, 1H), 8.30 (s, 1H), 7.90–7.80 (m, 2H), 7.69 (s, 1H), 7.57 (s, 1H), 7.36 (t, <i>J</i> = 6.0 Hz, 2H), 7.19 (d, <i>J</i> = 7.8 Hz, 2H), 6.40 (s, 1H), 6.26 (d, <i>J</i> = 3.0 Hz, 1H), 3.72 (s, 2H), 3.50–3.40 (m, 1H), 1.17 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.9, 158.0, 155.5, 155.1, 149.9, 142.4, 139.7, 138.3, 135.2, 131.4, 128.9, 124.3, 124.1, 123.8, 115.7, 113.7, 111.4, 110.9, 108.0, 105.3, 55.3, 36.5, 15.3. MS (ESI) <i>m</i>/<i>z</i> 526 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>25</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>4</sub>S [M +H], 526.1316; found 526.1315.</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> <i>N</i>-(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-2-(1<i>H</i>-indol-2-yl)acetamide (<b>47</b>)</h5><div class="NLM_p last">White solid (72%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub><b>+</b>MeOD) δ 8.48 (d, <i>J</i> = 8.4 Hz, 1H), 8.02 (s, 1H), 7.78 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.49 (dd, <i>J</i> = 16.2, 9.8 Hz, 3H), 7.33 (dd, <i>J</i> = 12.5, 4.6 Hz, 2H), 7.15–7.02 (m, 5H), 6.93 (d, <i>J</i> = 8.0 Hz, 1H), 3.78 (s, 2H), 3.15 (dd, <i>J</i> = 13.7, 6.8 Hz, 1H), 1.22 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 170.6, 157.4, 155.1, 154.7, 139.5, 138.0, 136.4, 134.5, 131.0, 129.0, 126.7, 124.1, 123.4, 123.2, 122.3, 119.8, 118.3, 116.3, 114.5, 111.7, 111.6, 107.6, 55.6, 34.3, 15.2. MS (ESI) <i>m</i>/<i>z</i> 573 [M – H]. HRMS: calcd for (C<sub>29</sub>H<sub>26</sub>N<sub>6</sub>O<sub>3</sub>ClS), 573.1470; found 573.1480.</div></div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Synthesis of <i>N</i>-(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-1-(4-(dimethylamino)butanoyl)azetidine-3-carboxamide (<b>33</b>)</h4><div class="NLM_p last">TBTU (128 mg, 0.4 mmol) and DIPEA (103 mg, 0.8 mmol) were added successively to a solution (<i>E</i>)-4-(dimethylamino)but-2-enoic acid (39 mg, 0.3 mmol) and compound <b>29</b> (100 mg, 0.2 mmol) in DMF (3 mL). The reaction was stirred overnight at rt and then diluted with water (8 mL). After filtration, the filter cake was dried. The residue was dissolved in MeOH (10 mL), and 10% Pd/C (15%) was added. The mixture was stirred for 2 h under H<sub>2</sub> atmosphere and then filtered. The filtrate was concentrated in vacuum, and the residue was subjected to column chromatography on silica gel (CHCl<sub>3</sub>/MeOH, 20/1) to give compound <b>33</b> (white solid, 65%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.61 (s, 1H), 8.59 (d, <i>J</i> = 12.7 Hz, 2H), 8.12 (s, 1H), 7.86 (d, <i>J</i> = 7.2 Hz, 1H), 7.75 (s, 1H), 7.58 (d, <i>J</i> = 18.1 Hz, 2H), 7.41 (s, 1H), 7.20 (s, 3H), 4.42 (d, <i>J</i> = 5.3 Hz, 1H), 4.18 (d, <i>J</i> = 28.9 Hz, 3H), 3.45 (s, 1H), 3.31–3.12 (m, 1H), 2.30 (d, <i>J</i> = 6.6 Hz, 2H), 2.21 (s, 6H), 2.11 (d, <i>J</i> = 6.7 Hz, 2H), 1.76 (d, <i>J</i> = 6.2 Hz, 2H), 1.29 (s, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 173.2, 169.9, 157.5, 155.2, 155.0, 139.9, 138.4, 134.5, 131.2, 129.2, 124.1, 123.3, 123.1, 116.1, 114.3, 111.4, 106.5, 58.7, 55.6, 52.2, 50.8, 45.1, 33.7, 28.7, 22.3, 15.3. MS (ESI) <i>m</i>/<i>z</i> 612 [M – H]. HRMS: calcd for C<sub>29</sub>H<sub>35</sub>N<sub>4</sub>O<sub>7</sub>ClS [M – H], 612.2154; found 612.2160.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> General Procedure for Synthesis of Compounds <b>34</b>–<b>37</b> and <b>40</b>–<b>44</b></h4><div class="NLM_p">An appropriate amine (0.2 mmol), Et<sub>3</sub>N (1 mmol), and K<sub>2</sub>CO<sub>3</sub> (1.2 mmol) were added successively to a solution of compound <b>30</b> (0.1 mmol) in MeCN (10 mL). The reaction was heated to reflux overnight. After removal of the solvent, the residue was diluted with water and extracted with CHCl<sub>3</sub>.The combined organic layers were washed with brine, dried, filtered, and then evaporated. The residue was subjected to column chromatography on silica gel (CHCl<sub>3</sub>/MeOH, 20/1) to give the expected compound.</div><div id="sec5_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> <i>N</i>-(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-2-morpholinoacetamide (<b>34</b>)</h5><div class="NLM_p last">White solid (61%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.66 (s, 1H), 9.07 (s, 1H), 8.62 (d, <i>J</i> = 8.4 Hz, 1H), 8.19 (s, 1H), 7.92 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 7.87 (t, <i>J</i> = 1.9 Hz, 1H), 7.65–7.58 (m, 1H), 7.50 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.29 (d, <i>J</i> = 8.8 Hz, 1H), 7.28–7.22 (m, 2H), 7.12 (dd, <i>J</i> = 8.0, 1.3 Hz, 1H), 3.82–3.73 (m, 4H), 3.31–3.21 (m, 1H), 3.15 (s, 2H), 2.67–2.60 (m, 4H), 1.33 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.9, 157.4, 155.2, 155.0, 139.9, 138.3, 137.9, 134.4, 131.2, 129.3, 124.4, 123.3, 123.0, 115.8, 113.7, 110.8, 106.7, 66.9, 62.4, 55.6, 53.7, 15.3. MS (ESI) <i>m</i>/<i>z</i> 545[M + H]<sup>+</sup>. HRMS: calcd for C<sub>25</sub>H<sub>30</sub>ClN<sub>6</sub>O<sub>4</sub>S [M + H], 545.1738; found 545.1732.</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> <i>N</i>-(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-2-((2<i>S</i>,6<i>R</i>)-2,6-dimethylmorpholino)acetamide (<b>35</b>)</h5><div class="NLM_p last">White solid (65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.67 (s, 1H), 9.08 (s, 1H), 8.63 (d, <i>J</i> = 8.4 Hz, 1H), 8.20 (s, 1H), 7.94–7.85 (m, 2H), 7.62 (t, <i>J</i> = 7.9 Hz, 1H), 7.50 (dd, <i>J</i> = 7.9, 1.7 Hz, 1H), 7.29–7.23 (m, 2H), 7.12 (dd, <i>J</i> = 8.0, 1.2 Hz, 1H), 3.72 (ddd, <i>J</i> = 10.0, 6.2, 2.0 Hz, 2H), 3.30–3.22 (m, 1H), 3.12 (s, 2H), 2.76 (d, <i>J</i> = 10.4 Hz, 2H), 2.08–2.01 (m, 2H), 1.33 (d, <i>J</i> = 6.9 Hz, 6H), 1.20 (d, <i>J</i> = 6.3 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.1, 157.5, 155.3, 155.1, 139.9, 138.3, 138.0, 134.5, 131.2, 129.3, 124.4, 123.3, 123.1, 115.7, 113.6, 110.8, 106.7, 71.9, 62.0, 59.4, 55.6, 18.9, 15.3. MS (ESI) <i>m</i>/<i>z</i>: 573 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>27</sub>H<sub>33</sub>ClN<sub>6</sub>O<sub>4</sub>S [M + H], 573.2051; found 573.2052.</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> <i>N</i>-(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-2-(piperazin-1-yl)acetamide (<b>36</b>)</h5><div class="NLM_p last">White solid (53%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.65 (s, 1H), 9.16 (s, 1H), 8.62 (d, <i>J</i> = 8.4 Hz, 1H), 8.19 (s, 1H), 7.91 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.86 (s, 1H), 7.61 (s, 1H), 7.50 (d, <i>J</i> = 8.1 Hz, 1H), 7.30 (s, 1H), 7.24 (d, <i>J</i> = 7.4 Hz, 1H), 7.12 (d, <i>J</i> = 7.9 Hz, 1H), 3.26 (dt, <i>J</i> = 13.8, 6.9 Hz, 1H), 3.12 (s, 2H), 2.99–2.92 (m, 4H), 2.60 (d, <i>J</i> = 4.3 Hz, 4H), 1.33 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.4, 157.4, 155.2, 155.1, 139.9, 138.3, 138.0, 134.4, 131.2, 129.3, 124.4, 123.4, 123.0, 115.7, 113.7, 110.8, 106.6, 62.6, 55.6, 54.6, 46.2, 15.3. MS (ESI) <i>m</i>/<i>z</i> 544 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>25</sub>H<sub>30</sub>ClN<sub>7</sub>O<sub>3</sub>S [M + H], 544.1898; found 544.1889.</div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> <i>N-</i>(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-2-(4-methylpiperazin-1-yl)acetamide (<b>37</b>)</h5><div class="NLM_p last">Off-white solid (73%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.65 (s, 1H), 9.12 (s, 1H), 8.62 (d, <i>J</i> = 8.2 Hz, 1H), 8.19 (s, 1H), 7.91 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 7.86 (t, <i>J</i> = 1.9 Hz, 1H), 7.63–7.56 (m, 1H), 7.50 (dd, <i>J</i> = 7.9, 1.9 Hz, 1H), 7.40 (s, 1H), 7.30–7.27 (m, 1H), 7.23 (dd, <i>J</i> = 10.1, 2.9 Hz, 1H), 7.13–7.09 (m, 1H), 3.26 (dt, <i>J</i> = 13.7, 6.8 Hz, 1H), 3.14 (s, 2H), 2.66 (s, 4H), 2.51 (s, 3H), 2.34 (s, 3H), 2.26 (s, 1H), 1.33 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.3, 157.5, 155.2, 155.0, 139.9, 138.3, 138.0, 134.4, 131.1, 129.2, 124.3, 123.4, 123.0, 115.8, 113.7, 110.9, 106.5, 61.8, 55.6, 55.1, 53.3, 45.9, 15.3. MS (ESI) <i>m</i>/<i>z</i> 558 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>26</sub>H<sub>33</sub>ClN<sub>7</sub>O<sub>3</sub>S [M + H], 558.2054; found 558.2056.</div></div><div id="sec5_4_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> <i>N</i>-(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-2-(4-(2-hydroxyacetyl)piperazin-1-yl)acetamide (<b>40</b>)</h5><div class="NLM_p last">White solid (55%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>/MeOD) δ 8.54 (d, <i>J</i> = 8.4 Hz, 1H), 8.05 (s, 1H), 7.80 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.66 (s, 1H), 7.51 (t, <i>J</i> = 7.9 Hz, 1H), 7.40 (d, <i>J</i> = 8.2 Hz, 1H), 7.17 (td, <i>J</i> = 7.9, 4.9 Hz, 2H), 7.07 (d, <i>J</i> = 7.2 Hz, 1H), 4.10 (s, 2H), 3.64 (s, 2H), 3.30 (d, <i>J</i> = 5.1 Hz, 2H), 3.17 (dt, <i>J</i> = 13.7, 6.9 Hz, 1H), 3.10 (s, 2H), 2.58–2.52 (m, 4H), 1.23 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.2, 167.9, 157.4, 155.2, 154.8, 139.9, 138.1, 137.5, 134.5, 129.2, 123.1, 116.4, 114.0, 111.3, 106.2, 61.7, 59.6, 55.6, 52.9, 52.6, 43.4, 42.0, 15.1. MS (ESI) <i>m</i>/<i>z</i> 602 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>27</sub>H<sub>32</sub>ClN<sub>7</sub>O<sub>5</sub>S [M + H], 602.1952; found 602.1945.</div></div><div id="sec5_4_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 2-(2,5-Diazabicyclo[2.2.1]heptan-2-yl)-<i>N</i>-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acetamide (<b>41</b>)</h5><div class="NLM_p last">Off-white solid (47%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.64 (s, 1H), 9.20 (s, 1H), 8.62 (d, <i>J</i> = 8.4 Hz, 1H), 8.18 (s, 1H), 7.92–7.84 (m, 2H), 7.64–7.55 (m, 2H), 7.50–7.43 (m, 1H), 7.27–7.20 (m, 2H), 7.12 (d, <i>J</i> = 8.9 Hz, 1H), 3.65 (s, 1H), 3.40 (d, <i>J</i> = 5.9 Hz, 1H), 3.35 (s, 1H), 3.31–3.21 (m, 2H), 3.11 (d, <i>J</i> = 10.4 Hz, 1H), 2.99–2.91 (m, 2H), 2.68 (d, <i>J</i> = 9.6 Hz, 1H), 2.26 (s, 1H), 1.82 (d, <i>J</i> = 9.6 Hz, 1H), 1.66 (d, <i>J</i> = 9.8 Hz, 1H), 1.32 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 169.0, 157.5, 155.1, 155.0, 139.8, 138.2, 138.0, 134.4, 131.1, 129.1, 124.2, 123.3, 122.9, 115.7, 113.7, 110.9, 106.4, 63.3, 62.6, 59.6, 56.9, 55.5, 49.7, 36.2, 15.2. MS (ESI) <i>m</i>/<i>z</i> 556 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>26</sub>H<sub>30</sub>ClN<sub>7</sub>O<sub>3</sub>S [M + Na], 578.1717; found 578.1719.</div></div><div id="sec5_4_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> 2-(8-Oxa-3-azabicyclo[3.2.1]octan-3-yl)-<i>N</i>-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acetamide (<b>42</b>)</h5><div class="NLM_p last">Off-white solid (52%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.64 (s, 1H), 9.14 (s, 1H), 8.60 (d, <i>J</i> = 8.4 Hz, 1H), 8.20–8.11 (m, 1H), 7.89 (dd, <i>J</i> = 5.7, 1.9 Hz, 2H), 7.59 (dd, <i>J</i> = 10.8, 4.9 Hz, 1H), 7.47 (d, <i>J</i> = 7.9 Hz, 1H), 7.29 (d, <i>J</i> = 2.6 Hz, 1H), 7.22 (d, <i>J</i> = 2.6 Hz, 1H), 7.08 (d, <i>J</i> = 7.9 Hz, 1H), 4.35 (s, 2H), 3.29–3.18 (m, 1H), 3.06 (d, <i>J</i> = 2.2 Hz, 2H), 2.63 (s, 4H), 2.01 (s, 4H), 1.30 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.7, 157.0, 154.8, 154.6, 139.6, 137.9, 137.6, 134.0, 130.8, 129.0, 123.9, 122.9, 122.6, 115.2, 112.8, 110.0, 106.2, 73.9, 60.9, 58.2, 55.2, 28.1, 14.9. MS (ESI) <i>m</i>/<i>z</i> 571 [M +H]<sup>+</sup>. HRMS: calcd for C<sub>27</sub>H<sub>31</sub>ClN<sub>6</sub>O4S [M + Na], 593.1714; found 593.1713.</div></div><div id="sec5_4_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> <i>N</i>-(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-2-(3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)acetamide (<b>43</b>)</h5><div class="NLM_p last">Off-white solid (41%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.64 (s, 2H), 8.61 (d, <i>J</i> = 8.4 Hz, 1H), 8.15 (s, 1H), 7.89 (d, <i>J</i> = 7.9 Hz, 1H), 7.82 (s, 1H), 7.58 (t, <i>J</i> = 7.7 Hz, 1H), 7.48 (d, <i>J</i> = 8.1 Hz, 1H), 7.33 (s, 1H), 7.21 (d, <i>J</i> = 8.1 Hz, 1H), 7.12 (d, <i>J</i> = 7.7 Hz, 1H), 4.09 (s, 1H), 3.19 (s, 3H), 3.10 (s, 2H), 2.20 (d, <i>J</i> = 7.5 Hz, 2H), 2.13 (s, 1H), 2.09 (s, 1H), 2.04 (s, 1H), 1.96 (s, 2H), 1.79 (d, <i>J</i> = 14.6 Hz, 2H), 1.31 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 168.6, 157.1, 154.8, 154.5, 139.4, 137.9, 137.7, 134.0, 130.7, 128.8, 123.9, 122.9, 122.6, 115.4, 113.4, 110.5, 106.1, 63.5, 59.5, 55.2, 26.0, 14.8. MS (ESI) <i>m</i>/<i>z</i> 583 [M – H]. HRMS: calcd for C<sub>28</sub>H<sub>32</sub>ClN<sub>6</sub>O<sub>4</sub>S [M – H], 583.1889; found 583.1897.</div></div></div><div id="sec5_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Synthesis of <i>N</i>-(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-2-(4-(oxetan-3-yl)piperazin-1-yl)acetamide (<b>38</b>)</h4><div class="NLM_p last">To a solution of <b>37</b> (54 mg, 0.1 mmol) in MeOH (5 mL), oxetan-3-one (14 mg, 0.2 mmol) was added. The mixture was stirred for 1 h, NaHB(CN)<sub>3</sub> (25 mg, 0.4 mmol) was added, and the reaction was stirred overnight. The reaction was quenched with saturated NH<sub>4</sub>Cl. After the solvent was evaporated, the residue was diluted with water and then extracted with CHCl<sub>3</sub>. The combined organic layers were washed with brine, dried, filtered, and then evaporated. The crude product was subjected to column chromatography on silica gel (CHCl<sub>3</sub>/MeOH, 20/1) to give compound <b>38</b> (white solid, 64%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.66 (s, 1H), 9.07 (s, 1H), 8.62 (d, <i>J</i> = 8.5 Hz, 1H), 8.19 (s, 1H), 7.92 (dd, <i>J</i> = 7.9, 1.4 Hz, 1H), 7.87 (s, 1H), 7.63 (t, <i>J</i> = 7.9 Hz, 1H), 7.52 (d, <i>J</i> = 8.2 Hz, 1H), 7.25 (d, <i>J</i> = 7.6 Hz, 1H), 7.16–7.05 (m, 2H), 4.67 (dt, <i>J</i> = 24.3, 6.3 Hz, 4H), 3.60–3.51 (m, 1H), 3.27 (dt, <i>J</i> = 13.5, 6.8 Hz, 1H), 3.17 (s, 2H), 2.70 (s, 4H), 2.43 (s, 4H), 1.34 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 168.2, 157.4, 155.3, 155.1, 139.9, 138.3, 138.0, 134.5, 131.2, 129.4, 124.4, 123.4, 123.1, 115.7, 113.7, 110.8, 106.7, 75.4, 61.9, 59.0, 55.6, 53.0, 49.7, 15.3. MS (ESI) <i>m</i>/<i>z</i> 600 [M +H]<sup>+</sup>. HRMS: calcd for C<sub>28</sub>H<sub>34</sub>ClN<sub>7</sub>O<sub>4</sub>S [M + Na], 622.1979; found 622.1980.</div></div><div id="sec5_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Synthesis of (<i>E</i>)-<i>N</i>-(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-2-(4-(4-(dimethylamino)but-2-enoyl)piperazin-1-yl)acetamide (<b>39</b>)</h4><div class="NLM_p last">This compound was prepared from (<i>E</i>)-4-(dimethylamino)but-2-enoic acid (39 mg, 0.3 mmol) and compound <b>37</b> as an off-white solid in 78% yield by following a similar procedure as that for preparation of compound <b>33</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.66 (s, 1H), 8.99 (s, 1H), 8.62 (d, <i>J</i> = 8.4 Hz, 1H), 8.19 (s, 1H), 7.95–7.85 (m, 2H), 7.62 (t, <i>J</i> = 7.9 Hz, 1H), 7.50 (dd, <i>J</i> = 7.9, 1.7 Hz, 1H), 7.26 (dd, <i>J</i> = 10.0, 5.2 Hz, 2H), 7.12 (dd, <i>J</i> = 7.9, 1.2 Hz, 1H), 6.89 (dt, <i>J</i> = 15.2, 5.9 Hz, 1H), 6.45 (d, <i>J</i> = 15.2 Hz, 1H), 3.71 (d, <i>J</i> = 40.5 Hz, 4H), 3.26 (dt, <i>J</i> = 13.7, 6.9 Hz, 1H), 3.18 (s, 2H), 3.11 (dd, <i>J</i> = 5.9, 1.4 Hz, 2H), 2.67–2.60 (m, 4H), 2.29 (s, 6H), 1.33 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.6, 165.2, 157.4, 155.3, 155.1, 143.1, 140.0, 138.3, 137.9, 134.4, 131.2, 129.4, 124.4, 123.3, 123.1, 121.5, 115.8, 113.7, 110.8, 106.8, 61.9, 60.6, 55.6, 45.4, 15.3. MS (ESI) <i>m</i>/<i>z</i> 655 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>31</sub>H<sub>40</sub>ClN<sub>8</sub>O<sub>4</sub>S [M + H]<sup>+</sup>, 655.2852; found 655.2853.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> General Procedure for Synthesis of Compounds <b>44</b> and <b>45</b></h4><div class="NLM_p">An appropriate amine (0.2 mmol), Et<sub>3</sub>N (1 mmol), and K<sub>2</sub>CO<sub>3</sub> (1.2 mmol) were added successively to a solution of compound <b>30</b> (0.1 mmol) in MeCN (10 mL). The reaction was heated to reflux overnight. After removal of the solvent, the residue was diluted with water and extracted with CHCl<sub>3</sub>. The combined organic layers were washed with brine, dried, filtered, and then evaporated. The residue was then dissolved in a mixed solvent system (CH<sub>2</sub>Cl<sub>2</sub>/TFA = 1:1, 5 mL) and the mixture was stirred at rt for 2 h. After removal of the solvent, the residue was taken up in water (5 mL), alkalified with NaHCO<sub>3</sub> to pH > 7, and then extracted with CHCl<sub>3</sub>.The combined organic layer was washed with brine, dried, filtered, and then evaporated. The residue was subjected to column chromatography on silica gel (CHCl<sub>3</sub>/MeOH, 20/1) to give the corresponding product.</div><div id="sec5_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> <i>N</i>-(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-2-(hexahydropyrrolo[3,4-<i>b</i>]pyrrol-1(2<i>H</i>)-yl)acetamide (<b>45</b>)</h5><div class="NLM_p last">Off-white solid (48%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.64 (s, 1H), 9.26 (s, 1H), 8.62 (d, <i>J</i> = 8.3 Hz, 1H), 8.18 (s, 1H), 7.91 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.83 (s, 1H), 7.62 (dd, <i>J</i> = 11.4, 4.3 Hz, 1H), 7.52 (d, <i>J</i> = 7.9 Hz, 1H), 7.27–7.17 (m, 4H), 3.48 (d, <i>J</i> = 16.7 Hz, 1H), 3.23 (ddd, <i>J</i> = 11.0, 10.5, 4.7 Hz, 3H), 3.14–3.05 (m, 1H), 2.98 (t, <i>J</i> = 7.8 Hz, 1H), 2.87 (d, <i>J</i> = 6.3 Hz, 2H), 2.75 (s, 1H), 2.62 (dd, <i>J</i> = 11.5, 4.7 Hz, 1H), 2.43–2.35 (m, 1H), 2.14 (d, <i>J</i> = 13.7 Hz, 1H), 1.62–1.53 (m, 1H), 1.33 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 169.4, 157.5, 155.3, 155.1, 139.7, 138.3, 134.5, 131.2, 129.2, 124.3, 123.4, 123.1, 115.8, 114.3, 111.3, 106.6, 70.3, 58.8, 55.7, 55.6, 54.0, 52.4, 42.6, 32.4, 15.3. MS (ESI) <i>m</i>/<i>z</i> 570 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>27</sub>H<sub>33</sub>ClN<sub>7</sub>O<sub>3</sub>S [M + H], 570.2054; found 570.2052.</div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> <i>N</i>-(3-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)-2-(hexahydropyrrolo[3,4-<i>c</i>]pyrrol-2(1<i>H</i>)-yl)acetamide (<b>44</b>)</h5><div class="NLM_p last">Off-white solid (56%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.65 (s, 1H), 9.34 (s, 1H), 8.63 (d, <i>J</i> = 8.5 Hz, 1H), 8.16 (s, 1H), 7.91 (d, <i>J</i> = 6.4 Hz, 1H), 7.78 (s, 1H), 7.62 (t, <i>J</i> = 7.9 Hz, 1H), 7.54 (d, <i>J</i> = 8.1 Hz, 1H), 7.40 (s, 1H), 7.33 (d, <i>J</i> = 8.4 Hz, 1H), 7.25 (t, <i>J</i> = 7.8 Hz, 2H), 3.31–3.24 (m, 3H), 3.22 (s, 2H), 3.01 (d, <i>J</i> = 11.2 Hz, 2H), 2.87 (s, 2H), 2.80 (d, <i>J</i> = 9.6 Hz, 2H), 2.61 (d, <i>J</i> = 6.2 Hz, 2H), 1.33 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.6, 157.5, 155.3, 155.0, 139.8, 138.4, 138.3, 134.6, 131.2, 129.2, 124.3, 123.5, 123.1, 115.8, 114.3, 111.3, 106.5, 60.4, 58.9, 55.6, 53.4, 42.4, 15.3. MS (ESI) <i>m</i>/<i>z</i> 570 [M + H]<sup>+</sup>. HRMS: calcd for C<sub>27</sub>H<sub>32</sub>ClN<sub>7</sub>O<sub>3</sub>S [M + H], 570.2054; found 570.2051.</div></div></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> ELISA Kinase Assay</h3><div class="NLM_p last">Kinase activity was evaluated according to the following procedure. Briefly, in enzyme-linked-immunosorbent assay (ELISA), 20 μg/mL poly(Glu, Tyr)<sub>4:1</sub> (Sigma) was precoated as a substrate in 96-well plates. ATP solution (50 μL of 10 μM) diluted in kinase reaction buffer (50 mM HEPES, pH 7.4, 50 mM MgCl<sub>2</sub>, 0.5 mM MnCl<sub>2</sub>, 0.2 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM DTT) was added to each well. One microliter of various concentrations of tested compounds diluted in 1% DMSO (v/v) (Sigma) was added to each reaction well. DMSO (1% v/v) was used as the negative control. The kinase reaction was initiated after the addition of purified tyrosine kinase proteins diluted in 49 μL of kinase reaction buffer solution. After incubation for 60 min at 37 °C, the plate was washed three times with phosphate buffered saline (PBS) containing 0.1% Tween 20 (T-PBS). Anti-phosphotyrosine (PY99) antibody (100 μL, 1:500 diluted in 5 mg/mL BSA T-PBS) was then added. After 30 min incubation at 37 °C, the plate was washed three times. Horseradish peroxidase-conjugated goat anti-mouse IgG (100 μL, 1:2000 diluted in 5 mg/mL BSA T-PBS) was added. The plate was then incubated at 37 °C for 30 min and washed 3 times. A solution (100 μL) containing 0.03% H<sub>2</sub>O<sub>2</sub> and 2 mg/mL <i>o</i>-phenylenediamine in 0.1 mol/L citrate buffer, pH 5.5, was added. The reaction was terminated by the addition of 50 μL of 2 mol/L H<sub>2</sub>SO<sub>4</sub> as color changed, and the plate was read using a multiwell spectrophotometer (SpectraMAX 190, Molecular Devices) at 490 nm. The inhibition rate (%) was calculated using the following equation: [1 – <i>A</i><sub>490</sub>/(<i>A</i><sub>490</sub> control)] × 100%. IC<sub>50</sub> values were calculated from the inhibition curves from two separate experiments.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Cell Proliferation Assay</h3><div class="NLM_p last">Cells were seeded in 96-well tissue culture plates. On the next day, cells were exposed to various concentrations of compounds and further cultured for 72 h. Cell proliferation was then determined using sulforhodamine B (SRB, Sigma) or thiazolyl blue tetrazolium bromide (MTT, Sigma) assay. IC<sub>50</sub> values were calculated by concentration–response curve fitting using the four-parameter method.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> In Vivo Antitumor Activity Assay</h3><div class="NLM_p last">Female nude mice (4–6 weeks) were housed five mice per cage in a specific pathogen-free room with a 12 h light/dark schedule at 25 ± 1 °C and were feed an autoclaved chow diet and water ad libitum. All animal experiments were performed according to institutional ethinical guidelines of animal care. The cells at a density of (5–10) × 10<sup>6</sup> in 200 μL were first implanted sc into the right flank of each nude mouse and then allowed to grow to 700–800 mm<sup>3</sup>, defined as a well-developed tumor. After that, the well-developed tumors were cut into 1 mm<sup>3</sup> fragments and transplanted sc into the right flank of nude mice using a trocar. When the tumor volume reached 80–100 mm<sup>3</sup>, the mice were randomly assigned into control and treatment groups (<i>n</i> = 5 in treated group, <i>n</i> = 10 in vehicle group). Control groups were given vehicle alone, and treatment groups received compound <b>15</b> hydrochloride salt with indicated doses via oral administration (with 0.5% CMC-Na (sodium carboxymethyl cellulose)) or crizotinib hydrochloride salt with water via oral administration once daily for 2 weeks. The sizes of the tumors were measured twice per week using a microcaliper. The tumor volume (TV) was calculated as TV = (length × width<sup>2</sup>)/2. Relative tumor volume (RTV) = TV<sup>Day-N</sup>/TV<sup>Day-0</sup> × 100%. Data was shown on indicated days as the median RTV ± SE. Percent (%) inhibition values were measured on the final day of study for drug-treated compared with vehicle-treated mice and are calculated as 100 × (1 – [(treated final day – treated day 1)/(control final day – control day 1)]). Significant differences between the treated versus control groups were determined using Student’s <i>t</i> test.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65"><a href="/doi/suppl/10.1021/jm5005144">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63203" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63203" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Copies of the <sup>1</sup>H and <sup>13</sup>C spectra of all new compounds. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm5005144/suppl_file/jm5005144_si_001.pdf">jm5005144_si_001.pdf (11.06 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm5005144" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74203" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74203" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Ai</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese
Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#016b60684172686c6c2f60622f626f"><span class="__cf_email__" data-cfemail="e389828aa3908a8e8ecd8280cd808d">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meiyu Geng</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese
Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f895819f9d969fb88b919595d6999bd69b96"><span class="__cf_email__" data-cfemail="107d6977757e775063797d7d3e71733e737e">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ao Zhang</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Synthetic Organic & Medicinal
Chemistry Laboratory, Shanghai Institute
of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3a5b5540525b545d7a49535757145b59145954"><span class="__cf_email__" data-cfemail="3d5c5247555c535a7d4e545050135c5e135e53">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zilan Song</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Synthetic Organic & Medicinal
Chemistry Laboratory, Shanghai Institute
of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanhong Yang</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese
Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhiqing Liu</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Synthetic Organic & Medicinal
Chemistry Laboratory, Shanghai Institute
of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xia Peng</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese
Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Junfeng Guo</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Synthetic Organic & Medicinal
Chemistry Laboratory, Shanghai Institute
of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xinying Yang</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese
Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kui Wu</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Synthetic Organic & Medicinal
Chemistry Laboratory, Shanghai Institute
of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Ding</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese
Academy of Sciences, Shanghai 201203, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Z. Song and Y. Yang contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1484e4623-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77425" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by grants from Chinese NSF (Nos. 81125021, 81373277, 81102461, and 91229205) and National Science & Technology Major Project on ‘Key New Drug Creation and Manufacturing Program’, China (Grants 2012ZX09103-101-035, 2012ZX09301001-007). Supporting grants from the “Interdisciplinary Cooperation Team” Program for Science and Technology Innovation (CAS), the National Program on Key Basic Research Project of China (Grant 2012CB910704), the Natural Science Foundation of China for Innovation Research Group (Grant 81321092), and the State Key Laboratory of Drug Research (Grant SIMM1302KF-08), Shanghai Institute of Materia Medica, were also appreciated.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i68" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i68"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i69" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i69"> Abbreviations Used</h2><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">ALCL</td><td class="NLM_def"><p class="first last">anaplastic large-cell lymphoma</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">EML4</td><td class="NLM_def"><p class="first last">echinoderm microtubule-associated protein-like 4</p></td></tr><tr><td class="NLM_term">NPM</td><td class="NLM_def"><p class="first last">nucleophosmin</p></td></tr><tr><td class="NLM_term">c-Met</td><td class="NLM_def"><p class="first last">mesenchymal epithelial transition growth factor</p></td></tr><tr><td class="NLM_term">DAAPalogues</td><td class="NLM_def"><p class="first last">2,4-diarylaminopyrimidine analogues</p></td></tr><tr><td class="NLM_term">crizotinib</td><td class="NLM_def"><p class="first last">3-[(1<i>R</i>)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridine-2-amine</p></td></tr><tr><td class="NLM_term">CSA</td><td class="NLM_def"><p class="first last">(1<i>S</i>)-(+)-10-camphorsulfonic acid</p></td></tr><tr><td class="NLM_term">X-Phos</td><td class="NLM_def"><p class="first last">2-(dicyclohexylphosphino)-2′,4′,6′-triisopropyl biphenyl</p></td></tr><tr><td class="NLM_term">IGF1R</td><td class="NLM_def"><p class="first last">insulin-like growth factor 1 receptor</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet derived growth factor receptor</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">KDR</td><td class="NLM_def"><p class="first last">kinase insert domain receptor</p></td></tr><tr><td class="NLM_term">FGFR1</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor 1</p></td></tr><tr><td class="NLM_term">Flt-1</td><td class="NLM_def"><p class="first last">fms-like tyrosine kinase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74501" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74501" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 48 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Pulford, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamant, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroud, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delsol, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, D. Y.</span><span> </span><span class="NLM_article-title">Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with themonoclonal antibody ALK1</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">1394</span><span class="NLM_x">–</span> <span class="NLM_lpage">1404</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=1394-1404&author=K.+Pulfordauthor=L.+Lamantauthor=S.+W.+Morrisauthor=L.+H.+Butlerauthor=K.+M.+Woodauthor=D.+Stroudauthor=G.+Delsolauthor=D.+Y.+Mason&title=Detection+of+anaplastic+lymphoma+kinase+%28ALK%29+and+nucleolar+protein+nucleophosmin+%28NPM%29-ALK+proteins+in+normal+and+neoplastic+cells+with+themonoclonal+antibody+ALK1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPulford%26aufirst%3DK.%26aulast%3DLamant%26aufirst%3DL.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DButler%26aufirst%3DL.%2BH.%26aulast%3DWood%26aufirst%3DK.%2BM.%26aulast%3DStroud%26aufirst%3DD.%26aulast%3DDelsol%26aufirst%3DG.%26aulast%3DMason%26aufirst%3DD.%2BY.%26atitle%3DDetection%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520nucleolar%2520protein%2520nucleophosmin%2520%2528NPM%2529-ALK%2520proteins%2520in%2520normal%2520and%2520neoplastic%2520cells%2520with%2520themonoclonal%2520antibody%2520ALK1%26jtitle%3DBlood%26date%3D1997%26volume%3D89%26spage%3D1394%26epage%3D1404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Bilsland, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeldon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mead, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Znamenskiy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thakur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heavens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiting, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAllister, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz-Sanjuan, I.</span><span> </span><span class="NLM_article-title">Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=685-700&author=J.+G.+Bilslandauthor=A.+Wheeldonauthor=A.+Meadauthor=P.+Znamenskiyauthor=S.+Almondauthor=K.+A.+Watersauthor=M.+Thakurauthor=V.+Beaumontauthor=T.+P.+Bonnertauthor=R.+Heavensauthor=P.+Whitingauthor=G.+McAllisterauthor=I.+Munoz-Sanjuan&title=Behavioral+and+neurochemical+alterations+in+mice+deficient+in+anaplastic+lymphoma+kinase+suggest+therapeutic+potential+for+psychiatric+indications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBilsland%26aufirst%3DJ.%2BG.%26aulast%3DWheeldon%26aufirst%3DA.%26aulast%3DMead%26aufirst%3DA.%26aulast%3DZnamenskiy%26aufirst%3DP.%26aulast%3DAlmond%26aufirst%3DS.%26aulast%3DWaters%26aufirst%3DK.%2BA.%26aulast%3DThakur%26aufirst%3DM.%26aulast%3DBeaumont%26aufirst%3DV.%26aulast%3DBonnert%26aufirst%3DT.%2BP.%26aulast%3DHeavens%26aufirst%3DR.%26aulast%3DWhiting%26aufirst%3DP.%26aulast%3DMcAllister%26aufirst%3DG.%26aulast%3DMunoz-Sanjuan%26aufirst%3DI.%26atitle%3DBehavioral%2520and%2520neurochemical%2520alterations%2520in%2520mice%2520deficient%2520in%2520anaplastic%2520lymphoma%2520kinase%2520suggest%2520therapeutic%2520potential%2520for%2520psychiatric%2520indications%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26spage%3D685%26epage%3D700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeve, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathew, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, D. P.</span><span> </span><span class="NLM_article-title">ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2175</span><span class="NLM_x">–</span> <span class="NLM_lpage">2188</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=2175-2188&author=S.+W.+Morrisauthor=C.+Naeveauthor=P.+Mathewauthor=P.+L.+Jamesauthor=M.+N.+Kirsteinauthor=X.+Cuiauthor=D.+P.+Witte&title=ALK%2C+the+chromosome+2+gene+locus+altered+by+the+t%282%3B5%29+in+non-Hodgkin%E2%80%99s+lymphoma%2C+encodes+a+novel+neural+receptor+tyrosine+kinase+that+is+highly+related+to+leukocyte+tyrosine+kinase+%28LTK%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DNaeve%26aufirst%3DC.%26aulast%3DMathew%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DP.%2BL.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DWitte%26aufirst%3DD.%2BP.%26atitle%3DALK%252C%2520the%2520chromosome%25202%2520gene%2520locus%2520altered%2520by%2520the%2520t%25282%253B5%2529%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%252C%2520encodes%2520a%2520novel%2520neural%2520receptor%2520tyrosine%2520kinase%2520that%2520is%2520highly%2520related%2520to%2520leukocyte%2520tyrosine%2520kinase%2520%2528LTK%2529%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D2175%26epage%3D2188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Rikova, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Possemato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeves, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetzel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macneill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakalarski, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornhauser, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gygi, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakiewicz, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comb, M. J.</span><span> </span><span class="NLM_article-title">Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">1190</span><span class="NLM_x">–</span> <span class="NLM_lpage">1203</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1190-1203&author=K.+Rikovaauthor=A.+Guoauthor=Q.+Zengauthor=A.+Possematoauthor=J.+Yuauthor=H.+Haackauthor=J.+Nardoneauthor=K.+Leeauthor=C.+Reevesauthor=Y.+Liauthor=Y.+Huauthor=Z.+Tanauthor=M.+Stokesauthor=L.+Sullivanauthor=J.+Mitchellauthor=R.+Wetzelauthor=J.+Macneillauthor=J.+M.+Renauthor=J.+Yuanauthor=C.+E.+Bakalarskiauthor=J.+Villenauthor=J.+M.+Kornhauserauthor=B.+Smithauthor=D.+Liauthor=X.+Zhouauthor=S.+P.+Gygiauthor=T.+L.+Guauthor=R.+D.+Polakiewiczauthor=J.+Rushauthor=M.+J.+Comb&title=Global+survey+of+phosphotyrosine+signaling+identifies+oncogenic+kinases+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRikova%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DPossemato%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DNardone%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DReeves%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DStokes%26aufirst%3DM.%26aulast%3DSullivan%26aufirst%3DL.%26aulast%3DMitchell%26aufirst%3DJ.%26aulast%3DWetzel%26aufirst%3DR.%26aulast%3DMacneill%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DBakalarski%26aufirst%3DC.%2BE.%26aulast%3DVillen%26aufirst%3DJ.%26aulast%3DKornhauser%26aufirst%3DJ.%2BM.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DGu%26aufirst%3DT.%2BL.%26aulast%3DPolakiewicz%26aufirst%3DR.%2BD.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DGlobal%2520survey%2520of%2520phosphotyrosine%2520signaling%2520identifies%2520oncogenic%2520kinases%2520in%2520lung%2520cancer%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D1190%26epage%3D1203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmer, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltman, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4-ALK+fusion+gene+in+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0lh8I6wdMpGnVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4-ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">2349</span><span class="NLM_x">–</span> <span class="NLM_lpage">2355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1111%2Fj.1349-7006.2008.00972.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=19032370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisF2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2008&pages=2349-2355&author=H.+Mano&title=Non-solid+oncogenes+in+solid+tumors%3A+EML4-ALK+fusion+genes+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer</span></div><div class="casAuthors">Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2349-2355</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  It is generally accepted that recurrent chromosome translocations play a major role in the mol. pathogenesis of hematol. malignancies but not of solid tumors.  However, chromosome translocations involving the e26 transformation-specific sequence transcription factor loci have been demonstrated recently in many prostate cancer cases.  Furthermore, through a functional screening with retroviral cDNA expression libraries, we have discovered the fusion-type protein tyrosine kinase echinoderm microtubule-assocd. protein like-4 (EML4)-anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) specimens.  A recurrent chromosome translocation, inv(2)(p21p23), in NSCLC generates fused mRNA encoding the amino-terminal half of EML4 ligated to the intracellular region of the receptor-type protein tyrosine kinase ALK.  EML4-ALK oligomerizes constitutively in cells through the coiled coil domain within the EML4 region, and becomes activated to exert a marked oncogenicity both in vitro and in vivo.  Break and fusion points within the EML4 locus may diverge in NSCLC cells to generate various isoforms of EML4-ALK, which may constitute -5% of NSCLC cases, at least in the Asian ethnic group.  In the present review I summarize how detection of EML4-ALK cDNA may become a sensitive diagnostic means for NSCLC cases that are pos. for the fusion gene, and discuss whether suppression of ALK enzymic activity could be an effective treatment strategy against this intractable disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbxSS7U51wKbVg90H21EOLACvtfcHk0lhGs9pAHRozbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisF2gsw%253D%253D&md5=84386550daedbd29b3a34b11a4774684</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.00972.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.00972.x%26sid%3Dliteratum%253Aachs%26aulast%3DMano%26aufirst%3DH.%26atitle%3DNon-solid%2520oncogenes%2520in%2520solid%2520tumors%253A%2520EML4-ALK%2520fusion%2520genes%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2008%26volume%3D99%26spage%3D2349%26epage%3D2355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span> </span><span class="NLM_article-title">Targeting anaplastic lymphoma kinase in lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2081</span><span class="NLM_x">–</span> <span class="NLM_lpage">2086</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1158%2F1078-0432.CCR-10-1591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=21288922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2081-2086&author=A.+T.+Shawauthor=B.+Solomon&title=Targeting+anaplastic+lymphoma+kinase+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Anaplastic Lymphoma Kinase in Lung Cancer</span></div><div class="casAuthors">Shaw, Alice T.; Solomon, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2081-2086</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Several decades of cancer research have revealed a pivotal role for tyrosine kinases as key regulators of signaling pathways, controlling cell growth and differentiation.  Deregulation of tyrosine kinase-mediated signaling occurs frequently in cancer and is believed to drive the initiation and progression of disease.  Chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (ALK) occur in a variety of human malignancies including non-small cell lung cancer (NSCLC), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.  The aberrant activation of ALK signaling leads to "oncogene addiction" and marked sensitivity to ALK inhibitors such as crizotinib (PF-02341066).  This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.  Current efforts seek to expand the role of ALK kinase inhibition in lung and other cancers and to address the mol. basis for the development of resistance.  Clin Cancer Res; 17(8); 2081-6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCqEzvXv0qJrVg90H21EOLACvtfcHk0lhGs9pAHRozbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D&md5=6d0f5e1174ba934f00c10a877a3b17e1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-1591%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%26atitle%3DTargeting%2520anaplastic%2520lymphoma%2520kinase%2520in%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2081%26epage%3D2086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Caren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinsson, I.</span><span> </span><span class="NLM_article-title">High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumors</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">416</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=416&publication_year=2008&pages=153-159&author=H.+Carenauthor=F.+Abelauthor=P.+Kognerauthor=I.+Martinsson&title=High+incidence+of+DNA+mutations+and+gene+amplifications+of+the+ALK+gene+in+advanced+sporadic+neuroblastoma+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaren%26aufirst%3DH.%26aulast%3DAbel%26aufirst%3DF.%26aulast%3DKogner%26aufirst%3DP.%26aulast%3DMartinsson%26aufirst%3DI.%26atitle%3DHigh%2520incidence%2520of%2520DNA%2520mutations%2520and%2520gene%2520amplifications%2520of%2520the%2520ALK%2520gene%2520in%2520advanced%2520sporadic%2520neuroblastoma%2520tumors%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D416%26spage%3D153%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Mossé, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudenslager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attiyeh, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquaglia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laureys, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speleman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakonarson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torkamani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schork, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodeur, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonini, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rappaport, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Identification of ALK as a major familial neuroblastoma predisposition gene</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">935</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+major+familial+neuroblastoma+predisposition+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520major%2520familial%2520neuroblastoma%2520predisposition%2520gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Janoueix-Lerosey, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lequin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugieres, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pontual, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combaret, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puisieux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schleiermacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valteau-Couanet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frebourg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyonnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delattre, O.</span><span> </span><span class="NLM_article-title">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1038%2Fnature07398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=18923523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=967-970&author=I.+Janoueix-Leroseyauthor=D.+Lequinauthor=L.+Brugieresauthor=A.+Ribeiroauthor=L.+de+Pontualauthor=V.+Combaretauthor=V.+Raynalauthor=A.+Puisieuxauthor=G.+Schleiermacherauthor=G.+Pierronauthor=D.+Valteau-Couanetauthor=T.+Frebourgauthor=J.+Michonauthor=S.+Lyonnetauthor=J.+Amielauthor=O.+Delattre&title=Somatic+and+germline+activating+mutations+of+the+ALK+kinase+receptor+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span></div><div class="casAuthors">Janoueix-Lerosey, Isabelle; Lequin, Delphine; Brugieres, Laurence; Ribeiro, Agnes; de Pontual, Loic; Combaret, Valerie; Raynal, Virginie; Puisieux, Alain; Schleiermacher, Gudrun; Pierron, Gaelle; Valteau-Couanet, Dominique; Frebourg, Thierry; Michon, Jean; Lyonnet, Stanislas; Amiel, Jeanne; Delattre, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">967-970</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma, a tumor derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumors in childhood.  It usually occurs sporadically but familial cases are obsd., with a subset of cases occurring in assocn. with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene.  Here the authors conducted genome-wide comparative genomic hybridization anal. on a large series of neuroblastomas.  Copy no. increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was obsd. recurrently.  One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development.  Through subsequent direct sequencing of cell lines and primary tumor DNAs the authors identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots.  Germline mutations were obsd. in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene.  Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity.  The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation.  Altogether, these data identify ALK as a crit. player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_O_BMCZk7rVg90H21EOLACvtfcHk0lgRgC8gcExaXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI&md5=7321fe0dc6408f9b5b3c53b8d83478ce</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnature07398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07398%26sid%3Dliteratum%253Aachs%26aulast%3DJanoueix-Lerosey%26aufirst%3DI.%26aulast%3DLequin%26aufirst%3DD.%26aulast%3DBrugieres%26aufirst%3DL.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3Dde%2BPontual%26aufirst%3DL.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DRaynal%26aufirst%3DV.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DSchleiermacher%26aufirst%3DG.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DValteau-Couanet%26aufirst%3DD.%26aulast%3DFrebourg%26aufirst%3DT.%26aulast%3DMichon%26aufirst%3DJ.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DDelattre%26aufirst%3DO.%26atitle%3DSomatic%2520and%2520germline%2520activating%2520mutations%2520of%2520the%2520ALK%2520kinase%2520receptor%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D967%26epage%3D970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takita, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Li.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igarashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, S.</span><span> </span><span class="NLM_article-title">Oncogenic mutations of ALK kinase in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=971-974&author=Y.+Chenauthor=J.+Takitaauthor=Y.+L.+Choiauthor=M.+Katoauthor=M.+Ohiraauthor=M.+Sanadaauthor=Li.+Wangauthor=M.+Sodaauthor=A.+Kikuchiauthor=T.+Igarashiauthor=A.+Nakagawaraauthor=Y.+Hayashiauthor=H.+Manoauthor=S.+Ogawa&title=Oncogenic+mutations+of+ALK+kinase+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTakita%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DSanada%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DLi.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DIgarashi%26aufirst%3DT.%26aulast%3DNakagawara%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DOncogenic%2520mutations%2520of%2520ALK%2520kinase%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D971%26epage%3D974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrady, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zozulya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanael, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Activating mutations in ALK provides a therapeutic target in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=975-978&author=R.+E.+Georgeauthor=T.+Sandaauthor=M.+Hannaauthor=S.+Frohlingauthor=W.+Lutherauthor=J.+Zhangauthor=Y.+Ahnauthor=W.+Zhouauthor=W.+B.+Londonauthor=P.+McGradyauthor=L.+Xueauthor=S.+Zozulyaauthor=V.+Gregorauthor=T.+R.+Webbauthor=S.+Nathanaelauthor=N.+S.+Grayauthor=D.+G.+Gillilandauthor=L.+Dillerauthor=H.+Greulichauthor=W.+Stephanauthor=S.+W.+Morrisauthor=M.+Meyersonauthor=A.+T.+Look&title=Activating+mutations+in+ALK+provides+a+therapeutic+target+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DV.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DNathanael%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDiller%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DStephan%26aufirst%3DW.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivating%2520mutations%2520in%2520ALK%2520provides%2520a%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D975%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Azarova, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautam, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, R. E.</span><span> </span><span class="NLM_article-title">Emerging importance of ALK in neuroblastoma</span> <span class="citation_source-journal">Semin. Cancer Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1016%2Fj.semcancer.2011.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=21945349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSktLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=267-275&author=A.+M.+Azarovaauthor=G.+Gautamauthor=R.+E.+George&title=Emerging+importance+of+ALK+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging importance of ALK in neuroblastoma</span></div><div class="casAuthors">Azarova, Anna M.; Gautam, Gargi; George, Rani E.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">267-275</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since the original descriptions of gain-of function mutations in anaplastic lymphoma kinase (ALK), interest in the role of this receptor tyrosine kinase in neuroblastoma development and as a potential therapeutic target has escalated.  As a group, the activating point mutations in full-length ALK, found in approx. 8% of all neuroblastoma tumors, are distributed evenly across different clin. stages.  However, the most frequent somatic mutation, F1174L, is assocd. with amplification of the MYCN oncogene.  This combination of features appears to confer a worse prognosis than MYCN amplification alone, suggesting a cooperative effect on neuroblastoma formation by these two proteins.  Indeed, F1174L has shown more potent transforming activity in vivo than the second most common activating mutation, R1275Q, and is responsible for innate and acquired resistance to crizotinib, a clin. relevant ALK inhibitor that will soon be com. available.  These advances cast ALK as a bona fide oncoprotein in neuroblastoma and emphasize the need to understand ALK-mediated signaling in this tumor.  This review addresses many of the current issues surrounding the role of ALK in normal development and neuroblastoma pathogenesis, and discusses the prospects for clin. effective targeted treatments based on ALK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpqmFzh9Q3frVg90H21EOLACvtfcHk0lgwUC624I0qGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSktLzN&md5=e07445aecd9829c465f1f4023124521f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2011.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2011.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DAzarova%26aufirst%3DA.%2BM.%26aulast%3DGautam%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26atitle%3DEmerging%2520importance%2520of%2520ALK%2520in%2520neuroblastoma%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2011%26volume%3D21%26spage%3D267%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Tuma, R. S.</span><span> </span><span class="NLM_article-title">ALK gene amplified in most inflammatory breast cancers</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1093%2Fjnci%2Fdjr553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=22215853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVWhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2012&pages=87-88&author=R.+S.+Tuma&title=ALK+gene+amplified+in+most+inflammatory+breast+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">ALK Gene Amplified in Most Inflammatory Breast Cancers</span></div><div class="casAuthors">Tuma, Rabiya S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-88</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Inflammatory breast cancer (IBC) is a rare form of the disease that differs substantially from non-inflammatory breast cancer in presentation and response to therapy. Despite those differences, researchers have uncovered few mol. characteristics that distinguish IBC from non-inflammatory breast cancer, and IBC treatment generally relies on std. breast cancer regimens.  Recently, it has been reported that ALK gene amplification is a common feature of IBC tumors and that small-mol. ALK inhibitors are effective in mouse xenograft models.  Current developments on this recent report are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB9yX6fegRi7Vg90H21EOLACvtfcHk0lgwUC624I0qGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVWhsb0%253D&md5=46e7633055aadc3aacfc6bac9b4cb591</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjr553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjr553%26sid%3Dliteratum%253Aachs%26aulast%3DTuma%26aufirst%3DR.%2BS.%26atitle%3DALK%2520gene%2520amplified%2520in%2520most%2520inflammatory%2520breast%2520cancers%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2012%26volume%3D104%26spage%3D87%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Ren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beausoleil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moritz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innocenti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comb, M. J.</span><span> </span><span class="NLM_article-title">Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">3312</span><span class="NLM_x">–</span> <span class="NLM_lpage">3323</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3312-3323&author=H.+Renauthor=Z.+P.+Tanauthor=X.+Zhuauthor=K.+Crosbyauthor=H.+Haackauthor=J.+M.+Renauthor=S.+Beausoleilauthor=A.+Moritzauthor=G.+Innocentiauthor=J.+Rushauthor=Y.+Zhangauthor=X.+M.+Zhouauthor=T.+L.+Guauthor=Y.+F.+Yangauthor=M.+J.+Comb&title=Identification+of+anaplastic+lymphoma+kinase+as+a+potential+therapeutic+target+in+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%2BP.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DBeausoleil%26aufirst%3DS.%26aulast%3DMoritz%26aufirst%3DA.%26aulast%3DInnocenti%26aufirst%3DG.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%2BM.%26aulast%3DGu%26aufirst%3DT.%2BL.%26aulast%3DYang%26aufirst%3DY.%2BF.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DIdentification%2520of%2520anaplastic%2520lymphoma%2520kinase%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3312%26epage%3D3323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span> </span><span class="NLM_article-title">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3314</span><span class="NLM_x">–</span> <span class="NLM_lpage">3322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+R.+Altonauthor=B.+Mroczkowskiauthor=G.+Los&title=Cytoreductive+antitumor+activity+of+PF-2341066%2C+a+novel+inhibitor+of+anaplastic+lymphoma+kinase+and+c-Met%2C+in+experimental+models+of+anaplastic+large-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, ∼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-γ, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0lggcpunwoHgWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%2BR.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DLos%26aufirst%3DG.%26atitle%3DCytoreductive%2520antitumor%2520activity%2520of%2520PF-2341066%252C%2520a%2520novel%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520c-Met%252C%2520in%2520experimental%2520models%2520of%2520anaplastic%2520large-cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.+P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-Met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lggcpunwoHgWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.-P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal%E2%80%93epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal%25E2%2580%2593epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Case History: Xalkori (crizotinib), a potent and selective dual inhibitor of mesenchymal epithelial transition (MET) and anaplastic lymphoma kinase (ALK) for cancer treatment</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2013&pages=421-432&author=J.+J.+Cuiauthor=M.+McTigueauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Case+History%3A+Xalkori+%28crizotinib%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal+epithelial+transition+%28MET%29+and+anaplastic+lymphoma+kinase+%28ALK%29+for+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DCase%2520History%253A%2520Xalkori%2520%2528crizotinib%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal%2520epithelial%2520transition%2520%2528MET%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520for%2520cancer%2520treatment%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2013%26volume%3D48%26spage%3D421%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butaney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulig, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selaru, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harboring ALK gene rearrangement: A retrospective analysis</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1004</span><span class="NLM_x">–</span> <span class="NLM_lpage">1012</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1016%2FS1470-2045%2811%2970232-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=21933749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1KmtrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=1004-1012&author=A.+T.+Shawauthor=B.+Y.+Yeapauthor=B.+J.+Solomonauthor=G.+J.+Rielyauthor=J.+Gainorauthor=J.+A.+Engelmanauthor=G.+I.+Shapiroauthor=D.+B.+Costaauthor=S.-H.+I.+Ouauthor=M.+Butaneyauthor=R.+Salgiaauthor=R.+G.+Makiauthor=M.+Varella-Garciaauthor=R.+C.+Doebeleauthor=Y.-J.+Bangauthor=K.+Kuligauthor=P.+Selaruauthor=Y.+Tangauthor=K.+D.+Wilnerauthor=E.+L.+Kwakauthor=J.+W.+Clarkauthor=A.+J.+Iafrateauthor=D.+R.+Camidge&title=Effect+of+crizotinib+on+overall+survival+in+patients+with+advanced+non-small-cell+lung+cancer+harboring+ALK+gene+rearrangement%3A+A+retrospective+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis</span></div><div class="casAuthors">Shaw, Alice T.; Yeap, Beow Y.; Solomon, Benjamin J.; Riely, Gregory J.; Gainor, Justin; Engelman, Jeffrey A.; Shapiro, Geoffrey I.; Costa, Daniel B.; Ou, Sai-Hong I.; Butaney, Mohit; Salgia, Ravi; Maki, Robert G.; Varella-Garcia, Marileila; Doebele, Robert C.; Bang, Yung-Jue; Kulig, Kimary; Selaru, Paulina; Tang, Yiyun; Wilner, Keith D.; Kwak, Eunice L.; Clark, Jeffrey W.; Iafrate, A. John; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1004-1012</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">ALK gene rearrangement defines a new mol. subtype of non-small-cell lung cancer (NSCLC).  In a recent phase 1 clin. trial, the ALK tyrosine-kinase inhibitor (TKI) crizotinib showed marked antitumor activity in patients with advanced, ALK-pos. NSCLC.  To assess whether crizotinib affects overall survival in these patients, we did a retrospective study comparing survival outcomes in crizotinib-treated patients in the trial and crizotinib-naive controls screened during the same time period.  We examd. overall survival in patients with advanced, ALK-pos. NSCLC who enrolled in the phase 1 clin. trial of crizotinib, focusing on the cohort of 82 patients who had enrolled through Feb 10, 2010.  For comparators, we identified 36 ALK-pos. patients from trial sites who were not given crizotinib (ALK-pos. controls), 67 patients without ALK rearrangement but pos. for EGFR mutation, and 253 wild-type patients lacking either ALK rearrangement or EGFR mutation.  To assess differences in overall survival, we assessed subsets of clin. comparable ALK-pos. and ALK-neg. patients.  Among 82 ALK-pos. patients who were given crizotinib, median overall survival from initiation of crizotinib has not been reached (95% CI 17 mo to not reached); 1-yr overall survival was 74% (95% CI 63-82), and 2-yr overall survival was 54% (40-66).  Overall survival did not differ based on age, sex, smoking history, or ethnic origin.  Survival in 30 ALK-pos. patients who were given crizotinib in the second-line or third-line setting was significantly longer than in 23 ALK-pos. controls given any second-line therapy (median overall survival not reached [95% CI 14 mo to not reached] vs 6 mo [4-17], 1-yr overall survival 70% [95% CI 50-83] vs 44% [23-64], and 2-yr overall survival 55% [33-72] vs 12% [2-30]; hazard ratio 0.36, 95% CI 0.17-0.75; p = 0.004).  Survival in 56 crizotinib-treated, ALK-pos. patients was similar to that in 63 ALK-neg., EGFR-pos. patients given EGFR TKI therapy (median overall survival not reached [95% CI 17 mo to not reached] vs 24 mo [15-34], 1-yr overall survival 71% [95% CI 58-81] vs 74% [61-83], and 2-yr overall survival 57% [40-71] vs 52% [38-65]; p = 0.786), whereas survival in 36 crizotinib-naive, ALK-pos. controls was similar to that in 253 wild-type controls (median overall survival 20 mo [95% CI 13-26] vs 15 mo [13-17]; p = 0.244).  In patients with advanced, ALK-pos. NSCLC, crizotinib therapy is assocd. with improved survival compared with that of crizotinib-naive controls.  ALK rearrangement is not a favorable prognostic factor in advanced NSCLC.  Funding: Pfizer Inc, V Foundation for Cancer Research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMS7fRYJSyrrVg90H21EOLACvtfcHk0ljKSp8xpvShbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1KmtrzL&md5=5482da97726293764c9fe42419d187cb</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970232-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970232-7%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DGainor%26aufirst%3DJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DKulig%26aufirst%3DK.%26aulast%3DSelaru%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DEffect%2520of%2520crizotinib%2520on%2520overall%2520survival%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520harboring%2520ALK%2520gene%2520rearrangement%253A%2520A%2520retrospective%2520analysis%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D1004%26epage%3D1012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilling, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutateladze, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weickhardt, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linderman, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heasley, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1472</span><span class="NLM_x">–</span> <span class="NLM_lpage">1482</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1158%2F1078-0432.CCR-11-2906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=22235099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1472-1482&author=R.+C.+Doebeleauthor=A.+B.+Pillingauthor=D.+L.+Aisnerauthor=T.+G.+Kutateladzeauthor=A.+T.+Leauthor=A.+J.+Weickhardtauthor=K.+L.+Kondoauthor=D.+J.+Lindermanauthor=L.+E.+Heasleyauthor=W.+A.+Franklinauthor=M.+Varella-Garciaauthor=D.+R.+Camidge&title=Mechanisms+of+Resistance+to+Crizotinib+in+Patients+with+ALK+Gene+Rearranged+Non-Small+Cell+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Doebele, Robert C.; Pilling, Amanda B.; Aisner, Dara L.; Kutateladze, Tatiana G.; Le, Anh T.; Weickhardt, Andrew J.; Kondo, Kimi L.; Linderman, Derek J.; Heasley, Lynn E.; Franklin, Wilbur A.; Varella-Garcia, Marileila; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1472-1482</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small-mol. ALK inhibitor.  Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those who do respond.  This study aimed to define mol. mechanisms of resistance to crizotinib in patients with ALK+ non-small cell lung cancer (NSCLC).  We analyzed tissue obtained from 14 patients with ALK+ NSCLC showing evidence of radiol. progression while on crizotinib to define mechanisms of intrinsic and acquired resistance to crizotinib.  Eleven patients had material evaluable for mol. anal.  Four patients (36%) developed secondary mutations in the tyrosine kinase domain of ALK.  A novel mutation in the ALK domain, encoding a G1269A amino acid substitution that confers resistance to crizotinib in vitro, was identified in two of these cases.  Two patients, one with a resistance mutation, exhibited new onset ALK copy no. gain (CNG).  One patient showed outgrowth of epidermal growth factor receptor (EGFR) mutant NSCLC without evidence of a persistent ALK gene rearrangement.  Two patients exhibited a KRAS mutation, one of which occurred without evidence of a persisting ALK gene rearrangement.  One patient showed the emergence of an ALK gene fusion-neg. tumor compared with the baseline sample but with no identifiable alternate driver.  Two patients retained ALK positivity with no identifiable resistance mechanism.  Crizotinib resistance in ALK+ NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of sep. oncogenic drivers.  Clin Cancer Res; 18(5); 1472-82.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhGQYtlS1w7Vg90H21EOLACvtfcHk0ljKSp8xpvShbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D&md5=575047615ef9e3d4af60d45605a747c5</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2906%26sid%3Dliteratum%253Aachs%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DKutateladze%26aufirst%3DT.%2BG.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DWeickhardt%26aufirst%3DA.%2BJ.%26aulast%3DKondo%26aufirst%3DK.%2BL.%26aulast%3DLinderman%26aufirst%3DD.%2BJ.%26aulast%3DHeasley%26aufirst%3DL.%2BE.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DMechanisms%2520of%2520Resistance%2520to%2520Crizotinib%2520in%2520Patients%2520with%2520ALK%2520Gene%2520Rearranged%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1472%26epage%3D1482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessop, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engleman, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_elocation-id">120ra17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1126%2Fscitranslmed.3003316" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&author=R.+Katayamaauthor=A.+T.+Shawauthor=T.+M.+Khanauthor=M.+Mino-Kenudsonauthor=B.+J.+Solomonauthor=B.+Halmosauthor=N.+A.+Jessopauthor=J.+C.+Wainauthor=A.+T.+Yeoauthor=C.+Benesauthor=L.+Drewauthor=J.+C.+Saehauthor=K.+Crosbyauthor=L.+V.+Sequistauthor=A.+J.+Iafrateauthor=J.+A.+Engleman&title=Mechanisms+of+Acquired+Crizotinib+Resistance+in+ALK-Rearranged+Lung+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003316%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DJessop%26aufirst%3DN.%2BA.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DYeo%26aufirst%3DA.%2BT.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngleman%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520Acquired%2520Crizotinib%2520Resistance%2520in%2520ALK-Rearranged%2520Lung%2520Cancers%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anjum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miret, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span> </span><span class="NLM_article-title">Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">999</span><span class="NLM_x">–</span> <span class="NLM_lpage">1005</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1111%2Fj.1747-0285.2011.01239.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=22034911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2011&pages=999-1005&author=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=X.+Zhuauthor=Y.+Ningauthor=S.+D.+Wardwellauthor=L.+Moranauthor=Q.+K.+Mohemmadauthor=R.+Anjumauthor=Y.+Wangauthor=N.+I.+Narasimhanauthor=D.+Dalgarnoauthor=W.+C.+Shakespeareauthor=J.+J.+Miretauthor=T.+Clacksonauthor=V.+M.+Rivera&title=Crizotinib-resistant+mutants+of+EML4-ALK+identified+through+an+accelerated+mutagenesis+screen"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen</span></div><div class="casAuthors">Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">999-1005</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Activating gene rearrangements of anaplastic lymphoma kinase (ALK) have been identified as driver mutations in non-small-cell lung cancer, inflammatory myofibroblastic tumors, and other cancers.  Crizotinib, a dual MET/ALK inhibitor, has demonstrated promising clin. activity in patients with non-small-cell lung cancer and inflammatory myofibroblastic tumors harboring ALK translocations.  Inhibitors of driver kinases often elicit kinase domain mutations that confer resistance, and such mutations have been successfully predicted using in vitro mutagenesis screens.  Here, this approach was used to discover an extensive set of ALK mutations that can confer resistance to crizotinib.  Mutations at 16 residues were identified, structurally clustered into five regions around the kinase active site, which conferred varying degrees of resistance.  The screen successfully predicted the L1196M, C1156Y, and F1174L mutations, recently identified in crizotinib-resistant patients.  In sep. studies, we demonstrated that crizotinib has relatively modest potency in ALK-pos. non-small-cell lung cancer cell lines.  A more potent ALK inhibitor, TAE684, maintained substantial activity against mutations that conferred resistance to crizotinib.  Our study identifies multiple novel mutations in ALK that may confer clin. resistance to crizotinib, suggests that crizotinib's narrow selectivity window may underlie its susceptibility to such resistance and demonstrates that a more potent ALK inhibitor may be effective at overcoming resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU21SkJFhWI7Vg90H21EOLACvtfcHk0ljCe_hF0HMQ6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsLbI&md5=7f1f1d4ad48d1801cd3f9c44f7ef4615</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2011.01239.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2011.01239.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DMiret%26aufirst%3DJ.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DCrizotinib-resistant%2520mutants%2520of%2520EML4-ALK%2520identified%2520through%2520an%2520accelerated%2520mutagenesis%2520screen%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2011%26volume%3D78%26spage%3D999%26epage%3D1005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Kinoshita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase inhibitors for the treatment of ALK-positive cancers</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">281</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1016%2FB978-0-12-396492-2.00019-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eju7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=281-293&author=K.+Kinoshitaauthor=N.+Oikawaauthor=T.+Tsukuda&title=Anaplastic+lymphoma+kinase+inhibitors+for+the+treatment+of+ALK-positive+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibitors for the treatment of ALK-positive cancers</span></div><div class="casAuthors">Kinoshita, Kazutomo; Oikawa, Nobuhiro; Tsukuda, Takuo</div><div class="citationInfo"><span class="NLM_cas:title">Annual Reports in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">281-293</span>CODEN:
                <span class="NLM_cas:coden">ARMCBI</span>;
        ISSN:<span class="NLM_cas:issn">0065-7743</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review on the development of anaplastic lymphoma kinase (ALK) inhibitors which is the most highly competitive drug targets in oncol. research.  A no. of research groups have identified promising drugs, where Pfizer succeeded in launching a potent ALK inhibitor, crizotinib, for treatment of EML4-ALK-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX549XOu0aZrVg90H21EOLACvtfcHk0lijAc_XrikU0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eju7vE&md5=2fb9597a39e7dd478a4ef41be4df7be6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396492-2.00019-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396492-2.00019-9%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520ALK-positive%2520cancers%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2012%26volume%3D47%26spage%3D281%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takashima, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haruta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanio, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1734</span><span class="NLM_x">–</span> <span class="NLM_lpage">1739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=EML4-ALK+mutations+in+lung+cancer+that+confer+resistance+to+ALK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0lijAc_XrikU0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DEML4-ALK%2520mutations%2520in%2520lung%2520cancer%2520that%2520confer%2520resistance%2520to%2520ALK%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1734%26epage%3D1739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butrynski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">A novel ALK sondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">6051</span><span class="NLM_x">–</span> <span class="NLM_lpage">6060</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=6051-6060&author=T.+Sasakiauthor=K.+Okudaauthor=W.+Zhengauthor=J.+Butrynskiauthor=M.+Capellettiauthor=L.+Wangauthor=N.+S.+Grayauthor=K.+Wilnerauthor=J.+G.+Christensenauthor=G.+Demetriauthor=G.+I.+Shapiroauthor=S.+J.+Rodigauthor=M.+J.+Eckauthor=P.+A.+Janne&title=A+novel+ALK+sondary+mutation+and+EGFR+signaling+cause+resistance+to+ALK+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DButrynski%26aufirst%3DJ.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DDemetri%26aufirst%3DG.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DA%2520novel%2520ALK%2520sondary%2520mutation%2520and%2520EGFR%2520signaling%2520cause%2520resistance%2520to%2520ALK%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D6051%26epage%3D6060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Giroux, S.</span><span> </span><span class="NLM_article-title">Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=394-401&author=S.+Giroux&title=Overcoming+acquired+resistance+to+kinase+inhibition%3A+The+cases+of+EGFR%2C+ALK+and+BRAF"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiroux%26aufirst%3DS.%26atitle%3DOvercoming%2520acquired%2520resistance%2520to%2520kinase%2520inhibition%253A%2520The%2520cases%2520of%2520EGFR%252C%2520ALK%2520and%2520BRAF%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D394%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">4500</span><span class="NLM_x">–</span> <span class="NLM_lpage">4505</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4500-4505&author=T.+O%E2%80%99Hareauthor=D.+K.+Waltersauthor=E.+P.+Stoffregenauthor=T.+Jiaauthor=P.+W.+Manleyauthor=J.+Mestanauthor=S.+W.+Cowan-Jacobauthor=F.+Y.+Leeauthor=M.+C.+Heinrichauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=In+vitro+activity+of+Bcr-Abl+inhibitors+AMN107+and+BMS-354825+against+clinically+relevant+imatinib-resistant+Abl+kinase+domain+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DJia%26aufirst%3DT.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DIn%2520vitro%2520activity%2520of%2520Bcr-Abl%2520inhibitors%2520AMN107%2520and%2520BMS-354825%2520against%2520clinically%2520relevant%2520imatinib-resistant%2520Abl%2520kinase%2520domain%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4500%26epage%3D4505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunker, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsaparikos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1170</span><span class="NLM_x">–</span> <span class="NLM_lpage">1187</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401805h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1170-1187&author=Q.+Huangauthor=T.+W.+Johnsonauthor=S.+Baileyauthor=A.+Broounauthor=K.+D.+Bunkerauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=A.+S.+Cookauthor=J.+J.+Cuiauthor=H.+Lamauthor=P.+F.+Richardsonauthor=N.+W.+Sachauthor=H.+Shenauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=K.+Tsaparikosauthor=H.+Wangauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Design+of+potent+and+selective+inhibitors+to+overcome+clinical+anaplastic+lymphoma+kinase+mutations+resistant+to+crizotinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span></div><div class="casAuthors">Huang, Qinhua; Johnson, Ted W.; Bailey, Simon; Brooun, Alexei; Bunker, Kevin D.; Burke, Benjamin J.; Collins, Michael R.; Cook, Andrew S.; Cui, J. Jean; Dack, Kevin N.; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Johnson, Patrick S.; Kania, Robert S.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Li, Qiuhua; Lingardo, Laura; Liu, Wei; Lu, Melissa West; McTigue, Michele; Palmer, Cynthia L.; Richardson, Paul F.; Sach, Neal W.; Shen, Hong; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Tsaparikos, Konstantinos; Wang, Hui; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1170-1187</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crizotinib, an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S.  Food and Drug Administration in 2011, is efficacious in ALK and ROS pos. patients.  Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease.  The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine (I), which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclin. pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnhF6vRWLUrrVg90H21EOLACvtfcHk0ljSbOkVFHuoCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D&md5=c12e0400ac92eb3321fde81ee13a5e92</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm401805h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401805h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBunker%26aufirst%3DK.%2BD.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDesign%2520of%2520potent%2520and%2520selective%2520inhibitors%2520to%2520overcome%2520clinical%2520anaplastic%2520lymphoma%2520kinase%2520mutations%2520resistant%2520to%2520crizotinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1170%26epage%3D1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Galkin, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopiuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span> </span><span class="NLM_article-title">Identification of NVPTAE684, a potent, selective, and efficacious inhibitor of NPM-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=270-275&author=A.+V.+Galkinauthor=J.+S.+Melnickauthor=S.+Kimauthor=T.+L.+Hoodauthor=N.+Liauthor=L.+Liauthor=G.+Xiaauthor=R.+Steensmaauthor=G.+Chopiukauthor=J.+Jiangauthor=Y.+Wanauthor=P.+Dingauthor=Y.+Liuauthor=F.+Sunauthor=P.+G.+Schultzauthor=N.+S.+Grayauthor=M.+Warmuth&title=Identification+of+NVPTAE684%2C+a+potent%2C+selective%2C+and+efficacious+inhibitor+of+NPM-ALK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGalkin%26aufirst%3DA.%2BV.%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWarmuth%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520NVPTAE684%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520inhibitor%2520of%2520NPM-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D270%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkisova, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phimister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P.-Y.</span><span> </span><span class="NLM_article-title">Synthesis, structure–activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl) phenyl)-N4-(2- (isopropylsulfonyl)-phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5675</span><span class="NLM_x">–</span> <span class="NLM_lpage">5690</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+structure%E2%80%93activity+relationships%2C+and+in+vivo+efficacy+of+the+novel+potent+and+selective+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+5-chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29+phenyl%29-N4-%282-+%28isopropylsulfonyl%29-phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+currently+in+phase+1+and+phase+2+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%25205-chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529%2520phenyl%2529-N4-%25282-%2520%2528isopropylsulfonyl%2529-phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520currently%2520in%2520phase%25201%2520and%2520phase%25202%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Kuromitsu, S.; Mori, M.; Shimada, I.; Kondoh, Y.; Shindoh, N.; Soga, T.; Furutani, T.; Konagai, S.; Sakagami, H.; Nakata, M.; Ueno, Y.; Saito, R.; Sasamata, M.; Kudou, M.</span><span> </span><span class="NLM_article-title">Anti-tumor activity of ASP3026, a novel and selective ALK inhibitor of anaplastic lymphoma kinase (ALK)</span>. Presented at the Annual Meeting of the American Association for Cancer Research (AACR), Orlando, FL,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Abstract 2821.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kuromitsu%2C+S.%3B+Mori%2C+M.%3B+Shimada%2C+I.%3B+Kondoh%2C+Y.%3B+Shindoh%2C+N.%3B+Soga%2C+T.%3B+Furutani%2C+T.%3B+Konagai%2C+S.%3B+Sakagami%2C+H.%3B+Nakata%2C+M.%3B+Ueno%2C+Y.%3B+Saito%2C+R.%3B+Sasamata%2C+M.%3B+Kudou%2C+M.+Anti-tumor+activity+of+ASP3026%2C+a+novel+and+selective+ALK+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29.+Presented+at+the+Annual+Meeting+of+the+American+Association+for+Cancer+Research+%28AACR%29%2C+Orlando%2C+FL%2C+2011%3B+Abstract+2821."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DAnti-tumor%2520activity%2520of%2520ASP3026%252C%2520a%2520novel%2520and%2520selective%2520ALK%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistant+gatekeeper+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistant%2520gatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Kinoshita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuichi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohwada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span> </span><span class="NLM_article-title">9-Substituted 6,6-dimethyl- 11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6286</span><span class="NLM_x">–</span> <span class="NLM_lpage">6294</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200652u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6286-6294&author=K.+Kinoshitaauthor=T.+Kobayashiauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=K.+Hattoriauthor=T.+Miyagiauthor=W.-S.+Hongauthor=M.-J.+Parkauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=9-Substituted+6%2C6-dimethyl-+11-oxo-6%2C11-dihydro-5H-benzo%5Bb%5Dcarbazoles+as+highly+selective+and+potent+anaplastic+lymphoma+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm200652u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200652u%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.-S.%26aulast%3DPark%26aufirst%3DM.-J.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3D9-Substituted%25206%252C6-dimethyl-%252011-oxo-6%252C11-dihydro-5H-benzo%255Bb%255Dcarbazoles%2520as%2520highly%2520selective%2520and%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6286%26epage%3D6294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maemondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshioka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nogami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span> </span><span class="NLM_article-title">CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">590</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1016%2FS1470-2045%2813%2970142-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=23639470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntV2gsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=590-598&author=T.+Setoauthor=K.+Kiuraauthor=M.+Nishioauthor=K.+Nakagawaauthor=M.+Maemondoauthor=A.+Inoueauthor=T.+Hidaauthor=N.+Yamamotoauthor=H.+Yoshiokaauthor=M.+Haradaauthor=Y.+Oheauthor=N.+Nogamiauthor=K.+Takeuchiauthor=T.+Shimadaauthor=T.+Tanakaauthor=T.+Tamura&title=CH5424802+%28RO5424802%29+for+patients+with+ALK-rearranged+advanced+non-small-cell+lung+cancer+%28AF-001JP+study%29%3A+a+single-arm%2C+open-label%2C+phase+1%E2%80%932+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study</span></div><div class="casAuthors">Seto, Takashi; Kiura, Katsuyuki; Nishio, Makoto; Nakagawa, Kazuhiko; Maemondo, Makoto; Inoue, Akira; Hida, Toyoaki; Yamamoto, Nobuyuki; Yoshioka, Hiroshige; Harada, Masao; Ohe, Yuichiro; Nogami, Naoyuki; Takeuchi, Kengo; Shimada, Tadashi; Tanaka, Tomohiro; Tamura, Tomohide</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">590-598</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Currently, crizotinib is the only drug that has been approved for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC).  We aimed to study the activity and safety of CH5424802, a potent, selective, and orally available ALK inhibitor.  In this multicenter, single-arm, open-label, phase 1-2 study of CH5424802, we recruited ALK inhibitor-naive patients with ALK-rearranged advanced NSCLC from 13 hospitals in Japan.  In the phase 1 portion of the study, patients received CH5424802 orally twice daily by dose escalation.  The primary endpoints of the phase 1 were dose limiting toxicity (DLT), max. tolerated dose (MTD), and pharmacokinetic parameters.  In the phase 2 portion of the study, patients received CH5424802 at the recommended dose identified in the phase 1 portion of the study orally twice a day.  The primary endpoint of the phase 2 was the proportion of patients who had an objective response.  Treatment was continued in 21-day cycles until disease progression, intolerable adverse events, or withdrawal of consent.  The anal. was done by intent to treat.  This study is registered with the Japan Pharmaceutical Information Center, no. JapicCTI-101264.  Patients were enrolled between Sept 10, 2010, and Apr. 18, 2012.  The data cutoff date was July 31, 2012.  In the phase 1 portion, 24 patients were treated at doses of 20-300 mg twice daily.  No DLTs or adverse events of grade 4 were noted up to the highest dose; thus 300 mg twice daily was the recommended phase 2 dose.  In the phase 2 portion of the study, 46 patients were treated with the recommended dose, of whom 43 achieved an objective response (93·5%, 95% CI 82·1-98·6) including two complete responses (4·3%, 0·5-14·8) and 41 partial responses (89·1%, 76·4-96·4).  Treatment-related adverse events of grade 3 were recorded in 12 (26%) of 46 patients, including two patients each experiencing decreased neutrophil count and increased blood creatine phosphokinase.  Serious adverse events occurred in five patients (11%).  No grade 4 adverse events or deaths were reported.  The study is still ongoing, since 40 of the 46 patients in the phase 2 portion remain on treatment.  CH5424802 is well tolerated and highly active in patients with advanced ALK-rearranged NSCLC.  Chugai Pharmaceutical Co, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXnUGKVRfsBbVg90H21EOLACvtfcHk0lgCRXVbATVqzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntV2gsrk%253D&md5=489043eede3a37bb8ce76c6f1dc0296d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970142-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970142-6%26sid%3Dliteratum%253Aachs%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMaemondo%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DHida%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DYoshioka%26aufirst%3DH.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DTamura%26aufirst%3DT.%26atitle%3DCH5424802%2520%2528RO5424802%2529%2520for%2520patients%2520with%2520ALK-rearranged%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528AF-001JP%2520study%2529%253A%2520a%2520single-arm%252C%2520open-label%252C%2520phase%25201%25E2%2580%25932%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3D590%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Ye, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of a series of benzo[de]-[1,7]naphthyridin-7(8<i>H</i>)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2885</span><span class="NLM_x">–</span> <span class="NLM_lpage">2903</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301825t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2885-2903&author=N.+Yeauthor=C.-H.+Chenauthor=T.+T.+Chenauthor=Z.+Songauthor=J.+Heauthor=X.+Huanauthor=S.+Songauthor=Q.+Liuauthor=Y.+Chenauthor=J.+Dingauthor=Y.+Xuauthor=Z.+Miaoauthor=A.+Zhang&title=Design%2C+synthesis+and+biological+evaluation+of+a+series+of+benzo%5Bde%5D-%5B1%2C7%5Dnaphthyridin-7%288H%29-ones+bearing+a+functionalized+longer+chain+appendage+as+novel+PARP1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm301825t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301825t%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DChen%26aufirst%3DT.%2BT.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DHuan%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520benzo%255Bde%255D-%255B1%252C7%255Dnaphthyridin-7%25288H%2529-ones%2520bearing%2520a%2520functionalized%2520longer%2520chain%2520appendage%2520as%2520novel%2520PARP1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2885%26epage%3D2903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ya, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent c-Met/ALK multikinase inhibitory activities</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml400373j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=304-308&author=Z.+Liuauthor=J.+Aiauthor=X.+Pengauthor=Z.+Songauthor=K.+Wuauthor=J.+Zhangauthor=Q.+Yaauthor=Y.+Chenauthor=Y.+Jiauthor=Y.+Yangauthor=M.+Gengauthor=A.+Zhang&title=Novel+2%2C4-diarylaminopyrimidine+analogues+%28DAAPalogues%29+showing+potent+c-Met%2FALK+multikinase+inhibitory+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fml400373j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400373j%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYa%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DNovel%25202%252C4-diarylaminopyrimidine%2520analogues%2520%2528DAAPalogues%2529%2520showing%2520potent%2520c-Met%252FALK%2520multikinase%2520inhibitory%2520activities%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D304%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Milkiewicz, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobelny, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoSardo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worrell, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeigler, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6274</span><span class="NLM_x">–</span> <span class="NLM_lpage">6284</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=6274-6284&author=K.+L.+Milkiewiczauthor=L.+D.+Aimoneauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=H.+Changauthor=J.+V.+Grobelnyauthor=J.+Hustenauthor=C.+LoSardoauthor=T.+L.+Underinerauthor=L.+R.+Weinbergauthor=C.+S.+Worrellauthor=K.+S.+Zeiglerauthor=B.+D.+Dorsey&title=Improvement+in+oral+bioavailability+of+2%2C4-diaminopyrimidine+c-Met+inhibitors+by+incorporation+of+a+3-amidobenzazepin-2-one+group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DGrobelny%26aufirst%3DJ.%2BV.%26aulast%3DHusten%26aufirst%3DJ.%26aulast%3DLoSardo%26aufirst%3DC.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DWeinberg%26aufirst%3DL.%2BR.%26aulast%3DWorrell%26aufirst%3DC.%2BS.%26aulast%3DZeigler%26aufirst%3DK.%2BS.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DImprovement%2520in%2520oral%2520bioavailability%2520of%25202%252C4-diaminopyrimidine%2520c-Met%2520inhibitors%2520by%2520incorporation%2520of%2520a%25203-amidobenzazepin-2-one%2520group%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D6274%26epage%3D6284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Song, Z.; Ai, J.; Liu, Z.; Peng, X.; Geng, M.; Zhang, A.</span><span> </span><span class="NLM_article-title">Discovery of 2,4-diarylaminopyrimidine SOMCL-12–81 as a potent inhibitor targeting both wild and mutant ALK kinase</span>. Presented at the Annual Meeting of the American Association for Cancer Research (AACR), Boston, MA,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Abstract B90.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Song%2C+Z.%3B+Ai%2C+J.%3B+Liu%2C+Z.%3B+Peng%2C+X.%3B+Geng%2C+M.%3B+Zhang%2C+A.+Discovery+of+2%2C4-diarylaminopyrimidine+SOMCL-12%E2%80%9381+as+a+potent+inhibitor+targeting+both+wild+and+mutant+ALK+kinase.+Presented+at+the+Annual+Meeting+of+the+American+Association+for+Cancer+Research+%28AACR%29%2C+Boston%2C+MA%2C+2013%3B+Abstract+B90."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%25202%252C4-diarylaminopyrimidine%2520SOMCL-12%25E2%2580%259381%2520as%2520a%2520potent%2520inhibitor%2520targeting%2520both%2520wild%2520and%2520mutant%2520ALK%2520kinase%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Gray, N. S.; Zhou, W.</span>. <span> </span><span class="NLM_article-title">Preparation of pyrimidinyl benzamides and similar compounds as therapeutic modulators of mutant EGFR activity</span>. PCT Int. Appl. WO 2011140338,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+S.+Gray&author=W.+Zhou&title=Preparation+of+pyrimidinyl+benzamides+and+similar+compounds+as+therapeutic+modulators+of+mutant+EGFR+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DPreparation%2520of%2520pyrimidinyl%2520benzamides%2520and%2520similar%2520compounds%2520as%2520therapeutic%2520modulators%2520of%2520mutant%2520EGFR%2520activity%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Khan, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taha, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maharvi, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saify, Z. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parveen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhary, M. I.</span><span> </span><span class="NLM_article-title">Leishmanicidal potential of N-substituted morpholine derivatives: Synthesis and structure-activity relationships</span> <span class="citation_source-journal">Nat. Prod. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1080%2F14786410802090359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=19296393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=479-484&author=K.+M.+Khanauthor=M.+Z.+Khanauthor=M.+Tahaauthor=G.+M.+Maharviauthor=Z.+S.+Saifyauthor=S.+Parveenauthor=M.+I.+Choudhary&title=Leishmanicidal+potential+of+N-substituted+morpholine+derivatives%3A+Synthesis+and+structure-activity+relationships"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Leishmanicidal potential of N-substituted morpholine derivatives: synthesis and structure-activity relationships</span></div><div class="casAuthors">Mohammed Khan, Khalid; Khan, Muhammad Zarrar; Taha, Muhammad; Maharvi, Ghulam Murtaza; Saify, Zafar Saeed; Parveen, Shahnaz; Choudhary, Muhammad Iqbal</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">479-484</span>CODEN:
                <span class="NLM_cas:coden">NPRAAT</span>;
        ISSN:<span class="NLM_cas:issn">1478-6419</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A series of N-substituted morpholines 2-20 was synthesized by reacting various acid chlorides and alkyl halides with morpholine (1).  All of the synthesized compds. 2-20 were screened for their leishmanicidal effects using amphotericin B (IC50 = 0.24 μg L-1) and pentamidine (IC50 = 2.56 μg mL-1) as stds. and a structure-activity relationship (SAR) study was established.  The compds. 2 (IC50 = 48 μg mL-1), 3 (IC50 = 30.0 μg mL-1), 10 (IC50 = 41.0 μg mL-1), 15 (IC50 = 33.0 μg mL-1), 16 (IC50 = 35.0 μg mL-1) and 20 (IC50 = 47.0 μg mL-1) showed weak leishmanicidal activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeTNqa0K11p7Vg90H21EOLACvtfcHk0ljOMAlgshaVRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWlsb0%253D&md5=67b1bd4421aa9be9d808d58cc14fa56a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1080%2F14786410802090359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14786410802090359%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DK.%2BM.%26aulast%3DKhan%26aufirst%3DM.%2BZ.%26aulast%3DTaha%26aufirst%3DM.%26aulast%3DMaharvi%26aufirst%3DG.%2BM.%26aulast%3DSaify%26aufirst%3DZ.%2BS.%26aulast%3DParveen%26aufirst%3DS.%26aulast%3DChoudhary%26aufirst%3DM.%2BI.%26atitle%3DLeishmanicidal%2520potential%2520of%2520N-substituted%2520morpholine%2520derivatives%253A%2520Synthesis%2520and%2520structure-activity%2520relationships%26jtitle%3DNat.%2520Prod.%2520Res.%26date%3D2009%26volume%3D23%26spage%3D479%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Mologni, L.</span><span> </span><span class="NLM_article-title">Inhibitors of the anaplastic lymphoma kinase</span> <span class="citation_source-journal">Expert Opin Investig. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">985</span><span class="NLM_x">–</span> <span class="NLM_lpage">994</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=985-994&author=L.+Mologni&title=Inhibitors+of+the+anaplastic+lymphoma+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26atitle%3DInhibitors%2520of%2520the%2520anaplastic%2520lymphoma%2520kinase%26jtitle%3DExpert%2520Opin%2520Investig.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D985%26epage%3D994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Galetta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisconti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colucci, G.</span><span> </span><span class="NLM_article-title">The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">S45</span><span class="NLM_x">–</span> <span class="NLM_lpage">S54</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=S45-S54&author=D.+Galettaauthor=A.+Rossiauthor=S.+Piscontiauthor=G.+Colucci&title=The+emerging+role+of+ALK+inhibitors+in+the+treatment+of+advanced+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGaletta%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DPisconti%26aufirst%3DS.%26aulast%3DColucci%26aufirst%3DG.%26atitle%3DThe%2520emerging%2520role%2520of%2520ALK%2520inhibitors%2520in%2520the%2520treatment%2520of%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2012%26volume%3D16%26spage%3DS45%26epage%3DS54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzalone, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml100158s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=493-498&author=G.+R.+Ottauthor=R.+Tripathyauthor=M.+Chengauthor=R.+McHughauthor=A.+V.+Anzaloneauthor=T.+L.+Underinerauthor=M.+A.+Curryauthor=M.+R.+Quailauthor=L.+Luauthor=W.+Wanauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+a+potent+inhibitor+of+anaplastic+lymphoma+kinase+with+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Tripathy, Rabindranath; Cheng, Mangeng; McHugh, Robert; Anzalone, Andrew V.; Underiner, Ted L.; Curry, Matthew A.; Quail, Matthew R.; Lu, Lihui; Wan, Weihua; Angeles, Thelma S.; Albom, Mark S.; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">493-498</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 7-amino-1,3,4,5-tetrahydrobenzo[b]azepin-2-one derivs. within the diaminopyrimidine class of kinase inhibitors were identified that target anaplastic lymphoma kinase (ALK).  These inhibitors are potent against ALK in an isolated enzyme assay and inhibit autophosphorylation of the oncogenic fusion protein NPM-ALK in anaplastic large cell lymphoma (ALCL) cell lines.  The lead inhibitor 15 (I), which incorporates a bicyclo[2.2.1]hept-5-ene ring system in place of an aryl moiety, activates the pro-apoptotic caspases (3 and 7) and displays selective cytotoxicity against ALK-pos. ALCL cells.  Furthermore, 15 provides more than 40-fold selectivity against the structurally related insulin receptor, is orally bioavailable in multiple species, and displays in vivo antitumor efficacy when dosed orally in ALK-pos. ALCL tumor xenografts in Scid mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof0qilbcAbZ7Vg90H21EOLACvtfcHk0lji0wD0KaGd0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ&md5=15d4f7aea64f212338d8c9cd88a36c64</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fml100158s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100158s%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DTripathy%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DMcHugh%26aufirst%3DR.%26aulast%3DAnzalone%26aufirst%3DA.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D493%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: Identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)-quinoline as a novel anticancer agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2127</span><span class="NLM_x">–</span> <span class="NLM_lpage">2142</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101340q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2127-2142&author=Y.+Wangauthor=J.+Aiauthor=Y.+Wangauthor=Y.+Chenauthor=L.+Wangauthor=G.+Liuauthor=M.+Gengauthor=A.+Zhang&title=Synthesis+and+c-Met+kinase+inhibition+of+3%2C5-disubstituted+and+3%2C5%2C7-trisubstituted+quinolines%3A+Identification+of+3-%284-acetylpiperazin-1-yl%29-5-%283-nitrobenzylamino%29-7-+%28trifluoromethyl%29-quinoline+as+a+novel+anticancer+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm101340q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101340q%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520c-Met%2520kinase%2520inhibition%2520of%25203%252C5-disubstituted%2520and%25203%252C5%252C7-trisubstituted%2520quinolines%253A%2520Identification%2520of%25203-%25284-acetylpiperazin-1-yl%2529-5-%25283-nitrobenzylamino%2529-7-%2520%2528trifluoromethyl%2529-quinoline%2520as%2520a%2520novel%2520anticancer%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2127%26epage%3D2142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristofani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machiorlatti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inghirami, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span> </span><span class="NLM_article-title">CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">670</span><span class="NLM_x">–</span> <span class="NLM_lpage">679</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1158%2F1535-7163.MCT-11-0776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=22203728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=670-679&author=M.+Chengauthor=M.+R.+Quailauthor=D.+E.+Gingrichauthor=G.+R.+Ottauthor=L.+Luauthor=W.+Wanauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=F.+Cristofaniauthor=R.+Machiorlattiauthor=C.+Abeleauthor=M.+A.+Atorauthor=B.+D.+Dorseyauthor=G.+Inghiramiauthor=B.+A.+Ruggeri&title=CEP-28122%2C+a+highly+potent+and+selective+orally+active+inhibitor+of+anaplastic+lymphoma+kinase+with+antitumor+activity+in+experimental+models+of+human+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers</span></div><div class="casAuthors">Cheng, Mangeng; Quail, Matthew R.; Gingrich, Diane E.; Ott, Gregory R.; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Cristofani, Flavio; Machiorlatti, Rodolfo; Abele, Cristina; Ator, Mark A.; Dorsey, Bruce D.; Inghirami, Giorgio; Ruggeri, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">670-679</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is constitutively activated in a no. of human cancer types due to chromosomal translocations, point mutations, and gene amplification and has emerged as an excellent mol. target for cancer therapy.  Here we report the identification and preclin. characterization of CEP-28122, a highly potent and selective orally active ALK inhibitor.  CEP-28122 is a potent inhibitor of recombinant ALK activity and cellular ALK tyrosine phosphorylation.  It induced concn.-dependent growth inhibition/cytotoxicity of ALK-pos. anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells, and displayed dose-dependent inhibition of ALK tyrosine phosphorylation in tumor xenografts in mice, with substantial target inhibition (>90%) for more than 12 h following single oral dosing at 30 mg/kg.  Dose-dependent antitumor activity was obsd. in ALK-pos. ALCL, NSCLC, and neuroblastoma tumor xenografts in mice administered CEP-28122 orally, with complete/near complete tumor regressions obsd. following treatment at doses of 30 mg/kg twice daily or higher.  Treatment of mice bearing Sup-M2 tumor xenografts for 4 wk and primary human ALCL tumor grafts for 2 wk at 55 or 100 mg/kg twice daily led to sustained tumor regression in all mice, with no tumor reemergence for more than 60 days postcessation of treatment.  Conversely, CEP-28122 displayed marginal antitumor activity against ALK-neg. human tumor xenografts under the same dosing regimens.  Administration of CEP-28122 was well tolerated in mice and rats.  In summary, CEP-28122 is a highly potent and selective orally active ALK inhibitor with a favorable pharmaceutical and pharmacokinetic profile and robust and selective pharmacol. efficacy against ALK-pos. human cancer cells and tumor xenograft models in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWAF2Kawjc8rVg90H21EOLACvtfcHk0lji0wD0KaGd0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D&md5=40001fb02de25d0f78bb11a41819651a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0776%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DCristofani%26aufirst%3DF.%26aulast%3DMachiorlatti%26aufirst%3DR.%26aulast%3DAbele%26aufirst%3DC.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DInghirami%26aufirst%3DG.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26atitle%3DCEP-28122%252C%2520a%2520highly%2520potent%2520and%2520selective%2520orally%2520active%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520with%2520antitumor%2520activity%2520in%2520experimental%2520models%2520of%2520human%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D670%26epage%3D679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieu, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lisko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesaros, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6328</span><span class="NLM_x">–</span> <span class="NLM_lpage">6341</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200758k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6328-6341&author=G.+R.+Ottauthor=G.+J.+Wellsauthor=T.+V.+Thieuauthor=M.+R.+Quailauthor=J.+G.+Liskoauthor=E.+F.+Mesarosauthor=D.+E.+Gingrichauthor=A.+K.+Ghoseauthor=W.+Wanauthor=L.+Luauthor=M.+Chengauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=2%2C7-Disubstituted-pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazines%3A+new+variant+of+an+old+template+and+application+to+the+discovery+of+anaplastic+lymphoma+kinase+%28ALK%29+inhibitors+with+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm200758k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200758k%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3D2%252C7-Disubstituted-pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazines%253A%2520new%2520variant%2520of%2520an%2520old%2520template%2520and%2520application%2520to%2520the%2520discovery%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitors%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6328%26epage%3D6341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 33 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, <span class="NLM_string-name hlFld-ContribAuthor">Tingjun Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 10927-10954. <a href="https://doi.org/10.1021/acs.jmedchem.9b00446" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00446</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BDiscovery%252BTargeting%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DKong%26aufirst%3DXiaotian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D26082019%26date%3D16082019%26volume%3D62%26issue%3D24%26spage%3D10927%26epage%3D10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James A.  Bull</span>, <span class="hlFld-ContribAuthor ">Rosemary A.  Croft</span>, <span class="hlFld-ContribAuthor ">Owen A.  Davis</span>, <span class="hlFld-ContribAuthor ">Robert  Doran</span>, and <span class="hlFld-ContribAuthor ">Kate F.  Morgan</span>  . </span><span class="cited-content_cbyCitation_article-title">Oxetanes: Recent Advances in Synthesis, Reactivity, and Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2016,</strong> <em>116 </em>
                                    (19)
                                     , 12150-12233. <a href="https://doi.org/10.1021/acs.chemrev.6b00274" title="DOI URL">https://doi.org/10.1021/acs.chemrev.6b00274</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.6b00274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.6b00274%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DOxetanes%25253A%252BRecent%252BAdvances%252Bin%252BSynthesis%25252C%252BReactivity%25252C%252Band%252BMedicinal%252BChemistry%26aulast%3DBull%26aufirst%3DJames%2BA.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D28042016%26date%3D15092016%26date%3D12102016%26volume%3D116%26issue%3D19%26spage%3D12150%26epage%3D12233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gregory R.  Ott</span>, <span class="hlFld-ContribAuthor ">Mangeng  Cheng</span>, <span class="hlFld-ContribAuthor ">Keith S.  Learn</span>, <span class="hlFld-ContribAuthor ">Jason  Wagner</span>, <span class="hlFld-ContribAuthor ">Diane E.  Gingrich</span>, <span class="hlFld-ContribAuthor ">Joseph G.  Lisko</span>, <span class="hlFld-ContribAuthor ">Matthew  Curry</span>, <span class="hlFld-ContribAuthor ">Eugen F.  Mesaros</span>, <span class="hlFld-ContribAuthor ">Arup K.  Ghose</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Quail</span>, <span class="hlFld-ContribAuthor ">Weihua  Wan</span>, <span class="hlFld-ContribAuthor ">Lihui  Lu</span>, <span class="hlFld-ContribAuthor ">Pawel  Dobrzanski</span>, <span class="hlFld-ContribAuthor ">Mark S.  Albom</span>, <span class="hlFld-ContribAuthor ">Thelma S.  Angeles</span>, <span class="hlFld-ContribAuthor ">Kevin  Wells-Knecht</span>, <span class="hlFld-ContribAuthor ">Zeqi  Huang</span>, <span class="hlFld-ContribAuthor ">Lisa D.  Aimone</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Bruckheimer</span>, <span class="hlFld-ContribAuthor ">Nathan  Anderson</span>, <span class="hlFld-ContribAuthor ">Jay  Friedman</span>, <span class="hlFld-ContribAuthor ">Sandra V.  Fernandez</span>, <span class="hlFld-ContribAuthor ">Mark A.  Ator</span>, <span class="hlFld-ContribAuthor ">Bruce A.  Ruggeri</span>, and <span class="hlFld-ContribAuthor ">Bruce D.  Dorsey</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (16)
                                     , 7478-7496. <a href="https://doi.org/10.1021/acs.jmedchem.6b00487" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00487%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BClinical%252BCandidate%252BCEP-37440%25252C%252Ba%252BSelective%252BInhibitor%252Bof%252BFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%252Band%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DOtt%26aufirst%3DGregory%2BR.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D01042016%26date%3D15082016%26date%3D25082016%26volume%3D59%26issue%3D16%26spage%3D7478%26epage%3D7496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei-Sheng  Huang</span>, <span class="hlFld-ContribAuthor ">Shuangying  Liu</span>, <span class="hlFld-ContribAuthor ">Dong  Zou</span>, <span class="hlFld-ContribAuthor ">Mathew  Thomas</span>, <span class="hlFld-ContribAuthor ">Yihan  Wang</span>, <span class="hlFld-ContribAuthor ">Tianjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Jan  Romero</span>, <span class="hlFld-ContribAuthor ">Anna  Kohlmann</span>, <span class="hlFld-ContribAuthor ">Feng  Li</span>, <span class="hlFld-ContribAuthor ">Jiwei  Qi</span>, <span class="hlFld-ContribAuthor ">Lisi  Cai</span>, <span class="hlFld-ContribAuthor ">Timothy A.  Dwight</span>, <span class="hlFld-ContribAuthor ">Yongjin  Xu</span>, <span class="hlFld-ContribAuthor ">Rongsong  Xu</span>, <span class="hlFld-ContribAuthor ">Rory  Dodd</span>, <span class="hlFld-ContribAuthor ">Angela  Toms</span>, <span class="hlFld-ContribAuthor ">Lois  Parillon</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Lu</span>, <span class="hlFld-ContribAuthor ">Rana  Anjum</span>, <span class="hlFld-ContribAuthor ">Sen  Zhang</span>, <span class="hlFld-ContribAuthor ">Frank  Wang</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Keats</span>, <span class="hlFld-ContribAuthor ">Scott D.  Wardwell</span>, <span class="hlFld-ContribAuthor ">Yaoyu  Ning</span>, <span class="hlFld-ContribAuthor ">Qihong  Xu</span>, <span class="hlFld-ContribAuthor ">Lauren E.  Moran</span>, <span class="hlFld-ContribAuthor ">Qurish K.  Mohemmad</span>, <span class="hlFld-ContribAuthor ">Hyun Gyung  Jang</span>, <span class="hlFld-ContribAuthor ">Tim  Clackson</span>, <span class="hlFld-ContribAuthor ">Narayana I.  Narasimhan</span>, <span class="hlFld-ContribAuthor ">Victor M.  Rivera</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Zhu</span>, <span class="hlFld-ContribAuthor ">David  Dalgarno</span>, and <span class="hlFld-ContribAuthor ">William C.  Shakespeare</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (10)
                                     , 4948-4964. <a href="https://doi.org/10.1021/acs.jmedchem.6b00306" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBrigatinib%252B%252528AP26113%252529%25252C%252Ba%252BPhosphine%252BOxide-Containing%25252C%252BPotent%25252C%252BOrally%252BActive%252BInhibitor%252Bof%252BAnaplastic%252BLymphoma%252BKinase%26aulast%3DHuang%26aufirst%3DWei-Sheng%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D26022016%26date%3D12052016%26date%3D26052016%26date%3D04052016%26volume%3D59%26issue%3D10%26spage%3D4948%26epage%3D4964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Jing  Pang</span>, <span class="hlFld-ContribAuthor ">Xiu-Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan  Liu</span>, <span class="hlFld-ContribAuthor ">Wen-Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Yin-Ru  Li</span>, <span class="hlFld-ContribAuthor ">Guang-Xi  Yu</span>, <span class="hlFld-ContribAuthor ">Xin-Yi  Tian</span>, <span class="hlFld-ContribAuthor ">Yan-Bing  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Song</span>, <span class="hlFld-ContribAuthor ">Cheng-Yun  Jin</span>, <span class="hlFld-ContribAuthor ">Sai-Yang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (14)
                                     , 4250. <a href="https://doi.org/10.3390/molecules26144250" title="DOI URL">https://doi.org/10.3390/molecules26144250</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26144250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26144250%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDrug%252BDiscovery%252BTargeting%252BFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%252Bas%252Ba%252BPromising%252BCancer%252BTherapy%26aulast%3DPang%26aufirst%3DXiao-Jing%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D14%26spage%3D4250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhou  Deng</span>, <span class="hlFld-ContribAuthor ">Guyue  Chen</span>, <span class="hlFld-ContribAuthor ">Shuang  Liu</span>, <span class="hlFld-ContribAuthor ">Yunzhan  Li</span>, <span class="hlFld-ContribAuthor ">Jiaji  Zhong</span>, <span class="hlFld-ContribAuthor ">Baoding  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Huiying  Huang</span>, <span class="hlFld-ContribAuthor ">Zheng  Wang</span>, <span class="hlFld-ContribAuthor ">Qingyan  Xu</span>, <span class="hlFld-ContribAuthor ">Xianming  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>206 </em>, 112697. <a href="https://doi.org/10.1016/j.ejmech.2020.112697" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112697</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112697%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bmethyl%252B3-%252528%2525282-%252528%2525281-%252528dimethylglycyl%252529-5-methoxyindolin-6-yl%252529amino%252529-5-%252528trifluoro-methyl%252529%252Bpyrimidin-4-yl%252529amino%252529thiophene-2-carboxylate%252Bas%252Ba%252Bpotent%252Band%252Bselective%252Bpolo-like%252Bkinase%252B1%252B%252528PLK1%252529%252Binhibitor%252Bfor%252Bcombating%252Bhepatocellular%252Bcarcinoma%26aulast%3DDeng%26aufirst%3DZhou%26date%3D2020%26volume%3D206%26spage%3D112697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minglin  Zhu</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Tianming  Zhao</span>, <span class="hlFld-ContribAuthor ">Yuxiang  Chen</span>, <span class="hlFld-ContribAuthor ">Tong  Li</span>, <span class="hlFld-ContribAuthor ">Shangfei  Wei</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (20)
                                     , 115719. <a href="https://doi.org/10.1016/j.bmc.2020.115719" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115719</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115719%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DFragment-based%252Bmodification%252Bof%252B2%25252C4-diarylaminopyrimidine%252Bderivatives%252Bas%252BALK%252Band%252BROS1%252Bdual%252Binhibitors%252Bto%252Bovercome%252Bsecondary%252Bmutants%26aulast%3DZhu%26aufirst%3DMinglin%26date%3D2020%26volume%3D28%26issue%3D20%26spage%3D115719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuqi  Miao</span>, <span class="hlFld-ContribAuthor ">Lingyun  Xing</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Hong  Zhang</span>, <span class="hlFld-ContribAuthor ">Sicong  Liu</span>, <span class="hlFld-ContribAuthor ">Shiliang  Yin</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Dajun  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 2-arylaminopyrimidine derivatives bearing 1,3,8-triazaspiro[4,5]decan-4-one or piperidine-3-carboxamide moiety as novel Type-I1/2 ALK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>94 </em>, 103456. <a href="https://doi.org/10.1016/j.bioorg.2019.103456" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103456</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103456%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2-arylaminopyrimidine%252Bderivatives%252Bbearing%252B1%25252C3%25252C8-triazaspiro%25255B4%25252C5%25255Ddecan-4-one%252Bor%252Bpiperidine-3-carboxamide%252Bmoiety%252Bas%252Bnovel%252BType-I1%25252F2%252BALK%252Binhibitors%26aulast%3DMiao%26aufirst%3DXiuqi%26date%3D2020%26volume%3D94%26spage%3D103456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Ridong  Li</span>, <span class="hlFld-ContribAuthor ">Xianling  Ning</span>, <span class="hlFld-ContribAuthor ">Xuyang  Zhao</span>, <span class="hlFld-ContribAuthor ">Yan  Jin</span>, <span class="hlFld-ContribAuthor ">Yuxin  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>178 </em>, 141-153. <a href="https://doi.org/10.1016/j.ejmech.2019.05.060" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.060%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Banti-tumor%252Befficacy%252Bof%252Bnovel%252B2%25252C%252B4-diarylaminopyrimidine%252Bderivatives%252Bbearing%252BN-%2525283-pyridinylmethyl%252529%252Burea%252Bmoiety%252Bas%252Banaplastic%252Blymphoma%252Bkinase%252Binhibitors%26aulast%3DChen%26aufirst%3DHong%26date%3D2019%26volume%3D178%26spage%3D141%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D.  Anusha</span>, <span class="hlFld-ContribAuthor ">S.  Sharanya</span>, <span class="hlFld-ContribAuthor ">Ramya  Ramya</span>, <span class="hlFld-ContribAuthor ">Darling Chellathai  David</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer Screening of the Phytochemicals Present in the Medicinal Plant Vitex Negundo Against Mutant Anaplastic Lymphoma Kinase (ALK) Protein: An In-Silico Approach. </span><span class="cited-content_cbyCitation_journal-name">Biomedical and Pharmacology Journal</span><span> <strong>2019,</strong> <em>12 </em>
                                    (2)
                                     , 993-1000. <a href="https://doi.org/10.13005/bpj/1727" title="DOI URL">https://doi.org/10.13005/bpj/1727</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.13005/bpj/1727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.13005%2Fbpj%2F1727%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedical%2520and%2520Pharmacology%2520Journal%26atitle%3DAnticancer%252BScreening%252Bof%252Bthe%252BPhytochemicals%252BPresent%252Bin%252Bthe%252BMedicinal%252BPlant%252BVitex%252BNegundo%252BAgainst%252BMutant%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%252BProtein%25253A%252BAn%252BIn-Silico%252BApproach%26aulast%3DAnusha%26aufirst%3DD.%26date%3D2019%26date%3D2019%26volume%3D12%26issue%3D2%26spage%3D993%26epage%3D1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Changwei  Chen</span>, <span class="hlFld-ContribAuthor ">Peichen  Pan</span>, <span class="hlFld-ContribAuthor ">Ziyang  Deng</span>, <span class="hlFld-ContribAuthor ">Dahai  Wang</span>, <span class="hlFld-ContribAuthor ">Qifan  Wu</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>, <span class="hlFld-ContribAuthor ">Sunliang  Cui</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3,6-diaryl-1H-pyrazolo[3,4-b]pyridines as potent anaplastic lymphoma kinase (ALK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (7)
                                     , 912-916. <a href="https://doi.org/10.1016/j.bmcl.2019.01.037" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.01.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.01.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.01.037%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B3%25252C6-diaryl-1H-pyrazolo%25255B3%25252C4-b%25255Dpyridines%252Bas%252Bpotent%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Binhibitors%26aulast%3DChen%26aufirst%3DChangwei%26date%3D2019%26volume%3D29%26issue%3D7%26spage%3D912%26epage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">You-Lu  Pan</span>, <span class="hlFld-ContribAuthor ">Yan-Ling  Liu</span>, <span class="hlFld-ContribAuthor ">Jian-Zhong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular simulation studies on the binding activity and selectivity of 3-amino-phenyl-5-chloro-pyrimidine-2, 4-diamine derivatives in complexes with kinases
              c
              -Met and ALK. </span><span class="cited-content_cbyCitation_journal-name">Molecular Simulation</span><span> <strong>2019,</strong> <em>45 </em>
                                    (1)
                                     , 1-14. <a href="https://doi.org/10.1080/08927022.2018.1515486" title="DOI URL">https://doi.org/10.1080/08927022.2018.1515486</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/08927022.2018.1515486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F08927022.2018.1515486%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Simulation%26atitle%3DMolecular%252Bsimulation%252Bstudies%252Bon%252Bthe%252Bbinding%252Bactivity%252Band%252Bselectivity%252Bof%252B3-amino-phenyl-5-chloro-pyrimidine-2%25252C%252B4-diamine%252Bderivatives%252Bin%252Bcomplexes%252Bwith%252Bkinases%252Bc%252B-Met%252Band%252BALK%26aulast%3DPan%26aufirst%3DYou-Lu%26date%3D2019%26date%3D2018%26volume%3D45%26issue%3D1%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun-Yan  Sang</span>, <span class="hlFld-ContribAuthor ">Wen-Wen  Qin</span>, <span class="hlFld-ContribAuthor ">Xiu-Juan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Xu</span>, <span class="hlFld-ContribAuthor ">You-Zhen  Ma</span>, <span class="hlFld-ContribAuthor ">Xing-Rong  Wang</span>, <span class="hlFld-ContribAuthor ">Ling  Hui</span>, <span class="hlFld-ContribAuthor ">Shi-Wu  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and identification of 2,4-bisanilinopyrimidines bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential Aurora A inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (1)
                                     , 65-78. <a href="https://doi.org/10.1016/j.bmc.2018.11.006" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.11.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.11.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bidentification%252Bof%252B2%25252C4-bisanilinopyrimidines%252Bbearing%252B2%25252C2%25252C6%25252C6-tetramethylpiperidine-N-oxyl%252Bas%252Bpotential%252BAurora%252BA%252Binhibitors%26aulast%3DSang%26aufirst%3DChun-Yan%26date%3D2019%26volume%3D27%26issue%3D1%26spage%3D65%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingyun  Xing</span>, <span class="hlFld-ContribAuthor ">Tongfei  Jing</span>, <span class="hlFld-ContribAuthor ">Junlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Xiuqi  Miao</span>, <span class="hlFld-ContribAuthor ">Feng  Jiang</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation N2-(2-alkyoxy-6-aliphatic aminopyridin-3-yl)-2,4-diaminepyrimidine derivatives bearing acylamino or DBTD ‘head’ as potential ALK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2018,</strong> <em>81 </em>, 689-699. <a href="https://doi.org/10.1016/j.bioorg.2018.09.019" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.09.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.09.019%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252BN2-%2525282-alkyoxy-6-aliphatic%252Baminopyridin-3-yl%252529-2%25252C4-diaminepyrimidine%252Bderivatives%252Bbearing%252Bacylamino%252Bor%252BDBTD%252B%2525E2%252580%252598head%2525E2%252580%252599%252Bas%252Bpotential%252BALK%252Binhibitors%26aulast%3DXing%26aufirst%3DLingyun%26date%3D2018%26volume%3D81%26spage%3D689%26epage%3D699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Tu</span>, <span class="hlFld-ContribAuthor ">Li Ting  Song</span>, <span class="hlFld-ContribAuthor ">Hong Lin  Zhai</span>, <span class="hlFld-ContribAuthor ">Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao Yun  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Selective mechanisms and molecular design of 2,4 Diarylaminopyrimidines as ALK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2018,</strong> <em>118 </em>, 1149-1156. <a href="https://doi.org/10.1016/j.ijbiomac.2018.06.192" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2018.06.192</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2018.06.192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2018.06.192%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DSelective%252Bmechanisms%252Band%252Bmolecular%252Bdesign%252Bof%252B2%25252C4%252BDiarylaminopyrimidines%252Bas%252BALK%252Binhibitors%26aulast%3DTu%26aufirst%3DJing%26date%3D2018%26volume%3D118%26spage%3D1149%26epage%3D1156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rosemary A.  Croft</span>, <span class="hlFld-ContribAuthor ">James J.  Mousseau</span>, <span class="hlFld-ContribAuthor ">Chulho  Choi</span>, <span class="hlFld-ContribAuthor ">James A.  Bull</span>. </span><span class="cited-content_cbyCitation_article-title">Oxetane ethers are formed reversibly in the lithium-catalyzed Friedel–Crafts alkylation of phenols with oxetanols: Synthesis of dihydrobenzofurans, diaryloxetanes, and oxetane ethers. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2018,</strong> <em>74 </em>
                                    (38)
                                     , 5427-5435. <a href="https://doi.org/10.1016/j.tet.2018.02.069" title="DOI URL">https://doi.org/10.1016/j.tet.2018.02.069</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2018.02.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2018.02.069%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DOxetane%252Bethers%252Bare%252Bformed%252Breversibly%252Bin%252Bthe%252Blithium-catalyzed%252BFriedel%2525E2%252580%252593Crafts%252Balkylation%252Bof%252Bphenols%252Bwith%252Boxetanols%25253A%252BSynthesis%252Bof%252Bdihydrobenzofurans%25252C%252Bdiaryloxetanes%25252C%252Band%252Boxetane%252Bethers%26aulast%3DCroft%26aufirst%3DRosemary%2BA.%26date%3D2018%26volume%3D74%26issue%3D38%26spage%3D5427%26epage%3D5435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nivya  James</span>, <span class="hlFld-ContribAuthor ">V.  Shanthi</span>, <span class="hlFld-ContribAuthor ">K.  Ramanathan</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Design for ALK-Positive NSCLC: an Integrated Pharmacophore-Based 3D QSAR and Virtual Screening Strategy. </span><span class="cited-content_cbyCitation_journal-name">Applied Biochemistry and Biotechnology</span><span> <strong>2018,</strong> <em>185 </em>
                                    (1)
                                     , 289-315. <a href="https://doi.org/10.1007/s12010-017-2650-x" title="DOI URL">https://doi.org/10.1007/s12010-017-2650-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12010-017-2650-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12010-017-2650-x%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Biochemistry%2520and%2520Biotechnology%26atitle%3DDrug%252BDesign%252Bfor%252BALK-Positive%252BNSCLC%25253A%252Ban%252BIntegrated%252BPharmacophore-Based%252B3D%252BQSAR%252Band%252BVirtual%252BScreening%252BStrategy%26aulast%3DJames%26aufirst%3DNivya%26date%3D2018%26date%3D2017%26volume%3D185%26issue%3D1%26spage%3D289%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaijun  Geng</span>, <span class="hlFld-ContribAuthor ">Hongchun  Liu</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Chi  Zhang</span>, <span class="hlFld-ContribAuthor ">Minmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong  Yang</span>, <span class="hlFld-ContribAuthor ">Jingchen  Cao</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Aijun  Shen</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>152 </em>, 76-86. <a href="https://doi.org/10.1016/j.ejmech.2018.04.019" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.04.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.04.019%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bpharmacological%252Bevaluation%252Bof%252BALK%252Band%252BHsp90%252Bdual%252Binhibitors%252Bbearing%252Bresorcinol%252Band%252B2%25252C4-diaminopyrimidine%252Bmotifs%26aulast%3DGeng%26aufirst%3DKaijun%26date%3D2018%26volume%3D152%26spage%3D76%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Shaowei  Chen</span>, <span class="hlFld-ContribAuthor ">Gang  Hu</span>, <span class="hlFld-ContribAuthor ">Jiao  Wang</span>, <span class="hlFld-ContribAuthor ">Wenfeng  Gou</span>, <span class="hlFld-ContribAuthor ">Daiying  Zuo</span>, <span class="hlFld-ContribAuthor ">Yucheng  Gu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 123-136. <a href="https://doi.org/10.1016/j.ejmech.2017.11.008" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.008%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B2%25252C4-diarylaminopyrimidine%252Banalogues%252Bas%252BALK%252Band%252BROS1%252Bdual%252Binhibitors%252Bto%252Bovercome%252Bcrizotinib-resistant%252Bmutants%252Bincluding%252BG1202R%26aulast%3DWang%26aufirst%3DYu%26date%3D2018%26volume%3D143%26spage%3D123%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaijun  Geng</span>, <span class="hlFld-ContribAuthor ">Zongjun  Xia</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Ruisi (Ruthy)  Zhang</span>, <span class="hlFld-ContribAuthor ">Deqiao  Sun</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>144 </em>, 386-397. <a href="https://doi.org/10.1016/j.ejmech.2017.12.060" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.12.060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.12.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.12.060%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4-diarylaminopyrimidines%252Bbearing%252Ba%252Bresorcinol%252Bmotif%252Bas%252Bnovel%252BALK%252Binhibitors%252Bto%252Bovercome%252Bthe%252BG1202R%252Bresistant%252Bmutation%26aulast%3DGeng%26aufirst%3DKaijun%26date%3D2018%26volume%3D144%26spage%3D386%26epage%3D397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanxin  Tian</span>, <span class="hlFld-ContribAuthor ">Tingting  Zhang</span>, <span class="hlFld-ContribAuthor ">Lifan  Long</span>, <span class="hlFld-ContribAuthor ">Zhonghuang  Li</span>, <span class="hlFld-ContribAuthor ">Shanhe  Wan</span>, <span class="hlFld-ContribAuthor ">Guangfa  Wang</span>, <span class="hlFld-ContribAuthor ">Yonghuan  Yu</span>, <span class="hlFld-ContribAuthor ">Ju  Hou</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Wu</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 182-199. <a href="https://doi.org/10.1016/j.ejmech.2017.11.002" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.002%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bmodeling%252Bof%252Bnovel%252B2-amino-4-%2525281-phenylethoxy%252529%252Bpyridine%252Bderivatives%252Bas%252Bpotential%252BROS1%252Binhibitors%26aulast%3DTian%26aufirst%3DYuanxin%26date%3D2018%26volume%3D143%26spage%3D182%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hyeonjeong  Choe</span>, <span class="hlFld-ContribAuthor ">Byeong Uk  Jeon</span>, <span class="hlFld-ContribAuthor ">Myoung Eun  Jung</span>, <span class="hlFld-ContribAuthor ">Moon-Kook  Jeon</span>, <span class="hlFld-ContribAuthor ">Inji  Shin</span>, <span class="hlFld-ContribAuthor ">Byoung Chul  Cho</span>, <span class="hlFld-ContribAuthor ">Gildon  Choi</span>, <span class="hlFld-ContribAuthor ">Chong Hak  Chae</span>, <span class="hlFld-ContribAuthor ">Kwangho  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Activity Relationship Study of 2,4-Dianilinopyrimidine Containing Methanesulfonamide (TRE-069) as Potent and Selective Epidermal Growth Factor Receptor T790M/C797S Mutant Inhibitor for Anticancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2017,</strong> <em>38 </em>
                                    (11)
                                     , 1353-1357. <a href="https://doi.org/10.1002/bkcs.11287" title="DOI URL">https://doi.org/10.1002/bkcs.11287</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bkcs.11287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbkcs.11287%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DStructure-Activity%252BRelationship%252BStudy%252Bof%252B2%25252C4-Dianilinopyrimidine%252BContaining%252BMethanesulfonamide%252B%252528TRE-069%252529%252Bas%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BT790M%25252FC797S%252BMutant%252BInhibitor%252Bfor%252BAnticancer%252BTreatment%26aulast%3DChoe%26aufirst%3DHyeonjeong%26date%3D2017%26date%3D2017%26volume%3D38%26issue%3D11%26spage%3D1353%26epage%3D1357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan-Dan  Li</span>, <span class="hlFld-ContribAuthor ">Fu-Long  Wu</span>, <span class="hlFld-ContribAuthor ">Zhong-Hua  Wang</span>, <span class="hlFld-ContribAuthor ">Lei-Lei  Huang</span>, <span class="hlFld-ContribAuthor ">Yan  Yin</span>, <span class="hlFld-ContribAuthor ">Fan-Hong  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of 2,4-diarylaminopyrimidine analogues as ALK inhibitors by using 3D-QSAR, molecular docking, and molecular dynamics simulations. </span><span class="cited-content_cbyCitation_journal-name">Monatshefte für Chemie - Chemical Monthly</span><span> <strong>2017,</strong> <em>148 </em>
                                    (10)
                                     , 1711-1725. <a href="https://doi.org/10.1007/s00706-017-1999-4" title="DOI URL">https://doi.org/10.1007/s00706-017-1999-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00706-017-1999-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00706-017-1999-4%26sid%3Dliteratum%253Aachs%26jtitle%3DMonatshefte%2520f%25C3%25BCr%2520Chemie%2520-%2520Chemical%2520Monthly%26atitle%3DIdentification%252Bof%252B2%25252C4-diarylaminopyrimidine%252Banalogues%252Bas%252BALK%252Binhibitors%252Bby%252Busing%252B3D-QSAR%25252C%252Bmolecular%252Bdocking%25252C%252Band%252Bmolecular%252Bdynamics%252Bsimulations%26aulast%3DLi%26aufirst%3DDan-Dan%26date%3D2017%26date%3D2017%26volume%3D148%26issue%3D10%26spage%3D1711%26epage%3D1725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raghavendra  Achary</span>, <span class="hlFld-ContribAuthor ">Gangadhar Rao  Mathi</span>, <span class="hlFld-ContribAuthor ">Dong Ho  Lee</span>, <span class="hlFld-ContribAuthor ">Chang Soo  Yun</span>, <span class="hlFld-ContribAuthor ">Chong Ock  Lee</span>, <span class="hlFld-ContribAuthor ">Hyoung Rae  Kim</span>, <span class="hlFld-ContribAuthor ">Chi Hoon  Park</span>, <span class="hlFld-ContribAuthor ">Pilho  Kim</span>, <span class="hlFld-ContribAuthor ">Jong Yeon  Hwang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (10)
                                     , 2185-2191. <a href="https://doi.org/10.1016/j.bmcl.2017.03.073" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.03.073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.03.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.03.073%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252B2%25252C4-diaminopyrimidines%252Bbearing%252Bfused%252Btricyclic%252Bring%252Bmoiety%252Bfor%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Binhibitor%26aulast%3DAchary%26aufirst%3DRaghavendra%26date%3D2017%26volume%3D27%26issue%3D10%26spage%3D2185%26epage%3D2191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gangadhar Rao  Mathi</span>, <span class="hlFld-ContribAuthor ">Chung Hyo  Kang</span>, <span class="hlFld-ContribAuthor ">Heung Kyoung  Lee</span>, <span class="hlFld-ContribAuthor ">Raghavendra  Achary</span>, <span class="hlFld-ContribAuthor ">Ha-Yeon  Lee</span>, <span class="hlFld-ContribAuthor ">Joo-Youn  Lee</span>, <span class="hlFld-ContribAuthor ">Jae Du  Ha</span>, <span class="hlFld-ContribAuthor ">Sunjoo  Ahn</span>, <span class="hlFld-ContribAuthor ">Chi Hoon  Park</span>, <span class="hlFld-ContribAuthor ">Chong Ock  Lee</span>, <span class="hlFld-ContribAuthor ">Jong Yeon  Hwang</span>, <span class="hlFld-ContribAuthor ">Chang-Soo  Yun</span>, <span class="hlFld-ContribAuthor ">Hee Jung  Jung</span>, <span class="hlFld-ContribAuthor ">Sung Yun  Cho</span>, <span class="hlFld-ContribAuthor ">Hyoung Rae  Kim</span>, <span class="hlFld-ContribAuthor ">Pilho  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>126 </em>, 536-549. <a href="https://doi.org/10.1016/j.ejmech.2016.11.046" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.11.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.11.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.11.046%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DReplacing%252Bthe%252Bterminal%252Bpiperidine%252Bin%252Bceritinib%252Bwith%252Baliphatic%252Bamines%252Bconfers%252Bactivities%252Bagainst%252Bcrizotinib-resistant%252Bmutants%252Bincluding%252BG1202R%26aulast%3DMathi%26aufirst%3DGangadhar%2BRao%26date%3D2017%26volume%3D126%26spage%3D536%26epage%3D549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Guogang  Zhang</span>, <span class="hlFld-ContribAuthor ">Gang  Hu</span>, <span class="hlFld-ContribAuthor ">Yanxin  Bu</span>, <span class="hlFld-ContribAuthor ">Hongrui  Lei</span>, <span class="hlFld-ContribAuthor ">Daiying  Zuo</span>, <span class="hlFld-ContribAuthor ">Mengting  Han</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>123 </em>, 80-89. <a href="https://doi.org/10.1016/j.ejmech.2016.06.056" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.06.056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.06.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.06.056%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B4-arylaminopyrimidine%252Bderivatives%252Bpossessing%252Ba%252Bhydrazone%252Bmoiety%252Bas%252Bdual%252Binhibitors%252Bof%252BL1196M%252BALK%252Band%252BROS1%26aulast%3DWang%26aufirst%3DYu%26date%3D2016%26volume%3D123%26spage%3D80%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mei  Han</span>, <span class="hlFld-ContribAuthor ">Chengyan  Wang</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Li  Xing</span>, <span class="hlFld-ContribAuthor ">Yi  Su</span>, <span class="hlFld-ContribAuthor ">Xisheng  Wang</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (22)
                                     , 5399-5402. <a href="https://doi.org/10.1016/j.bmcl.2016.10.039" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.10.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.10.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.10.039%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMetabolism-based%252Bstructure%252Boptimization%25253A%252BDiscovery%252Bof%252Ba%252Bpotent%252Band%252Borally%252Bavailable%252Btyrosine%252Bkinase%252BALK%252Binhibitor%252Bbearing%252Bthe%252Btetracyclic%252Bbenzo%25255Bb%25255Dcarbazolone%252Bcore%26aulast%3DHan%26aufirst%3DMei%26date%3D2016%26volume%3D26%26issue%3D22%26spage%3D5399%26epage%3D5402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Zongjun  Xia</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Li  Xing</span>, <span class="hlFld-ContribAuthor ">Yinglei  Gao</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>118 </em>, 244-249. <a href="https://doi.org/10.1016/j.ejmech.2016.04.046" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.04.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.04.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.04.046%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252Borally%252Bavailable%252Btyrosine%252Bkinase%252BALK%252Band%252BRET%252Bdual%252Binhibitor%252Bbearing%252Bthe%252Btetracyclic%252Bbenzo%25255Bb%25255Dcarbazolone%252Bcore%26aulast%3DSong%26aufirst%3DZilan%26date%3D2016%26volume%3D118%26spage%3D244%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E. V.  Koroleva</span>, <span class="hlFld-ContribAuthor ">Zh. I.  Ignatovich</span>, <span class="hlFld-ContribAuthor ">Yu. V.  Sinyutich</span>, <span class="hlFld-ContribAuthor ">K. N.  Gusak</span>. </span><span class="cited-content_cbyCitation_article-title">Aminopyrimidine derivatives as protein kinases inhibitors. Molecular design, synthesis, and biologic activity. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>52 </em>
                                    (2)
                                     , 139-177. <a href="https://doi.org/10.1134/S1070428016020019" title="DOI URL">https://doi.org/10.1134/S1070428016020019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428016020019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428016020019%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAminopyrimidine%252Bderivatives%252Bas%252Bprotein%252Bkinases%252Binhibitors.%252BMolecular%252Bdesign%25252C%252Bsynthesis%25252C%252Band%252Bbiologic%252Bactivity%26aulast%3DKoroleva%26aufirst%3DE.%2BV.%26date%3D2016%26date%3D2016%26volume%3D52%26issue%3D2%26spage%3D139%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raghavendra  Achary</span>, <span class="hlFld-ContribAuthor ">Jeong In  Yun</span>, <span class="hlFld-ContribAuthor ">Chi Min  Park</span>, <span class="hlFld-ContribAuthor ">Gangadhar Rao  Mathi</span>, <span class="hlFld-ContribAuthor ">Joo Yun  Lee</span>, <span class="hlFld-ContribAuthor ">Jae Du  Ha</span>, <span class="hlFld-ContribAuthor ">Chong Hak  Chae</span>, <span class="hlFld-ContribAuthor ">Sunjoo  Ahn</span>, <span class="hlFld-ContribAuthor ">Chi Hoon  Park</span>, <span class="hlFld-ContribAuthor ">Chong Ock  Lee</span>, <span class="hlFld-ContribAuthor ">Jong Yeon  Hwang</span>, <span class="hlFld-ContribAuthor ">Chang-Soo  Yun</span>, <span class="hlFld-ContribAuthor ">Hee Jung  Jung</span>, <span class="hlFld-ContribAuthor ">Sung Yun  Cho</span>, <span class="hlFld-ContribAuthor ">Hyoung Rae  Kim</span>, <span class="hlFld-ContribAuthor ">Pilho  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (2)
                                     , 207-219. <a href="https://doi.org/10.1016/j.bmc.2015.12.004" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.12.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.12.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Btetrahydroisoquinoline-containing%252Bpyrimidines%252Bas%252BALK%252Binhibitors%26aulast%3DAchary%26aufirst%3DRaghavendra%26date%3D2016%26volume%3D24%26issue%3D2%26spage%3D207%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaolong  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Zhou</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Li  Xing</span>, <span class="hlFld-ContribAuthor ">Yong  Xi</span>, <span class="hlFld-ContribAuthor ">Junfeng  Guo</span>, <span class="hlFld-ContribAuthor ">Qizheng  Yao</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: Design, synthesis, and structure—activity relationship study. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>105 </em>, 39-56. <a href="https://doi.org/10.1016/j.ejmech.2015.10.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.10.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.10.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Btetracyclic%252Bbenzo%25255Bb%25255Dcarbazolones%252Bas%252Bhighly%252Bpotent%252Band%252Borally%252Bbioavailable%252BALK%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Band%252Bstructure%2525E2%252580%252594activity%252Brelationship%252Bstudy%26aulast%3DJiang%26aufirst%3DXiaolong%26date%3D2015%26volume%3D105%26spage%3D39%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhiqing  Liu</span>, <span class="hlFld-ContribAuthor ">Xihua  Yue</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Junfeng  Guo</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Zhen  Cheng</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>86 </em>, 438-448. <a href="https://doi.org/10.1016/j.ejmech.2014.09.003" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.09.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.09.003%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bpharmacological%252Bevaluation%252Bof%252B2-%252528thiazol-2-amino%252529-4-arylaminopyrimidines%252Bas%252Bpotent%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Binhibitors%26aulast%3DLiu%26aufirst%3DZhiqing%26date%3D2014%26volume%3D86%26spage%3D438%26epage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Marketed ALK inhibitor <b>1</b> and new clinical inhibitors <b>2</b>–<b>4</b> (blue color denotes solvent region).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Proposed new DAAPalogues containing an amino acid side chain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>10</b>–<b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) for <b>8a</b>, <b>8b</b>, <b>8d</b>, <b>8e</b>, and <b>8f</b>, DIPEA, IPA; for <b>8c</b>, NaH, DMF; (ii) for <b>10</b>, CSA, IPA, MW, 80 °C; for <b>11</b>, Pd(OAc)<sub>2</sub>, X-Phos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, MW, 100 °C; (iii) 1-pyrrolidinecarbonyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (iv) (a) Boc-<span class="smallcaps smallerCapital">l</span>-Proline, TBTU, DIPEA, DMF; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>; (v) (a) TFA, CH<sub>2</sub>Cl<sub>2</sub>; (b) <i>tert</i>-butylisocyanate, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>15</b>–<b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) DIPEA, IPA; (ii) CSA, IPA, MW,80 °C.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>28</b>–<b>48</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) CPA, IPA, MW, 80 °C; (ii) 10% Pd/C, H<sub>2</sub>, MeOH; (iii) chloroacetyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (iv) TBTU, DIPEA, DMF; (v) K<sub>2</sub>CO<sub>3</sub>, Et<sub>3</sub>N, MeCN.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Preliminary PK results.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/medium/jm-2014-005144_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antitumor activity of compound <b>15</b> in SUP-M2 xenograft model. Mice bearing SUP-M2 were orally administered compound <b>15</b> in the HCl salt form with 0.5% CMC-Na (sodium carboxymethyl cellulose) or crizotinib in water once daily for 14 days after the tumor volume reached 80 to 100 mm<sup>3</sup> at the indicated doses. The results were expressed as the mean ± standard error (drug-treated group, <i>n</i> = 5; vehicle group, <i>n</i> = 10) **<i>p</i> < 0.01 vs vehicle group on final day, using Student’s <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5005144&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 48 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Pulford, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamant, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroud, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delsol, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, D. Y.</span><span> </span><span class="NLM_article-title">Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with themonoclonal antibody ALK1</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">1394</span><span class="NLM_x">–</span> <span class="NLM_lpage">1404</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=1394-1404&author=K.+Pulfordauthor=L.+Lamantauthor=S.+W.+Morrisauthor=L.+H.+Butlerauthor=K.+M.+Woodauthor=D.+Stroudauthor=G.+Delsolauthor=D.+Y.+Mason&title=Detection+of+anaplastic+lymphoma+kinase+%28ALK%29+and+nucleolar+protein+nucleophosmin+%28NPM%29-ALK+proteins+in+normal+and+neoplastic+cells+with+themonoclonal+antibody+ALK1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPulford%26aufirst%3DK.%26aulast%3DLamant%26aufirst%3DL.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DButler%26aufirst%3DL.%2BH.%26aulast%3DWood%26aufirst%3DK.%2BM.%26aulast%3DStroud%26aufirst%3DD.%26aulast%3DDelsol%26aufirst%3DG.%26aulast%3DMason%26aufirst%3DD.%2BY.%26atitle%3DDetection%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520nucleolar%2520protein%2520nucleophosmin%2520%2528NPM%2529-ALK%2520proteins%2520in%2520normal%2520and%2520neoplastic%2520cells%2520with%2520themonoclonal%2520antibody%2520ALK1%26jtitle%3DBlood%26date%3D1997%26volume%3D89%26spage%3D1394%26epage%3D1404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Bilsland, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeldon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mead, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Znamenskiy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thakur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heavens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiting, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAllister, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz-Sanjuan, I.</span><span> </span><span class="NLM_article-title">Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=685-700&author=J.+G.+Bilslandauthor=A.+Wheeldonauthor=A.+Meadauthor=P.+Znamenskiyauthor=S.+Almondauthor=K.+A.+Watersauthor=M.+Thakurauthor=V.+Beaumontauthor=T.+P.+Bonnertauthor=R.+Heavensauthor=P.+Whitingauthor=G.+McAllisterauthor=I.+Munoz-Sanjuan&title=Behavioral+and+neurochemical+alterations+in+mice+deficient+in+anaplastic+lymphoma+kinase+suggest+therapeutic+potential+for+psychiatric+indications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBilsland%26aufirst%3DJ.%2BG.%26aulast%3DWheeldon%26aufirst%3DA.%26aulast%3DMead%26aufirst%3DA.%26aulast%3DZnamenskiy%26aufirst%3DP.%26aulast%3DAlmond%26aufirst%3DS.%26aulast%3DWaters%26aufirst%3DK.%2BA.%26aulast%3DThakur%26aufirst%3DM.%26aulast%3DBeaumont%26aufirst%3DV.%26aulast%3DBonnert%26aufirst%3DT.%2BP.%26aulast%3DHeavens%26aufirst%3DR.%26aulast%3DWhiting%26aufirst%3DP.%26aulast%3DMcAllister%26aufirst%3DG.%26aulast%3DMunoz-Sanjuan%26aufirst%3DI.%26atitle%3DBehavioral%2520and%2520neurochemical%2520alterations%2520in%2520mice%2520deficient%2520in%2520anaplastic%2520lymphoma%2520kinase%2520suggest%2520therapeutic%2520potential%2520for%2520psychiatric%2520indications%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26spage%3D685%26epage%3D700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeve, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathew, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, D. P.</span><span> </span><span class="NLM_article-title">ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2175</span><span class="NLM_x">–</span> <span class="NLM_lpage">2188</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=2175-2188&author=S.+W.+Morrisauthor=C.+Naeveauthor=P.+Mathewauthor=P.+L.+Jamesauthor=M.+N.+Kirsteinauthor=X.+Cuiauthor=D.+P.+Witte&title=ALK%2C+the+chromosome+2+gene+locus+altered+by+the+t%282%3B5%29+in+non-Hodgkin%E2%80%99s+lymphoma%2C+encodes+a+novel+neural+receptor+tyrosine+kinase+that+is+highly+related+to+leukocyte+tyrosine+kinase+%28LTK%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DNaeve%26aufirst%3DC.%26aulast%3DMathew%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DP.%2BL.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DWitte%26aufirst%3DD.%2BP.%26atitle%3DALK%252C%2520the%2520chromosome%25202%2520gene%2520locus%2520altered%2520by%2520the%2520t%25282%253B5%2529%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%252C%2520encodes%2520a%2520novel%2520neural%2520receptor%2520tyrosine%2520kinase%2520that%2520is%2520highly%2520related%2520to%2520leukocyte%2520tyrosine%2520kinase%2520%2528LTK%2529%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D2175%26epage%3D2188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Rikova, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Possemato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeves, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetzel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macneill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakalarski, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornhauser, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gygi, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakiewicz, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comb, M. J.</span><span> </span><span class="NLM_article-title">Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">1190</span><span class="NLM_x">–</span> <span class="NLM_lpage">1203</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1190-1203&author=K.+Rikovaauthor=A.+Guoauthor=Q.+Zengauthor=A.+Possematoauthor=J.+Yuauthor=H.+Haackauthor=J.+Nardoneauthor=K.+Leeauthor=C.+Reevesauthor=Y.+Liauthor=Y.+Huauthor=Z.+Tanauthor=M.+Stokesauthor=L.+Sullivanauthor=J.+Mitchellauthor=R.+Wetzelauthor=J.+Macneillauthor=J.+M.+Renauthor=J.+Yuanauthor=C.+E.+Bakalarskiauthor=J.+Villenauthor=J.+M.+Kornhauserauthor=B.+Smithauthor=D.+Liauthor=X.+Zhouauthor=S.+P.+Gygiauthor=T.+L.+Guauthor=R.+D.+Polakiewiczauthor=J.+Rushauthor=M.+J.+Comb&title=Global+survey+of+phosphotyrosine+signaling+identifies+oncogenic+kinases+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRikova%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DPossemato%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DNardone%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DReeves%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DStokes%26aufirst%3DM.%26aulast%3DSullivan%26aufirst%3DL.%26aulast%3DMitchell%26aufirst%3DJ.%26aulast%3DWetzel%26aufirst%3DR.%26aulast%3DMacneill%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DBakalarski%26aufirst%3DC.%2BE.%26aulast%3DVillen%26aufirst%3DJ.%26aulast%3DKornhauser%26aufirst%3DJ.%2BM.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DGu%26aufirst%3DT.%2BL.%26aulast%3DPolakiewicz%26aufirst%3DR.%2BD.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DGlobal%2520survey%2520of%2520phosphotyrosine%2520signaling%2520identifies%2520oncogenic%2520kinases%2520in%2520lung%2520cancer%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D1190%26epage%3D1203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmer, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltman, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4-ALK+fusion+gene+in+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0lhmyEvEYnXL6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4-ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">2349</span><span class="NLM_x">–</span> <span class="NLM_lpage">2355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1111%2Fj.1349-7006.2008.00972.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=19032370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisF2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2008&pages=2349-2355&author=H.+Mano&title=Non-solid+oncogenes+in+solid+tumors%3A+EML4-ALK+fusion+genes+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer</span></div><div class="casAuthors">Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2349-2355</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  It is generally accepted that recurrent chromosome translocations play a major role in the mol. pathogenesis of hematol. malignancies but not of solid tumors.  However, chromosome translocations involving the e26 transformation-specific sequence transcription factor loci have been demonstrated recently in many prostate cancer cases.  Furthermore, through a functional screening with retroviral cDNA expression libraries, we have discovered the fusion-type protein tyrosine kinase echinoderm microtubule-assocd. protein like-4 (EML4)-anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) specimens.  A recurrent chromosome translocation, inv(2)(p21p23), in NSCLC generates fused mRNA encoding the amino-terminal half of EML4 ligated to the intracellular region of the receptor-type protein tyrosine kinase ALK.  EML4-ALK oligomerizes constitutively in cells through the coiled coil domain within the EML4 region, and becomes activated to exert a marked oncogenicity both in vitro and in vivo.  Break and fusion points within the EML4 locus may diverge in NSCLC cells to generate various isoforms of EML4-ALK, which may constitute -5% of NSCLC cases, at least in the Asian ethnic group.  In the present review I summarize how detection of EML4-ALK cDNA may become a sensitive diagnostic means for NSCLC cases that are pos. for the fusion gene, and discuss whether suppression of ALK enzymic activity could be an effective treatment strategy against this intractable disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbxSS7U51wKbVg90H21EOLACvtfcHk0lg0v0MggEjDzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisF2gsw%253D%253D&md5=84386550daedbd29b3a34b11a4774684</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.00972.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.00972.x%26sid%3Dliteratum%253Aachs%26aulast%3DMano%26aufirst%3DH.%26atitle%3DNon-solid%2520oncogenes%2520in%2520solid%2520tumors%253A%2520EML4-ALK%2520fusion%2520genes%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2008%26volume%3D99%26spage%3D2349%26epage%3D2355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span> </span><span class="NLM_article-title">Targeting anaplastic lymphoma kinase in lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2081</span><span class="NLM_x">–</span> <span class="NLM_lpage">2086</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1158%2F1078-0432.CCR-10-1591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=21288922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2081-2086&author=A.+T.+Shawauthor=B.+Solomon&title=Targeting+anaplastic+lymphoma+kinase+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Anaplastic Lymphoma Kinase in Lung Cancer</span></div><div class="casAuthors">Shaw, Alice T.; Solomon, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2081-2086</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Several decades of cancer research have revealed a pivotal role for tyrosine kinases as key regulators of signaling pathways, controlling cell growth and differentiation.  Deregulation of tyrosine kinase-mediated signaling occurs frequently in cancer and is believed to drive the initiation and progression of disease.  Chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (ALK) occur in a variety of human malignancies including non-small cell lung cancer (NSCLC), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.  The aberrant activation of ALK signaling leads to "oncogene addiction" and marked sensitivity to ALK inhibitors such as crizotinib (PF-02341066).  This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.  Current efforts seek to expand the role of ALK kinase inhibition in lung and other cancers and to address the mol. basis for the development of resistance.  Clin Cancer Res; 17(8); 2081-6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCqEzvXv0qJrVg90H21EOLACvtfcHk0lg0v0MggEjDzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D&md5=6d0f5e1174ba934f00c10a877a3b17e1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-1591%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%26atitle%3DTargeting%2520anaplastic%2520lymphoma%2520kinase%2520in%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2081%26epage%3D2086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Caren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinsson, I.</span><span> </span><span class="NLM_article-title">High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumors</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">416</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=416&publication_year=2008&pages=153-159&author=H.+Carenauthor=F.+Abelauthor=P.+Kognerauthor=I.+Martinsson&title=High+incidence+of+DNA+mutations+and+gene+amplifications+of+the+ALK+gene+in+advanced+sporadic+neuroblastoma+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaren%26aufirst%3DH.%26aulast%3DAbel%26aufirst%3DF.%26aulast%3DKogner%26aufirst%3DP.%26aulast%3DMartinsson%26aufirst%3DI.%26atitle%3DHigh%2520incidence%2520of%2520DNA%2520mutations%2520and%2520gene%2520amplifications%2520of%2520the%2520ALK%2520gene%2520in%2520advanced%2520sporadic%2520neuroblastoma%2520tumors%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D416%26spage%3D153%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Mossé, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudenslager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attiyeh, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquaglia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laureys, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speleman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakonarson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torkamani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schork, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodeur, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonini, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rappaport, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Identification of ALK as a major familial neuroblastoma predisposition gene</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">935</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+major+familial+neuroblastoma+predisposition+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520major%2520familial%2520neuroblastoma%2520predisposition%2520gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Janoueix-Lerosey, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lequin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugieres, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pontual, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combaret, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puisieux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schleiermacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valteau-Couanet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frebourg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyonnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delattre, O.</span><span> </span><span class="NLM_article-title">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1038%2Fnature07398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=18923523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=967-970&author=I.+Janoueix-Leroseyauthor=D.+Lequinauthor=L.+Brugieresauthor=A.+Ribeiroauthor=L.+de+Pontualauthor=V.+Combaretauthor=V.+Raynalauthor=A.+Puisieuxauthor=G.+Schleiermacherauthor=G.+Pierronauthor=D.+Valteau-Couanetauthor=T.+Frebourgauthor=J.+Michonauthor=S.+Lyonnetauthor=J.+Amielauthor=O.+Delattre&title=Somatic+and+germline+activating+mutations+of+the+ALK+kinase+receptor+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span></div><div class="casAuthors">Janoueix-Lerosey, Isabelle; Lequin, Delphine; Brugieres, Laurence; Ribeiro, Agnes; de Pontual, Loic; Combaret, Valerie; Raynal, Virginie; Puisieux, Alain; Schleiermacher, Gudrun; Pierron, Gaelle; Valteau-Couanet, Dominique; Frebourg, Thierry; Michon, Jean; Lyonnet, Stanislas; Amiel, Jeanne; Delattre, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">967-970</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma, a tumor derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumors in childhood.  It usually occurs sporadically but familial cases are obsd., with a subset of cases occurring in assocn. with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene.  Here the authors conducted genome-wide comparative genomic hybridization anal. on a large series of neuroblastomas.  Copy no. increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was obsd. recurrently.  One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development.  Through subsequent direct sequencing of cell lines and primary tumor DNAs the authors identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots.  Germline mutations were obsd. in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene.  Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity.  The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation.  Altogether, these data identify ALK as a crit. player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_O_BMCZk7rVg90H21EOLACvtfcHk0lgHB9leIj-9UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI&md5=7321fe0dc6408f9b5b3c53b8d83478ce</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnature07398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07398%26sid%3Dliteratum%253Aachs%26aulast%3DJanoueix-Lerosey%26aufirst%3DI.%26aulast%3DLequin%26aufirst%3DD.%26aulast%3DBrugieres%26aufirst%3DL.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3Dde%2BPontual%26aufirst%3DL.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DRaynal%26aufirst%3DV.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DSchleiermacher%26aufirst%3DG.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DValteau-Couanet%26aufirst%3DD.%26aulast%3DFrebourg%26aufirst%3DT.%26aulast%3DMichon%26aufirst%3DJ.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DDelattre%26aufirst%3DO.%26atitle%3DSomatic%2520and%2520germline%2520activating%2520mutations%2520of%2520the%2520ALK%2520kinase%2520receptor%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D967%26epage%3D970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takita, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Li.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igarashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, S.</span><span> </span><span class="NLM_article-title">Oncogenic mutations of ALK kinase in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=971-974&author=Y.+Chenauthor=J.+Takitaauthor=Y.+L.+Choiauthor=M.+Katoauthor=M.+Ohiraauthor=M.+Sanadaauthor=Li.+Wangauthor=M.+Sodaauthor=A.+Kikuchiauthor=T.+Igarashiauthor=A.+Nakagawaraauthor=Y.+Hayashiauthor=H.+Manoauthor=S.+Ogawa&title=Oncogenic+mutations+of+ALK+kinase+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTakita%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DSanada%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DLi.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DIgarashi%26aufirst%3DT.%26aulast%3DNakagawara%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DOncogenic%2520mutations%2520of%2520ALK%2520kinase%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D971%26epage%3D974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrady, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zozulya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanael, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Activating mutations in ALK provides a therapeutic target in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=975-978&author=R.+E.+Georgeauthor=T.+Sandaauthor=M.+Hannaauthor=S.+Frohlingauthor=W.+Lutherauthor=J.+Zhangauthor=Y.+Ahnauthor=W.+Zhouauthor=W.+B.+Londonauthor=P.+McGradyauthor=L.+Xueauthor=S.+Zozulyaauthor=V.+Gregorauthor=T.+R.+Webbauthor=S.+Nathanaelauthor=N.+S.+Grayauthor=D.+G.+Gillilandauthor=L.+Dillerauthor=H.+Greulichauthor=W.+Stephanauthor=S.+W.+Morrisauthor=M.+Meyersonauthor=A.+T.+Look&title=Activating+mutations+in+ALK+provides+a+therapeutic+target+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DV.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DNathanael%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDiller%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DStephan%26aufirst%3DW.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivating%2520mutations%2520in%2520ALK%2520provides%2520a%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D975%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Azarova, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautam, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, R. E.</span><span> </span><span class="NLM_article-title">Emerging importance of ALK in neuroblastoma</span> <span class="citation_source-journal">Semin. Cancer Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1016%2Fj.semcancer.2011.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=21945349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSktLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=267-275&author=A.+M.+Azarovaauthor=G.+Gautamauthor=R.+E.+George&title=Emerging+importance+of+ALK+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging importance of ALK in neuroblastoma</span></div><div class="casAuthors">Azarova, Anna M.; Gautam, Gargi; George, Rani E.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">267-275</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since the original descriptions of gain-of function mutations in anaplastic lymphoma kinase (ALK), interest in the role of this receptor tyrosine kinase in neuroblastoma development and as a potential therapeutic target has escalated.  As a group, the activating point mutations in full-length ALK, found in approx. 8% of all neuroblastoma tumors, are distributed evenly across different clin. stages.  However, the most frequent somatic mutation, F1174L, is assocd. with amplification of the MYCN oncogene.  This combination of features appears to confer a worse prognosis than MYCN amplification alone, suggesting a cooperative effect on neuroblastoma formation by these two proteins.  Indeed, F1174L has shown more potent transforming activity in vivo than the second most common activating mutation, R1275Q, and is responsible for innate and acquired resistance to crizotinib, a clin. relevant ALK inhibitor that will soon be com. available.  These advances cast ALK as a bona fide oncoprotein in neuroblastoma and emphasize the need to understand ALK-mediated signaling in this tumor.  This review addresses many of the current issues surrounding the role of ALK in normal development and neuroblastoma pathogenesis, and discusses the prospects for clin. effective targeted treatments based on ALK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpqmFzh9Q3frVg90H21EOLACvtfcHk0ljxZFWtgclvsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSktLzN&md5=e07445aecd9829c465f1f4023124521f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2011.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2011.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DAzarova%26aufirst%3DA.%2BM.%26aulast%3DGautam%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26atitle%3DEmerging%2520importance%2520of%2520ALK%2520in%2520neuroblastoma%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2011%26volume%3D21%26spage%3D267%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Tuma, R. S.</span><span> </span><span class="NLM_article-title">ALK gene amplified in most inflammatory breast cancers</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1093%2Fjnci%2Fdjr553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=22215853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVWhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2012&pages=87-88&author=R.+S.+Tuma&title=ALK+gene+amplified+in+most+inflammatory+breast+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">ALK Gene Amplified in Most Inflammatory Breast Cancers</span></div><div class="casAuthors">Tuma, Rabiya S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-88</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Inflammatory breast cancer (IBC) is a rare form of the disease that differs substantially from non-inflammatory breast cancer in presentation and response to therapy. Despite those differences, researchers have uncovered few mol. characteristics that distinguish IBC from non-inflammatory breast cancer, and IBC treatment generally relies on std. breast cancer regimens.  Recently, it has been reported that ALK gene amplification is a common feature of IBC tumors and that small-mol. ALK inhibitors are effective in mouse xenograft models.  Current developments on this recent report are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB9yX6fegRi7Vg90H21EOLACvtfcHk0ljxZFWtgclvsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVWhsb0%253D&md5=46e7633055aadc3aacfc6bac9b4cb591</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjr553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjr553%26sid%3Dliteratum%253Aachs%26aulast%3DTuma%26aufirst%3DR.%2BS.%26atitle%3DALK%2520gene%2520amplified%2520in%2520most%2520inflammatory%2520breast%2520cancers%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2012%26volume%3D104%26spage%3D87%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Ren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beausoleil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moritz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innocenti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comb, M. J.</span><span> </span><span class="NLM_article-title">Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">3312</span><span class="NLM_x">–</span> <span class="NLM_lpage">3323</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3312-3323&author=H.+Renauthor=Z.+P.+Tanauthor=X.+Zhuauthor=K.+Crosbyauthor=H.+Haackauthor=J.+M.+Renauthor=S.+Beausoleilauthor=A.+Moritzauthor=G.+Innocentiauthor=J.+Rushauthor=Y.+Zhangauthor=X.+M.+Zhouauthor=T.+L.+Guauthor=Y.+F.+Yangauthor=M.+J.+Comb&title=Identification+of+anaplastic+lymphoma+kinase+as+a+potential+therapeutic+target+in+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%2BP.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DBeausoleil%26aufirst%3DS.%26aulast%3DMoritz%26aufirst%3DA.%26aulast%3DInnocenti%26aufirst%3DG.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%2BM.%26aulast%3DGu%26aufirst%3DT.%2BL.%26aulast%3DYang%26aufirst%3DY.%2BF.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DIdentification%2520of%2520anaplastic%2520lymphoma%2520kinase%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3312%26epage%3D3323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span> </span><span class="NLM_article-title">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3314</span><span class="NLM_x">–</span> <span class="NLM_lpage">3322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+R.+Altonauthor=B.+Mroczkowskiauthor=G.+Los&title=Cytoreductive+antitumor+activity+of+PF-2341066%2C+a+novel+inhibitor+of+anaplastic+lymphoma+kinase+and+c-Met%2C+in+experimental+models+of+anaplastic+large-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, ∼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-γ, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0lgFjYXg54Nxzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%2BR.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DLos%26aufirst%3DG.%26atitle%3DCytoreductive%2520antitumor%2520activity%2520of%2520PF-2341066%252C%2520a%2520novel%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520c-Met%252C%2520in%2520experimental%2520models%2520of%2520anaplastic%2520large-cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.+P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-Met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lhwQ9U2jrz6Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.-P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal%E2%80%93epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal%25E2%2580%2593epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Case History: Xalkori (crizotinib), a potent and selective dual inhibitor of mesenchymal epithelial transition (MET) and anaplastic lymphoma kinase (ALK) for cancer treatment</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2013&pages=421-432&author=J.+J.+Cuiauthor=M.+McTigueauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Case+History%3A+Xalkori+%28crizotinib%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal+epithelial+transition+%28MET%29+and+anaplastic+lymphoma+kinase+%28ALK%29+for+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DCase%2520History%253A%2520Xalkori%2520%2528crizotinib%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal%2520epithelial%2520transition%2520%2528MET%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520for%2520cancer%2520treatment%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2013%26volume%3D48%26spage%3D421%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butaney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulig, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selaru, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harboring ALK gene rearrangement: A retrospective analysis</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1004</span><span class="NLM_x">–</span> <span class="NLM_lpage">1012</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1016%2FS1470-2045%2811%2970232-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=21933749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1KmtrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=1004-1012&author=A.+T.+Shawauthor=B.+Y.+Yeapauthor=B.+J.+Solomonauthor=G.+J.+Rielyauthor=J.+Gainorauthor=J.+A.+Engelmanauthor=G.+I.+Shapiroauthor=D.+B.+Costaauthor=S.-H.+I.+Ouauthor=M.+Butaneyauthor=R.+Salgiaauthor=R.+G.+Makiauthor=M.+Varella-Garciaauthor=R.+C.+Doebeleauthor=Y.-J.+Bangauthor=K.+Kuligauthor=P.+Selaruauthor=Y.+Tangauthor=K.+D.+Wilnerauthor=E.+L.+Kwakauthor=J.+W.+Clarkauthor=A.+J.+Iafrateauthor=D.+R.+Camidge&title=Effect+of+crizotinib+on+overall+survival+in+patients+with+advanced+non-small-cell+lung+cancer+harboring+ALK+gene+rearrangement%3A+A+retrospective+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis</span></div><div class="casAuthors">Shaw, Alice T.; Yeap, Beow Y.; Solomon, Benjamin J.; Riely, Gregory J.; Gainor, Justin; Engelman, Jeffrey A.; Shapiro, Geoffrey I.; Costa, Daniel B.; Ou, Sai-Hong I.; Butaney, Mohit; Salgia, Ravi; Maki, Robert G.; Varella-Garcia, Marileila; Doebele, Robert C.; Bang, Yung-Jue; Kulig, Kimary; Selaru, Paulina; Tang, Yiyun; Wilner, Keith D.; Kwak, Eunice L.; Clark, Jeffrey W.; Iafrate, A. John; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1004-1012</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">ALK gene rearrangement defines a new mol. subtype of non-small-cell lung cancer (NSCLC).  In a recent phase 1 clin. trial, the ALK tyrosine-kinase inhibitor (TKI) crizotinib showed marked antitumor activity in patients with advanced, ALK-pos. NSCLC.  To assess whether crizotinib affects overall survival in these patients, we did a retrospective study comparing survival outcomes in crizotinib-treated patients in the trial and crizotinib-naive controls screened during the same time period.  We examd. overall survival in patients with advanced, ALK-pos. NSCLC who enrolled in the phase 1 clin. trial of crizotinib, focusing on the cohort of 82 patients who had enrolled through Feb 10, 2010.  For comparators, we identified 36 ALK-pos. patients from trial sites who were not given crizotinib (ALK-pos. controls), 67 patients without ALK rearrangement but pos. for EGFR mutation, and 253 wild-type patients lacking either ALK rearrangement or EGFR mutation.  To assess differences in overall survival, we assessed subsets of clin. comparable ALK-pos. and ALK-neg. patients.  Among 82 ALK-pos. patients who were given crizotinib, median overall survival from initiation of crizotinib has not been reached (95% CI 17 mo to not reached); 1-yr overall survival was 74% (95% CI 63-82), and 2-yr overall survival was 54% (40-66).  Overall survival did not differ based on age, sex, smoking history, or ethnic origin.  Survival in 30 ALK-pos. patients who were given crizotinib in the second-line or third-line setting was significantly longer than in 23 ALK-pos. controls given any second-line therapy (median overall survival not reached [95% CI 14 mo to not reached] vs 6 mo [4-17], 1-yr overall survival 70% [95% CI 50-83] vs 44% [23-64], and 2-yr overall survival 55% [33-72] vs 12% [2-30]; hazard ratio 0.36, 95% CI 0.17-0.75; p = 0.004).  Survival in 56 crizotinib-treated, ALK-pos. patients was similar to that in 63 ALK-neg., EGFR-pos. patients given EGFR TKI therapy (median overall survival not reached [95% CI 17 mo to not reached] vs 24 mo [15-34], 1-yr overall survival 71% [95% CI 58-81] vs 74% [61-83], and 2-yr overall survival 57% [40-71] vs 52% [38-65]; p = 0.786), whereas survival in 36 crizotinib-naive, ALK-pos. controls was similar to that in 253 wild-type controls (median overall survival 20 mo [95% CI 13-26] vs 15 mo [13-17]; p = 0.244).  In patients with advanced, ALK-pos. NSCLC, crizotinib therapy is assocd. with improved survival compared with that of crizotinib-naive controls.  ALK rearrangement is not a favorable prognostic factor in advanced NSCLC.  Funding: Pfizer Inc, V Foundation for Cancer Research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMS7fRYJSyrrVg90H21EOLACvtfcHk0lgjkmNz2uGIzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1KmtrzL&md5=5482da97726293764c9fe42419d187cb</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970232-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970232-7%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DGainor%26aufirst%3DJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DKulig%26aufirst%3DK.%26aulast%3DSelaru%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DEffect%2520of%2520crizotinib%2520on%2520overall%2520survival%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520harboring%2520ALK%2520gene%2520rearrangement%253A%2520A%2520retrospective%2520analysis%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D1004%26epage%3D1012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilling, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutateladze, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weickhardt, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linderman, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heasley, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1472</span><span class="NLM_x">–</span> <span class="NLM_lpage">1482</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1158%2F1078-0432.CCR-11-2906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=22235099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1472-1482&author=R.+C.+Doebeleauthor=A.+B.+Pillingauthor=D.+L.+Aisnerauthor=T.+G.+Kutateladzeauthor=A.+T.+Leauthor=A.+J.+Weickhardtauthor=K.+L.+Kondoauthor=D.+J.+Lindermanauthor=L.+E.+Heasleyauthor=W.+A.+Franklinauthor=M.+Varella-Garciaauthor=D.+R.+Camidge&title=Mechanisms+of+Resistance+to+Crizotinib+in+Patients+with+ALK+Gene+Rearranged+Non-Small+Cell+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Doebele, Robert C.; Pilling, Amanda B.; Aisner, Dara L.; Kutateladze, Tatiana G.; Le, Anh T.; Weickhardt, Andrew J.; Kondo, Kimi L.; Linderman, Derek J.; Heasley, Lynn E.; Franklin, Wilbur A.; Varella-Garcia, Marileila; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1472-1482</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small-mol. ALK inhibitor.  Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those who do respond.  This study aimed to define mol. mechanisms of resistance to crizotinib in patients with ALK+ non-small cell lung cancer (NSCLC).  We analyzed tissue obtained from 14 patients with ALK+ NSCLC showing evidence of radiol. progression while on crizotinib to define mechanisms of intrinsic and acquired resistance to crizotinib.  Eleven patients had material evaluable for mol. anal.  Four patients (36%) developed secondary mutations in the tyrosine kinase domain of ALK.  A novel mutation in the ALK domain, encoding a G1269A amino acid substitution that confers resistance to crizotinib in vitro, was identified in two of these cases.  Two patients, one with a resistance mutation, exhibited new onset ALK copy no. gain (CNG).  One patient showed outgrowth of epidermal growth factor receptor (EGFR) mutant NSCLC without evidence of a persistent ALK gene rearrangement.  Two patients exhibited a KRAS mutation, one of which occurred without evidence of a persisting ALK gene rearrangement.  One patient showed the emergence of an ALK gene fusion-neg. tumor compared with the baseline sample but with no identifiable alternate driver.  Two patients retained ALK positivity with no identifiable resistance mechanism.  Crizotinib resistance in ALK+ NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of sep. oncogenic drivers.  Clin Cancer Res; 18(5); 1472-82.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhGQYtlS1w7Vg90H21EOLACvtfcHk0lgjkmNz2uGIzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D&md5=575047615ef9e3d4af60d45605a747c5</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2906%26sid%3Dliteratum%253Aachs%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DKutateladze%26aufirst%3DT.%2BG.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DWeickhardt%26aufirst%3DA.%2BJ.%26aulast%3DKondo%26aufirst%3DK.%2BL.%26aulast%3DLinderman%26aufirst%3DD.%2BJ.%26aulast%3DHeasley%26aufirst%3DL.%2BE.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DMechanisms%2520of%2520Resistance%2520to%2520Crizotinib%2520in%2520Patients%2520with%2520ALK%2520Gene%2520Rearranged%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1472%26epage%3D1482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessop, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engleman, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_elocation-id">120ra17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1126%2Fscitranslmed.3003316" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&author=R.+Katayamaauthor=A.+T.+Shawauthor=T.+M.+Khanauthor=M.+Mino-Kenudsonauthor=B.+J.+Solomonauthor=B.+Halmosauthor=N.+A.+Jessopauthor=J.+C.+Wainauthor=A.+T.+Yeoauthor=C.+Benesauthor=L.+Drewauthor=J.+C.+Saehauthor=K.+Crosbyauthor=L.+V.+Sequistauthor=A.+J.+Iafrateauthor=J.+A.+Engleman&title=Mechanisms+of+Acquired+Crizotinib+Resistance+in+ALK-Rearranged+Lung+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003316%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DJessop%26aufirst%3DN.%2BA.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DYeo%26aufirst%3DA.%2BT.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngleman%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520Acquired%2520Crizotinib%2520Resistance%2520in%2520ALK-Rearranged%2520Lung%2520Cancers%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anjum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miret, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span> </span><span class="NLM_article-title">Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">999</span><span class="NLM_x">–</span> <span class="NLM_lpage">1005</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1111%2Fj.1747-0285.2011.01239.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=22034911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2011&pages=999-1005&author=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=X.+Zhuauthor=Y.+Ningauthor=S.+D.+Wardwellauthor=L.+Moranauthor=Q.+K.+Mohemmadauthor=R.+Anjumauthor=Y.+Wangauthor=N.+I.+Narasimhanauthor=D.+Dalgarnoauthor=W.+C.+Shakespeareauthor=J.+J.+Miretauthor=T.+Clacksonauthor=V.+M.+Rivera&title=Crizotinib-resistant+mutants+of+EML4-ALK+identified+through+an+accelerated+mutagenesis+screen"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen</span></div><div class="casAuthors">Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">999-1005</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Activating gene rearrangements of anaplastic lymphoma kinase (ALK) have been identified as driver mutations in non-small-cell lung cancer, inflammatory myofibroblastic tumors, and other cancers.  Crizotinib, a dual MET/ALK inhibitor, has demonstrated promising clin. activity in patients with non-small-cell lung cancer and inflammatory myofibroblastic tumors harboring ALK translocations.  Inhibitors of driver kinases often elicit kinase domain mutations that confer resistance, and such mutations have been successfully predicted using in vitro mutagenesis screens.  Here, this approach was used to discover an extensive set of ALK mutations that can confer resistance to crizotinib.  Mutations at 16 residues were identified, structurally clustered into five regions around the kinase active site, which conferred varying degrees of resistance.  The screen successfully predicted the L1196M, C1156Y, and F1174L mutations, recently identified in crizotinib-resistant patients.  In sep. studies, we demonstrated that crizotinib has relatively modest potency in ALK-pos. non-small-cell lung cancer cell lines.  A more potent ALK inhibitor, TAE684, maintained substantial activity against mutations that conferred resistance to crizotinib.  Our study identifies multiple novel mutations in ALK that may confer clin. resistance to crizotinib, suggests that crizotinib's narrow selectivity window may underlie its susceptibility to such resistance and demonstrates that a more potent ALK inhibitor may be effective at overcoming resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU21SkJFhWI7Vg90H21EOLACvtfcHk0lhCg6dLtt6rOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsLbI&md5=7f1f1d4ad48d1801cd3f9c44f7ef4615</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2011.01239.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2011.01239.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DMiret%26aufirst%3DJ.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DCrizotinib-resistant%2520mutants%2520of%2520EML4-ALK%2520identified%2520through%2520an%2520accelerated%2520mutagenesis%2520screen%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2011%26volume%3D78%26spage%3D999%26epage%3D1005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Kinoshita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase inhibitors for the treatment of ALK-positive cancers</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">281</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1016%2FB978-0-12-396492-2.00019-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eju7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=281-293&author=K.+Kinoshitaauthor=N.+Oikawaauthor=T.+Tsukuda&title=Anaplastic+lymphoma+kinase+inhibitors+for+the+treatment+of+ALK-positive+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibitors for the treatment of ALK-positive cancers</span></div><div class="casAuthors">Kinoshita, Kazutomo; Oikawa, Nobuhiro; Tsukuda, Takuo</div><div class="citationInfo"><span class="NLM_cas:title">Annual Reports in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">281-293</span>CODEN:
                <span class="NLM_cas:coden">ARMCBI</span>;
        ISSN:<span class="NLM_cas:issn">0065-7743</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review on the development of anaplastic lymphoma kinase (ALK) inhibitors which is the most highly competitive drug targets in oncol. research.  A no. of research groups have identified promising drugs, where Pfizer succeeded in launching a potent ALK inhibitor, crizotinib, for treatment of EML4-ALK-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX549XOu0aZrVg90H21EOLACvtfcHk0lhCg6dLtt6rOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eju7vE&md5=2fb9597a39e7dd478a4ef41be4df7be6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396492-2.00019-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396492-2.00019-9%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520ALK-positive%2520cancers%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2012%26volume%3D47%26spage%3D281%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takashima, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haruta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanio, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1734</span><span class="NLM_x">–</span> <span class="NLM_lpage">1739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=EML4-ALK+mutations+in+lung+cancer+that+confer+resistance+to+ALK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0lhCg6dLtt6rOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DEML4-ALK%2520mutations%2520in%2520lung%2520cancer%2520that%2520confer%2520resistance%2520to%2520ALK%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1734%26epage%3D1739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butrynski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">A novel ALK sondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">6051</span><span class="NLM_x">–</span> <span class="NLM_lpage">6060</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=6051-6060&author=T.+Sasakiauthor=K.+Okudaauthor=W.+Zhengauthor=J.+Butrynskiauthor=M.+Capellettiauthor=L.+Wangauthor=N.+S.+Grayauthor=K.+Wilnerauthor=J.+G.+Christensenauthor=G.+Demetriauthor=G.+I.+Shapiroauthor=S.+J.+Rodigauthor=M.+J.+Eckauthor=P.+A.+Janne&title=A+novel+ALK+sondary+mutation+and+EGFR+signaling+cause+resistance+to+ALK+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DButrynski%26aufirst%3DJ.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DDemetri%26aufirst%3DG.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DA%2520novel%2520ALK%2520sondary%2520mutation%2520and%2520EGFR%2520signaling%2520cause%2520resistance%2520to%2520ALK%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D6051%26epage%3D6060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Giroux, S.</span><span> </span><span class="NLM_article-title">Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=394-401&author=S.+Giroux&title=Overcoming+acquired+resistance+to+kinase+inhibition%3A+The+cases+of+EGFR%2C+ALK+and+BRAF"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiroux%26aufirst%3DS.%26atitle%3DOvercoming%2520acquired%2520resistance%2520to%2520kinase%2520inhibition%253A%2520The%2520cases%2520of%2520EGFR%252C%2520ALK%2520and%2520BRAF%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D394%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">4500</span><span class="NLM_x">–</span> <span class="NLM_lpage">4505</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4500-4505&author=T.+O%E2%80%99Hareauthor=D.+K.+Waltersauthor=E.+P.+Stoffregenauthor=T.+Jiaauthor=P.+W.+Manleyauthor=J.+Mestanauthor=S.+W.+Cowan-Jacobauthor=F.+Y.+Leeauthor=M.+C.+Heinrichauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=In+vitro+activity+of+Bcr-Abl+inhibitors+AMN107+and+BMS-354825+against+clinically+relevant+imatinib-resistant+Abl+kinase+domain+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DJia%26aufirst%3DT.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DIn%2520vitro%2520activity%2520of%2520Bcr-Abl%2520inhibitors%2520AMN107%2520and%2520BMS-354825%2520against%2520clinically%2520relevant%2520imatinib-resistant%2520Abl%2520kinase%2520domain%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4500%26epage%3D4505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunker, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsaparikos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1170</span><span class="NLM_x">–</span> <span class="NLM_lpage">1187</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401805h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1170-1187&author=Q.+Huangauthor=T.+W.+Johnsonauthor=S.+Baileyauthor=A.+Broounauthor=K.+D.+Bunkerauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=A.+S.+Cookauthor=J.+J.+Cuiauthor=H.+Lamauthor=P.+F.+Richardsonauthor=N.+W.+Sachauthor=H.+Shenauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=K.+Tsaparikosauthor=H.+Wangauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Design+of+potent+and+selective+inhibitors+to+overcome+clinical+anaplastic+lymphoma+kinase+mutations+resistant+to+crizotinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span></div><div class="casAuthors">Huang, Qinhua; Johnson, Ted W.; Bailey, Simon; Brooun, Alexei; Bunker, Kevin D.; Burke, Benjamin J.; Collins, Michael R.; Cook, Andrew S.; Cui, J. Jean; Dack, Kevin N.; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Johnson, Patrick S.; Kania, Robert S.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Li, Qiuhua; Lingardo, Laura; Liu, Wei; Lu, Melissa West; McTigue, Michele; Palmer, Cynthia L.; Richardson, Paul F.; Sach, Neal W.; Shen, Hong; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Tsaparikos, Konstantinos; Wang, Hui; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1170-1187</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crizotinib, an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S.  Food and Drug Administration in 2011, is efficacious in ALK and ROS pos. patients.  Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease.  The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine (I), which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclin. pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnhF6vRWLUrrVg90H21EOLACvtfcHk0lh1D3XtPR8hkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D&md5=c12e0400ac92eb3321fde81ee13a5e92</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm401805h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401805h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBunker%26aufirst%3DK.%2BD.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDesign%2520of%2520potent%2520and%2520selective%2520inhibitors%2520to%2520overcome%2520clinical%2520anaplastic%2520lymphoma%2520kinase%2520mutations%2520resistant%2520to%2520crizotinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1170%26epage%3D1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Galkin, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopiuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span> </span><span class="NLM_article-title">Identification of NVPTAE684, a potent, selective, and efficacious inhibitor of NPM-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=270-275&author=A.+V.+Galkinauthor=J.+S.+Melnickauthor=S.+Kimauthor=T.+L.+Hoodauthor=N.+Liauthor=L.+Liauthor=G.+Xiaauthor=R.+Steensmaauthor=G.+Chopiukauthor=J.+Jiangauthor=Y.+Wanauthor=P.+Dingauthor=Y.+Liuauthor=F.+Sunauthor=P.+G.+Schultzauthor=N.+S.+Grayauthor=M.+Warmuth&title=Identification+of+NVPTAE684%2C+a+potent%2C+selective%2C+and+efficacious+inhibitor+of+NPM-ALK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGalkin%26aufirst%3DA.%2BV.%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWarmuth%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520NVPTAE684%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520inhibitor%2520of%2520NPM-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D270%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkisova, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phimister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P.-Y.</span><span> </span><span class="NLM_article-title">Synthesis, structure–activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl) phenyl)-N4-(2- (isopropylsulfonyl)-phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5675</span><span class="NLM_x">–</span> <span class="NLM_lpage">5690</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+structure%E2%80%93activity+relationships%2C+and+in+vivo+efficacy+of+the+novel+potent+and+selective+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+5-chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29+phenyl%29-N4-%282-+%28isopropylsulfonyl%29-phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+currently+in+phase+1+and+phase+2+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%25205-chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529%2520phenyl%2529-N4-%25282-%2520%2528isopropylsulfonyl%2529-phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520currently%2520in%2520phase%25201%2520and%2520phase%25202%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Kuromitsu, S.; Mori, M.; Shimada, I.; Kondoh, Y.; Shindoh, N.; Soga, T.; Furutani, T.; Konagai, S.; Sakagami, H.; Nakata, M.; Ueno, Y.; Saito, R.; Sasamata, M.; Kudou, M.</span><span> </span><span class="NLM_article-title">Anti-tumor activity of ASP3026, a novel and selective ALK inhibitor of anaplastic lymphoma kinase (ALK)</span>. Presented at the Annual Meeting of the American Association for Cancer Research (AACR), Orlando, FL,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Abstract 2821.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kuromitsu%2C+S.%3B+Mori%2C+M.%3B+Shimada%2C+I.%3B+Kondoh%2C+Y.%3B+Shindoh%2C+N.%3B+Soga%2C+T.%3B+Furutani%2C+T.%3B+Konagai%2C+S.%3B+Sakagami%2C+H.%3B+Nakata%2C+M.%3B+Ueno%2C+Y.%3B+Saito%2C+R.%3B+Sasamata%2C+M.%3B+Kudou%2C+M.+Anti-tumor+activity+of+ASP3026%2C+a+novel+and+selective+ALK+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29.+Presented+at+the+Annual+Meeting+of+the+American+Association+for+Cancer+Research+%28AACR%29%2C+Orlando%2C+FL%2C+2011%3B+Abstract+2821."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DAnti-tumor%2520activity%2520of%2520ASP3026%252C%2520a%2520novel%2520and%2520selective%2520ALK%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistant+gatekeeper+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistant%2520gatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Kinoshita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuichi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohwada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span> </span><span class="NLM_article-title">9-Substituted 6,6-dimethyl- 11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6286</span><span class="NLM_x">–</span> <span class="NLM_lpage">6294</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200652u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6286-6294&author=K.+Kinoshitaauthor=T.+Kobayashiauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=K.+Hattoriauthor=T.+Miyagiauthor=W.-S.+Hongauthor=M.-J.+Parkauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=9-Substituted+6%2C6-dimethyl-+11-oxo-6%2C11-dihydro-5H-benzo%5Bb%5Dcarbazoles+as+highly+selective+and+potent+anaplastic+lymphoma+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm200652u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200652u%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.-S.%26aulast%3DPark%26aufirst%3DM.-J.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3D9-Substituted%25206%252C6-dimethyl-%252011-oxo-6%252C11-dihydro-5H-benzo%255Bb%255Dcarbazoles%2520as%2520highly%2520selective%2520and%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6286%26epage%3D6294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maemondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshioka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nogami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span> </span><span class="NLM_article-title">CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">590</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1016%2FS1470-2045%2813%2970142-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=23639470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntV2gsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=590-598&author=T.+Setoauthor=K.+Kiuraauthor=M.+Nishioauthor=K.+Nakagawaauthor=M.+Maemondoauthor=A.+Inoueauthor=T.+Hidaauthor=N.+Yamamotoauthor=H.+Yoshiokaauthor=M.+Haradaauthor=Y.+Oheauthor=N.+Nogamiauthor=K.+Takeuchiauthor=T.+Shimadaauthor=T.+Tanakaauthor=T.+Tamura&title=CH5424802+%28RO5424802%29+for+patients+with+ALK-rearranged+advanced+non-small-cell+lung+cancer+%28AF-001JP+study%29%3A+a+single-arm%2C+open-label%2C+phase+1%E2%80%932+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study</span></div><div class="casAuthors">Seto, Takashi; Kiura, Katsuyuki; Nishio, Makoto; Nakagawa, Kazuhiko; Maemondo, Makoto; Inoue, Akira; Hida, Toyoaki; Yamamoto, Nobuyuki; Yoshioka, Hiroshige; Harada, Masao; Ohe, Yuichiro; Nogami, Naoyuki; Takeuchi, Kengo; Shimada, Tadashi; Tanaka, Tomohiro; Tamura, Tomohide</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">590-598</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Currently, crizotinib is the only drug that has been approved for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC).  We aimed to study the activity and safety of CH5424802, a potent, selective, and orally available ALK inhibitor.  In this multicenter, single-arm, open-label, phase 1-2 study of CH5424802, we recruited ALK inhibitor-naive patients with ALK-rearranged advanced NSCLC from 13 hospitals in Japan.  In the phase 1 portion of the study, patients received CH5424802 orally twice daily by dose escalation.  The primary endpoints of the phase 1 were dose limiting toxicity (DLT), max. tolerated dose (MTD), and pharmacokinetic parameters.  In the phase 2 portion of the study, patients received CH5424802 at the recommended dose identified in the phase 1 portion of the study orally twice a day.  The primary endpoint of the phase 2 was the proportion of patients who had an objective response.  Treatment was continued in 21-day cycles until disease progression, intolerable adverse events, or withdrawal of consent.  The anal. was done by intent to treat.  This study is registered with the Japan Pharmaceutical Information Center, no. JapicCTI-101264.  Patients were enrolled between Sept 10, 2010, and Apr. 18, 2012.  The data cutoff date was July 31, 2012.  In the phase 1 portion, 24 patients were treated at doses of 20-300 mg twice daily.  No DLTs or adverse events of grade 4 were noted up to the highest dose; thus 300 mg twice daily was the recommended phase 2 dose.  In the phase 2 portion of the study, 46 patients were treated with the recommended dose, of whom 43 achieved an objective response (93·5%, 95% CI 82·1-98·6) including two complete responses (4·3%, 0·5-14·8) and 41 partial responses (89·1%, 76·4-96·4).  Treatment-related adverse events of grade 3 were recorded in 12 (26%) of 46 patients, including two patients each experiencing decreased neutrophil count and increased blood creatine phosphokinase.  Serious adverse events occurred in five patients (11%).  No grade 4 adverse events or deaths were reported.  The study is still ongoing, since 40 of the 46 patients in the phase 2 portion remain on treatment.  CH5424802 is well tolerated and highly active in patients with advanced ALK-rearranged NSCLC.  Chugai Pharmaceutical Co, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXnUGKVRfsBbVg90H21EOLACvtfcHk0ljlrRk3ZHCpwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntV2gsrk%253D&md5=489043eede3a37bb8ce76c6f1dc0296d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970142-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970142-6%26sid%3Dliteratum%253Aachs%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMaemondo%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DHida%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DYoshioka%26aufirst%3DH.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DTamura%26aufirst%3DT.%26atitle%3DCH5424802%2520%2528RO5424802%2529%2520for%2520patients%2520with%2520ALK-rearranged%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528AF-001JP%2520study%2529%253A%2520a%2520single-arm%252C%2520open-label%252C%2520phase%25201%25E2%2580%25932%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3D590%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Ye, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of a series of benzo[de]-[1,7]naphthyridin-7(8<i>H</i>)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2885</span><span class="NLM_x">–</span> <span class="NLM_lpage">2903</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301825t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2885-2903&author=N.+Yeauthor=C.-H.+Chenauthor=T.+T.+Chenauthor=Z.+Songauthor=J.+Heauthor=X.+Huanauthor=S.+Songauthor=Q.+Liuauthor=Y.+Chenauthor=J.+Dingauthor=Y.+Xuauthor=Z.+Miaoauthor=A.+Zhang&title=Design%2C+synthesis+and+biological+evaluation+of+a+series+of+benzo%5Bde%5D-%5B1%2C7%5Dnaphthyridin-7%288H%29-ones+bearing+a+functionalized+longer+chain+appendage+as+novel+PARP1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm301825t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301825t%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DChen%26aufirst%3DT.%2BT.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DHuan%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520benzo%255Bde%255D-%255B1%252C7%255Dnaphthyridin-7%25288H%2529-ones%2520bearing%2520a%2520functionalized%2520longer%2520chain%2520appendage%2520as%2520novel%2520PARP1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2885%26epage%3D2903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ya, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent c-Met/ALK multikinase inhibitory activities</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml400373j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=304-308&author=Z.+Liuauthor=J.+Aiauthor=X.+Pengauthor=Z.+Songauthor=K.+Wuauthor=J.+Zhangauthor=Q.+Yaauthor=Y.+Chenauthor=Y.+Jiauthor=Y.+Yangauthor=M.+Gengauthor=A.+Zhang&title=Novel+2%2C4-diarylaminopyrimidine+analogues+%28DAAPalogues%29+showing+potent+c-Met%2FALK+multikinase+inhibitory+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fml400373j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400373j%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYa%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DNovel%25202%252C4-diarylaminopyrimidine%2520analogues%2520%2528DAAPalogues%2529%2520showing%2520potent%2520c-Met%252FALK%2520multikinase%2520inhibitory%2520activities%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D304%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Milkiewicz, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobelny, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoSardo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worrell, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeigler, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6274</span><span class="NLM_x">–</span> <span class="NLM_lpage">6284</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=6274-6284&author=K.+L.+Milkiewiczauthor=L.+D.+Aimoneauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=H.+Changauthor=J.+V.+Grobelnyauthor=J.+Hustenauthor=C.+LoSardoauthor=T.+L.+Underinerauthor=L.+R.+Weinbergauthor=C.+S.+Worrellauthor=K.+S.+Zeiglerauthor=B.+D.+Dorsey&title=Improvement+in+oral+bioavailability+of+2%2C4-diaminopyrimidine+c-Met+inhibitors+by+incorporation+of+a+3-amidobenzazepin-2-one+group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DGrobelny%26aufirst%3DJ.%2BV.%26aulast%3DHusten%26aufirst%3DJ.%26aulast%3DLoSardo%26aufirst%3DC.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DWeinberg%26aufirst%3DL.%2BR.%26aulast%3DWorrell%26aufirst%3DC.%2BS.%26aulast%3DZeigler%26aufirst%3DK.%2BS.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DImprovement%2520in%2520oral%2520bioavailability%2520of%25202%252C4-diaminopyrimidine%2520c-Met%2520inhibitors%2520by%2520incorporation%2520of%2520a%25203-amidobenzazepin-2-one%2520group%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D6274%26epage%3D6284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Song, Z.; Ai, J.; Liu, Z.; Peng, X.; Geng, M.; Zhang, A.</span><span> </span><span class="NLM_article-title">Discovery of 2,4-diarylaminopyrimidine SOMCL-12–81 as a potent inhibitor targeting both wild and mutant ALK kinase</span>. Presented at the Annual Meeting of the American Association for Cancer Research (AACR), Boston, MA,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Abstract B90.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Song%2C+Z.%3B+Ai%2C+J.%3B+Liu%2C+Z.%3B+Peng%2C+X.%3B+Geng%2C+M.%3B+Zhang%2C+A.+Discovery+of+2%2C4-diarylaminopyrimidine+SOMCL-12%E2%80%9381+as+a+potent+inhibitor+targeting+both+wild+and+mutant+ALK+kinase.+Presented+at+the+Annual+Meeting+of+the+American+Association+for+Cancer+Research+%28AACR%29%2C+Boston%2C+MA%2C+2013%3B+Abstract+B90."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%25202%252C4-diarylaminopyrimidine%2520SOMCL-12%25E2%2580%259381%2520as%2520a%2520potent%2520inhibitor%2520targeting%2520both%2520wild%2520and%2520mutant%2520ALK%2520kinase%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Gray, N. S.; Zhou, W.</span>. <span> </span><span class="NLM_article-title">Preparation of pyrimidinyl benzamides and similar compounds as therapeutic modulators of mutant EGFR activity</span>. PCT Int. Appl. WO 2011140338,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+S.+Gray&author=W.+Zhou&title=Preparation+of+pyrimidinyl+benzamides+and+similar+compounds+as+therapeutic+modulators+of+mutant+EGFR+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DPreparation%2520of%2520pyrimidinyl%2520benzamides%2520and%2520similar%2520compounds%2520as%2520therapeutic%2520modulators%2520of%2520mutant%2520EGFR%2520activity%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Khan, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taha, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maharvi, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saify, Z. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parveen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhary, M. I.</span><span> </span><span class="NLM_article-title">Leishmanicidal potential of N-substituted morpholine derivatives: Synthesis and structure-activity relationships</span> <span class="citation_source-journal">Nat. Prod. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1080%2F14786410802090359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=19296393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=479-484&author=K.+M.+Khanauthor=M.+Z.+Khanauthor=M.+Tahaauthor=G.+M.+Maharviauthor=Z.+S.+Saifyauthor=S.+Parveenauthor=M.+I.+Choudhary&title=Leishmanicidal+potential+of+N-substituted+morpholine+derivatives%3A+Synthesis+and+structure-activity+relationships"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Leishmanicidal potential of N-substituted morpholine derivatives: synthesis and structure-activity relationships</span></div><div class="casAuthors">Mohammed Khan, Khalid; Khan, Muhammad Zarrar; Taha, Muhammad; Maharvi, Ghulam Murtaza; Saify, Zafar Saeed; Parveen, Shahnaz; Choudhary, Muhammad Iqbal</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">479-484</span>CODEN:
                <span class="NLM_cas:coden">NPRAAT</span>;
        ISSN:<span class="NLM_cas:issn">1478-6419</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A series of N-substituted morpholines 2-20 was synthesized by reacting various acid chlorides and alkyl halides with morpholine (1).  All of the synthesized compds. 2-20 were screened for their leishmanicidal effects using amphotericin B (IC50 = 0.24 μg L-1) and pentamidine (IC50 = 2.56 μg mL-1) as stds. and a structure-activity relationship (SAR) study was established.  The compds. 2 (IC50 = 48 μg mL-1), 3 (IC50 = 30.0 μg mL-1), 10 (IC50 = 41.0 μg mL-1), 15 (IC50 = 33.0 μg mL-1), 16 (IC50 = 35.0 μg mL-1) and 20 (IC50 = 47.0 μg mL-1) showed weak leishmanicidal activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeTNqa0K11p7Vg90H21EOLACvtfcHk0liwY1ONoOHbpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWlsb0%253D&md5=67b1bd4421aa9be9d808d58cc14fa56a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1080%2F14786410802090359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14786410802090359%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DK.%2BM.%26aulast%3DKhan%26aufirst%3DM.%2BZ.%26aulast%3DTaha%26aufirst%3DM.%26aulast%3DMaharvi%26aufirst%3DG.%2BM.%26aulast%3DSaify%26aufirst%3DZ.%2BS.%26aulast%3DParveen%26aufirst%3DS.%26aulast%3DChoudhary%26aufirst%3DM.%2BI.%26atitle%3DLeishmanicidal%2520potential%2520of%2520N-substituted%2520morpholine%2520derivatives%253A%2520Synthesis%2520and%2520structure-activity%2520relationships%26jtitle%3DNat.%2520Prod.%2520Res.%26date%3D2009%26volume%3D23%26spage%3D479%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Mologni, L.</span><span> </span><span class="NLM_article-title">Inhibitors of the anaplastic lymphoma kinase</span> <span class="citation_source-journal">Expert Opin Investig. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">985</span><span class="NLM_x">–</span> <span class="NLM_lpage">994</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=985-994&author=L.+Mologni&title=Inhibitors+of+the+anaplastic+lymphoma+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26atitle%3DInhibitors%2520of%2520the%2520anaplastic%2520lymphoma%2520kinase%26jtitle%3DExpert%2520Opin%2520Investig.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D985%26epage%3D994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Galetta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisconti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colucci, G.</span><span> </span><span class="NLM_article-title">The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">S45</span><span class="NLM_x">–</span> <span class="NLM_lpage">S54</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=S45-S54&author=D.+Galettaauthor=A.+Rossiauthor=S.+Piscontiauthor=G.+Colucci&title=The+emerging+role+of+ALK+inhibitors+in+the+treatment+of+advanced+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGaletta%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DPisconti%26aufirst%3DS.%26aulast%3DColucci%26aufirst%3DG.%26atitle%3DThe%2520emerging%2520role%2520of%2520ALK%2520inhibitors%2520in%2520the%2520treatment%2520of%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2012%26volume%3D16%26spage%3DS45%26epage%3DS54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzalone, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml100158s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=493-498&author=G.+R.+Ottauthor=R.+Tripathyauthor=M.+Chengauthor=R.+McHughauthor=A.+V.+Anzaloneauthor=T.+L.+Underinerauthor=M.+A.+Curryauthor=M.+R.+Quailauthor=L.+Luauthor=W.+Wanauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+a+potent+inhibitor+of+anaplastic+lymphoma+kinase+with+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Tripathy, Rabindranath; Cheng, Mangeng; McHugh, Robert; Anzalone, Andrew V.; Underiner, Ted L.; Curry, Matthew A.; Quail, Matthew R.; Lu, Lihui; Wan, Weihua; Angeles, Thelma S.; Albom, Mark S.; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">493-498</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 7-amino-1,3,4,5-tetrahydrobenzo[b]azepin-2-one derivs. within the diaminopyrimidine class of kinase inhibitors were identified that target anaplastic lymphoma kinase (ALK).  These inhibitors are potent against ALK in an isolated enzyme assay and inhibit autophosphorylation of the oncogenic fusion protein NPM-ALK in anaplastic large cell lymphoma (ALCL) cell lines.  The lead inhibitor 15 (I), which incorporates a bicyclo[2.2.1]hept-5-ene ring system in place of an aryl moiety, activates the pro-apoptotic caspases (3 and 7) and displays selective cytotoxicity against ALK-pos. ALCL cells.  Furthermore, 15 provides more than 40-fold selectivity against the structurally related insulin receptor, is orally bioavailable in multiple species, and displays in vivo antitumor efficacy when dosed orally in ALK-pos. ALCL tumor xenografts in Scid mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof0qilbcAbZ7Vg90H21EOLACvtfcHk0lhzQL90KD9F0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ&md5=15d4f7aea64f212338d8c9cd88a36c64</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fml100158s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100158s%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DTripathy%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DMcHugh%26aufirst%3DR.%26aulast%3DAnzalone%26aufirst%3DA.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D493%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: Identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)-quinoline as a novel anticancer agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2127</span><span class="NLM_x">–</span> <span class="NLM_lpage">2142</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101340q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2127-2142&author=Y.+Wangauthor=J.+Aiauthor=Y.+Wangauthor=Y.+Chenauthor=L.+Wangauthor=G.+Liuauthor=M.+Gengauthor=A.+Zhang&title=Synthesis+and+c-Met+kinase+inhibition+of+3%2C5-disubstituted+and+3%2C5%2C7-trisubstituted+quinolines%3A+Identification+of+3-%284-acetylpiperazin-1-yl%29-5-%283-nitrobenzylamino%29-7-+%28trifluoromethyl%29-quinoline+as+a+novel+anticancer+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm101340q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101340q%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520c-Met%2520kinase%2520inhibition%2520of%25203%252C5-disubstituted%2520and%25203%252C5%252C7-trisubstituted%2520quinolines%253A%2520Identification%2520of%25203-%25284-acetylpiperazin-1-yl%2529-5-%25283-nitrobenzylamino%2529-7-%2520%2528trifluoromethyl%2529-quinoline%2520as%2520a%2520novel%2520anticancer%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2127%26epage%3D2142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristofani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machiorlatti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inghirami, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span> </span><span class="NLM_article-title">CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">670</span><span class="NLM_x">–</span> <span class="NLM_lpage">679</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm5005144&amp;key=10.1158%2F1535-7163.MCT-11-0776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm5005144&amp;key=22203728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm5005144&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=670-679&author=M.+Chengauthor=M.+R.+Quailauthor=D.+E.+Gingrichauthor=G.+R.+Ottauthor=L.+Luauthor=W.+Wanauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=F.+Cristofaniauthor=R.+Machiorlattiauthor=C.+Abeleauthor=M.+A.+Atorauthor=B.+D.+Dorseyauthor=G.+Inghiramiauthor=B.+A.+Ruggeri&title=CEP-28122%2C+a+highly+potent+and+selective+orally+active+inhibitor+of+anaplastic+lymphoma+kinase+with+antitumor+activity+in+experimental+models+of+human+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers</span></div><div class="casAuthors">Cheng, Mangeng; Quail, Matthew R.; Gingrich, Diane E.; Ott, Gregory R.; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Cristofani, Flavio; Machiorlatti, Rodolfo; Abele, Cristina; Ator, Mark A.; Dorsey, Bruce D.; Inghirami, Giorgio; Ruggeri, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">670-679</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is constitutively activated in a no. of human cancer types due to chromosomal translocations, point mutations, and gene amplification and has emerged as an excellent mol. target for cancer therapy.  Here we report the identification and preclin. characterization of CEP-28122, a highly potent and selective orally active ALK inhibitor.  CEP-28122 is a potent inhibitor of recombinant ALK activity and cellular ALK tyrosine phosphorylation.  It induced concn.-dependent growth inhibition/cytotoxicity of ALK-pos. anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells, and displayed dose-dependent inhibition of ALK tyrosine phosphorylation in tumor xenografts in mice, with substantial target inhibition (>90%) for more than 12 h following single oral dosing at 30 mg/kg.  Dose-dependent antitumor activity was obsd. in ALK-pos. ALCL, NSCLC, and neuroblastoma tumor xenografts in mice administered CEP-28122 orally, with complete/near complete tumor regressions obsd. following treatment at doses of 30 mg/kg twice daily or higher.  Treatment of mice bearing Sup-M2 tumor xenografts for 4 wk and primary human ALCL tumor grafts for 2 wk at 55 or 100 mg/kg twice daily led to sustained tumor regression in all mice, with no tumor reemergence for more than 60 days postcessation of treatment.  Conversely, CEP-28122 displayed marginal antitumor activity against ALK-neg. human tumor xenografts under the same dosing regimens.  Administration of CEP-28122 was well tolerated in mice and rats.  In summary, CEP-28122 is a highly potent and selective orally active ALK inhibitor with a favorable pharmaceutical and pharmacokinetic profile and robust and selective pharmacol. efficacy against ALK-pos. human cancer cells and tumor xenograft models in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWAF2Kawjc8rVg90H21EOLACvtfcHk0lhzQL90KD9F0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D&md5=40001fb02de25d0f78bb11a41819651a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0776%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DCristofani%26aufirst%3DF.%26aulast%3DMachiorlatti%26aufirst%3DR.%26aulast%3DAbele%26aufirst%3DC.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DInghirami%26aufirst%3DG.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26atitle%3DCEP-28122%252C%2520a%2520highly%2520potent%2520and%2520selective%2520orally%2520active%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520with%2520antitumor%2520activity%2520in%2520experimental%2520models%2520of%2520human%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D670%26epage%3D679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieu, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lisko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesaros, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6328</span><span class="NLM_x">–</span> <span class="NLM_lpage">6341</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200758k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6328-6341&author=G.+R.+Ottauthor=G.+J.+Wellsauthor=T.+V.+Thieuauthor=M.+R.+Quailauthor=J.+G.+Liskoauthor=E.+F.+Mesarosauthor=D.+E.+Gingrichauthor=A.+K.+Ghoseauthor=W.+Wanauthor=L.+Luauthor=M.+Chengauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=2%2C7-Disubstituted-pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazines%3A+new+variant+of+an+old+template+and+application+to+the+discovery+of+anaplastic+lymphoma+kinase+%28ALK%29+inhibitors+with+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm200758k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200758k%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3D2%252C7-Disubstituted-pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazines%253A%2520new%2520variant%2520of%2520an%2520old%2520template%2520and%2520application%2520to%2520the%2520discovery%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitors%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6328%26epage%3D6341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i65"><a href="/doi/suppl/10.1021/jm5005144">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_51426"></div></div></div></div></div><hr /></hr><p class="last">Copies of the <sup>1</sup>H and <sup>13</sup>C spectra of all new compounds. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm5005144/suppl_file/jm5005144_si_001.pdf">jm5005144_si_001.pdf (11.06 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm5005144&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm5005144%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-1%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm5005144" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798f305e9133c88","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
